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GENERAL INTRODUCTION
Upon pathogen invasion, the innate and adaptive immune systems function in concert 
to evoke a pathogen specific immune response. Initially, pattern recognition receptors 
(PRRs) recognise pathogen-associated molecular patterns (PAMPs) and activate innate 
immune responses such as professional antigen presenting cells (APCs). Consequently, 
APCs (i.e. dendritic cells (DC), macrophages, B cells) instigate the induction of adaptive 
immune responses (cytotoxic T cells, helper T cells and antibodies) leading to pathogen 
clearance [1]. After pathogen eradication, immunological memory is formed and a rapid 
and more efficient adaptive immune response arises when encountering the same 
pathogen in the future. Immunological memory can be short- or long– lived, depending 
on the type and persistence of the pathogen. 
Immunisation is the strategy of stimulating the host’s defence with i.e. a dead or 
attenuated pathogen to establish protective or therapeutic immunity [2]. Vaccine 
development is a complex and multicomponent activity which requires comprehensive 
understanding of the host-pathogen interactions. Selection of the correct antigenic 
targets and delivery systems that will shape an effective vaccine-elicited immune 
response is a crucial step of the vaccine development process. The majority of 
the peptide- and protein-based vaccine platforms demonstrate low immunogenicity 
when adjuvants are lacking. Adjuvants act by providing innate and adaptive immune 
triggers and are currently used in several vaccine models [3-5]. The ultimate goal, is an 




T cells (thymus-derived) and B cells (bone marrow-derived) are major cellular 
components of the adaptive immune response. T cell are crucial for mediating cellular 
immunity and B cells are primary responsible for humoral immunity. T cell activation 
occurs when a naïve T cell bearing a unique T cell receptor (TCR) encounters a DC 
presenting cognate antigen in the context of MHC molecules (Signal 1) [6]. In particular, 
peptides cleaved from endogenously produced proteins are presented by MHC class I 
molecules and subsequently recognized by T cell receptors of CD8+ T cells leading into 
the induction of cytotoxic CD8+ T cell responses. Extracellular proteins can be presented 
by MHC class II molecules to CD4+ T cells leading to helper CD4+ T cell induction [7]. 
Nevertheless, in some cases antigens from extracellular environment can be presented 
by APCs on MHC class I molecules and stimulate T- cell immunity, a process widely 
known as cross-presentation [8]. Priming of T cells requires approximately 16 to 20 
hours of antigenic stimulation and activated T cells can be measured within 2 days. 
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Recruitment of CD8+ T cells ends between 48-96 hours after antigenic challenge due to 
a feedback mechanisms that limits the duration of effective antigen presentation [9,10]. 
However, if the antigenic stimulation is less than 4-6 hour the programmed proliferation 
response is abortive.
Costimulatory signals (Signal 2) are considered essential for appropriate T cell 
activation. Mature DCs express several costimulatory ligands (i.e CD70, OX40L, , ICOSL, 
and the B7 molecules CD80 and CD86) which upon inflammatory conditions ligate to 
the equivalent costimulatory molecules (e.g. CD27, OX40, ICOS, CD28) expressed on T 
cells and strengthen T cell activation [11]. Certain inflammatory cytokines like IL-12 and 
type I interferons (Signal 3) play a crucial role in regulating adaptive immune responses 
and influence both primary and memory T cell development [12]. For generation of 
fully functional T cells concerted activation of all the three signals described above 
is required. 
T cell expansion, contraction and memory formation
After virus encounter, T cell responses undergo through three phases i) expansion, ii) 
contraction and iii) memory development [13]. During the expansion phase, activated 
T cells clonally expand and acquire effector cell properties. In mice, the frequency of 
specific CD8+ T cells can increase in size from 100-200 cells up to 1 x 107 cells during 
bacterial and viral infections [14,15]. Notably, the expression of interleukin-12 (IL-12) and 
interleukin-4 (IL-4) pro-inflammatory cytokines by innate immune cells (DCs) stimulates 
primary T cell activation and induction of Type 1 and Type 2 cytokine producing 
T cells. Activated CD4+ and CD8+ T cells acquire either a Type 1 or Type 2 cytokine 
profile. The cytokines produced by Type 1 T cells promote cell-mediated immunity and 
they include interferon- γ (IFN-γ), tumor necrosis factor (TNF) and interleukin-2 (IL-2) 
[16,17]. Type 2 T cells, secrete IL-4, IL-5, IL-6, IL-10 and IL-13 cytokines and promote B 
cell development and antibody responses [18]. Generally, cytokine production by CD8+ 
T cells occurs in a rapid and transient, tightly regulated by antigenic contact [19]. In 
addition, CD8+ T cells are also equipped with the cytolysis-inducing molecules perforin 
and granzyme and the apoptosis-inducing CD95 ligand (FasL/APO-1L) to execute 
antigen-bearing target cells [20]. 
CD4+ T cell help is critical for proper priming of CD8+ CTL cells. CD4+ T cell help 
works by stimulating APCs through the CD40-CD40L pathway to prime CD8+ T cell 
proliferation [21]. Although primary CD8+ T cell responses to several infectious 
pathogens such as viruses and bacteria are generally unaffected by the absence of CD4+ 
T cells, the memory and recall CD8+ T cell response to these agents requires CD4+ T cell 
help to initiate a second round of clonal expansion [22-24]. Moreover, a growing body of 
evidence indicates a capacity of CD4+ T cells for potent cytolytic killing of virus infected 
cells [25-28]. 
After the expansion phase and termination of disease, more than 90% of the effector 
antigen-specific T cell pool is eliminated by programmed cell death (PCD) [29]. Several 
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factors are implicated in modulating this phase and retard or accelerate T cell contraction. 
For instance, IL-2 administration has been clearly shown to augment the magnitude 
and survival of the antigen-specific T cells, indicating that IL-2 signals are important for 
T cell expansion and maintenance [30,31]. However, expression of IFN-γ and cytolytic 
effector molecules such as perforin and granzyme have downsizing influence [32]. 
The role of TNF and CD95 on cells in the apoptosis of mature T cells is controversial 
[33-35]. Whether other factors also have contraction-modulating properties remains 
to be investigated. Down-regulation of activated T cells is of great importance for 
preventing immunopathology since excessive expansion or defective contraction of T 
cells (particularly CD8) results in severe or even fatal outcome [36]. 
After contraction, a small portion of antigen-specific T cells, termed memory T cells, 
remains. Memory T cell are endowed with the ability to generate a rapid and powerful 
immune response in case of re-infection with the same pathogen. In particular, extensive 
literature from animal models describes the superiority of memory T cells precursor 
frequency (>1000 fold) compared to naïve T cells which fosters induction of stronger and 
more plethoric immune responses during a secondary antigenic encounter. Memory 
T cells frequencies are stable over a long time [37]. Memory CD8+ T cell homeostatic 
proliferation and long term survival is MHC interaction independent and is driven by 
the cytokines IL-7 and IL-15 [38]. Memory CD4+ T cell replenishment is similar to CD8+ 
T cells, whilst the need for IL-15 is less marked [39]. Remarkably, memory T cells show 
delayed secondary contraction and resistance to apoptosis through the upregulation 
of various anti-apoptotic molecules (e.g. BCL-2, BCL-XL) [40,41]. Memory T cells exhibit 
also better differentiation capacities and produce IFN-γ, RANTES, and the cytotoxic 
molecules perforin and granzyme B in larger quantities and more rapidly than naïve T 
cells [42-44]. 
Memory T cells can be categorized into effector-memory (TEM), central memory (TCM) 
or tissue-resident memory (TRM) T cells based on the expression of certain homing and 
differentiation molecules [45]. TEM  can be distinguished based on the expression or 
lack of CD62L+CCR7- surface molecules and the TCM cells express CD62L
+CCR7+ [46]. An 
important discrete difference between these two subsets is that TEM cells predominantly 
circulate in non-lymphoid organs whereas TCM cells preferentially localize in lymphoid 
tissues [47,48]. TRM cells do not circulate but permanently exist in tissues.
CYTOMEGALOVIRUS INFECTION
Cytomegalovirus
Cytomegalovirus (CMV) belongs to the family of the β herpesviruses and it is also known 
as herpesvirus type 5. CMV has a long life cycle and has a genome size of over 230kb. 
The virus contains a double-stranded linear DNA enveloped by a proteinaceous matrix, 
which is packed into a lipid bilayer that contains viral glycoproteins. Transmission of 
the virus cannot occur through casual contact but via exposure to infected body fluids 
12 | Chapter 1
(i.e blood, urine, saliva, breast milk, tears). As a result of productive virus replication 
immediate early, early and late viral proteins are synthesized [49]. After primary infection, 
the virus establishes lifelong latency within myeloid, endothelial and epithelial cell 
lineages. Cytomegalovirus replication is cell-type specific and depends on the stage of 
differentiation of the infected cells. Specifically, while monocytes repress transcription 
of the major immediate-early promoter and thus impede the production of new virions, 
macrophages and immature dendritic cells sustain productive infection [50-52]. During 
the lytic cycle of the infection, the virus replicates in diverse tissues (i.e spleen, liver 
and lungs) whereas the salivary glands are the primary site where viral replication is 
detected during latency [53,54].
The incidence of the CMV infection varies and its true sero-prevalence rate is difficult 
to determine due to virus latency and difficulty to be detected. Recent epidemiologic 
evidence suggests that approximately 60-80% of the human population is infected by 
the virus and  90% or more of the infected individuals acquire the virus till aged 40 years 
old age [55]. CMV infection usually is benign, with no clinical disease manifestations in 
immunocompetent individuals but it can reactivate and lead to severe complications 
in immunosuppressed and immunocompromised individuals, including allograft 
recipients and HIV patients. Moreover, CMV is currently the leading cause of congenital 
infections, and can cause long term neurological consequences such as hearing 
loss, visual impairment, and cognitive delays. Antiviral therapy for CMV exists, but it 
is accompanied with significant toxicity and prolonged treatment periods. The most 
commonly used antivirals for CMV disease include ganciclovir, valganciclovir, foscanet 
and cidofovir, all of which target to inhibit viral DNA amplification. At present there are 
no licensed vaccine-based countermeasures against CMV [56].
Vaccines against CMV seek to recapitulate or to improve the degree of protection 
bestowed by natural infection. In the last decades, many prophylactic and therapeutic 
vaccine strategies have been explored such as live attenuated viruses, human dense 
bodies, recombinant viral vectors, DNA, and subunit/adjuvant vaccines. The majority 
of those vaccines focused on the induction of broad neutralizing antibodies against 
the major envelope protein B (gB) or, more recently, against the gH pentamer complex 
[57]. Although some highly potent humoral-inducing vaccines have been developed, 
their main limitation is that they fail to provide long term protection. A series of studies 
on mice, non-human primates and humans provide evidence that vaccines against 
CMV should engage cellular T cell immunity. T-cell based vaccines designed to induce 
CD4+ and/or CD8+ T cell responses of sufficient magnitude, particular phenotype 
and functional traits that directly contribute to pathogen clearance, although not 
yet providing sterilizing immunity via cell mediated effector mechanisms is a rapidly 
expanding vaccination strategy that gains increasing attention [58-62]. Clinical phase 
I and II trials, incorporating humoral immune targets in combination with cellular 
immune targets, predominantly focus on the immediate early 1 protein (IE1) and protein 
65 (pp65) as immunogens for cytotoxic T cells and gB as immunogen for neutralizing 
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antibodies. In these trials promising immune responses have been elicited. To this end, 
numerous novel vaccines modalities including replication-defective viral vectors and 
genetically disabled CMV are currently tested in experimental studies and preliminary 
results engender optimism that a successful vaccine will be developed [56,63].
T cell responses to cytomegalovirus 
CMV-specific T cell responses exhibit unique features and follow an atypical kinetic 
profile. T cell responses to CMV dominate the memory T cell pool more than other 
(known) viruses. It is estimated that about 10% of the total circulating CD4+ and CD8+ 
memory T cell responses are CMV specific and these percentages may rise throughout 
the course of life [64]. The unique nature of CMV-specific T cell responses has been 
studied in depth using mouse CMV (MCMV) [54]. The majority of the MCMV-specific CD8+ 
T cell responses that predominate during the acute infection phase follow the typical 
course, which is characterised by massive proliferation after antigen encounter, rapid 
contraction and long term maintenance at low levels [65]. These CD8+ T cells are 
characterised by a conventional central memory phenotype (CD127+, CD62L+, CD27+, 
CD28+, KLRG-1-, CD44- and IL-2+) during the persistent phase of infection.
However, CD8+ T cell responses to certain proteins do not contract but continue 
to intensify gradually over time and display an effector-memory phenotype (CD127-, 
CD62L-, CD27-, CD28- , KLRG-1+, CD44+ and IL-2-). These T cells were termed inflationary 
to denote an ongoing rise in the response rate [66]. Inflation of memory CMV-specific 
CD4+ T cells has also been observed [67]. Inflationary CMV-specific CD8+ T cells with 
similar phenotypic features have been detected in humans and in primate models of 
CMV. Inflationary T cells often show restricted T cell receptor (TCR) usage, with many 
carrying T cell receptors specific for immunodominant CMV antigens. Despite their 
ongoing proliferation capacity, inflationary T cells retain their functionality and do not 
exhibit features of exhaustion as observed with certain other persistent viral infections. 
For establishment of memory T cell inflation, repetitive antigen exposure is required, 
whilst systemic viral production does not seem to be a prerequisite to drive memory 
inflation. Also differences in the functional avidity for peptide-MHC complexes were 
not predictive whether epitopes elicit inflationary or non-inflationary T cell responses. 
Importantly, CD4+ T cells, costimulatory molecules such as CD27 and OX40 and IL-2, IL-7, 
and IL-15 cytokines provide important signals for the maintenance of the inflationary T 
cell population but their precise mechanisms are under investigated [66,68,69] . 
Animal models to study CMV pathogenesis and therapies
Treatments for CMV infections have been studied in murine, guinea pig, non-primate 
and primate models before being tested in humans. All models of CMV infection have 
significantly contributed to CMV research and they all contain a plethora of advantages 
and disadvantages.
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Mice are widely used to study CMV immune functions and pathogenesis. MCMV 
infection resembles at a great extend HCMV biology. C57BL/6 mice alike humans are 
not considered particularly sensitive to CMV infection. Thus, C57BL/6 mice are a suitable 
model to study CMV immune responses and to investigate virus immune evasion 
mechanisms and new therapies in the context of immunocompetent settings. On 
the other hand, the BALB/c mouse strain lacks Ly49-associated NK cell functions and 
it is considerably susceptible to CMV infection [54]. Importantly, BALB/c mice infected 
with high dose MCMV (10^6 plaque-forming units) develop viremia rapidly (day 4-7 
post infection) in several organs (e.g. liver, lungs, spleen, kidney) and direct disease 
manifestation that can even be lethal. Based on the aforementioned characteristics of 
MCMV infection in BALB/c mice, this mouse strain is particularly useful for studying CMV 
disease and testing potential antiviral treatments in the context of immunocompromised 
individuals. Whereas MCMV animal models recapitulate at most HCMV and there is 
increased availability of inbred mouse strains, a limitation of this model is that no vertical 
virus transmission can occur making MCMV a less suitable model to study congenital 
CMV infection [70,71]. 
Recently, humanised mice models have been developed for HCMV research. 
Humanised mice allow direct investigation of HCMV tropism, latency, reactivation and 
antiviral treatments. However, the generation of humanized mice requires technical 
modifications that restricts their use, and the development of immunity to HCMV is 
crippled [72].
Figure 1. Longitudinal analysis of the CMV-specific T cell subsets. During CMV infection two types 
of T cells arise i) Conventional (non-inflationary) T cells which undergo expansion, contraction 
and development of stable memory pools and ii) Inflationary T cell pools which do not contract 
but gradually continue to accumulate in frequency throughout time. Phenotypic characteristics 
of inflationary and non-inflationary T cells are displayed. (Figure adapted from O’Hara, Weltens, 
Klenerman and Arens, Trends in Immunology, 2012; 33:84-90.)
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Unlike mice, guinea pig models enable the study of congenital CMV infection. 
Specifically, guinea pig’s placenta has a single trophoblast layer similar to humans which 
allows the virus to cross the placenta and infect the foetus. Vertical transmission rate in 
quinea pigs is approximately 40-60%, similar to what observed in the human settings. 
Notably, lytic guinea pig CMV (GPCMV) infection of immunocompetent guinea pigs leads 
to clinical disease symptoms such as splenomegaly, peripheral blood mononucleosis 
and self-limited viremia, analogous to what it is observed during HCMV infection. As 
with HCMV, the most important target of humoral immune response following GPCMV 
infection appears to be the gB homolog. This animal model has numerous advantages 
in terms of monitoring disease progression (i.e virologic endpoints) and evaluating 
therapeutic interventions. However, the usage of guinea pigs is less practical when 
it comes to large-scale vaccine testing, studies of the role of the immune system or 
experiments with (long term) follow up as compared to mice or rats [70]. 
Like mice also rats display human-like physiological responses to CMV infection. 
Importantly, almost all human genes noted to be associated with disease have 
known counterparts in the rat genome and extensive literature on rat CMV (RCMV) 
pathogenesis exists [73]. Furthermore, as with the guinea pig model RCMV can cross 
the placenta and infect the foetus, although the exact mechanism is still unclear. 
Recent studies suggest the potential use of the RCMV model to study CMV congenital 
transmission and vaccine development [74,75]. Hence, the rat model is significantly 
advanced compared to the guinea pig and mouse model for studying various aspects 
of CMV pathogenesis, therapeutic interventions and evaluating vaccine candidates for 
CMV congenital infection in humans. However, a major limitation in the study of RCMV 
is like for GPCMV the restricted availability of tools (e.g. monoclonal antibodies) to study 
the role of the immune system [70]. 
Finally, Rhesus macaques infected with Rhesus cytomegalovirus (RhCMV) is studied 
extensively. The RhCMV model showed a strong antigenic relationship with the HCMV 
and the chimpanzee CMV (CCMV) genome [76]. Some important limitations of the use 
of Rhesus macaques is the limited availability of inbred animals, the significantly higher 
cost for breeding and the requirement for specialised facilities and trained personnel 
compared to the rest available CMV animal models [77,78].
CMV AS A VACCINE VECTOR 
Today numerous viral vectors are being exploited for potential clinical application 
against tumour malignancies and a broad range of infectious pathogens. Viral vaccine 
vectors are usually harmless, well tolerated viruses which carry an inserted antigen of 
choice. Viral vectors can be manufactured similarly to conventional vaccines and their 
safety prolife can be easily assessed, which makes them particularly attractive as vaccine 
platforms [79,80]. Modified vaccinia Ankara (MVA) and the adenovirus (Ad) vectors 
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are among the most popular and well investigated vectors which have shown very 
promising results [81-90]. The success of viral vector vaccines relies on their capacity to 
express antigens intracellularly, thereby inducing robust cellular immune responses in 
tissues, and in addition can carry proteins on their surface eliciting humoral (antibody-
mediated) immunity. Early-phase trials have shown that targeted delivery via viral 
vector vaccines is feasible and ample opportunities for further improvement exist. 
The majority of the viral vectors tested do not establish sufficient immunological 
memory, which may be related to their attenuated status [91]. Moreover, T cell 
responses to most viral vectors follow the conventional course which leads mostly to 
the formation of TCM cells. Hence, upon antigen re-encounter, TCM cells first undergo 
a phase of expansion and effector differentiation. In certain instances, this delay in 
the response may be detrimental for the host. Finally, immunological memory wanes 
over time and repetitive stimulation with the same viral vector or targeted antigen is 
required to maintain lifelong immunity [79,92,93]. All these crucial limitations led to 
the conceptualization of an alternative T cell based vaccine model that induces TEM that 
are maintained for a long time. Unlike TCM cells, TEM cells are equipped with immediate 
cytotoxic function and localise in peripheral sites such as the mucus, one of the main 
portals for pathogens entry [94,95]. Hence, a vaccine with the ability to induce and 
maintain a large population of TEM cells is expected to provide rapid effector activity and 
intercept pathogen replication at the most vulnerable phase of infection. TEM -inducing 
vaccine vectors might overcome conventional viral vector vaccine limitations and 
establish long term efficacy. 
CMV elicits a unique T cell repertoire containing both the conventional TCM 
phenotype and the unconventional inflationary TEM -like phenotype. The inflationary 
CMV T cells exhibit no signs of exhaustion and form a promising T cell subset that can 
be exploited in various vaccination settings [66,68,96,97]. Experimental studies with 
RhCMV vectors expressing SIV antigens have been conducted with very encouraging 
outcomes. Specifically, RhCMV-SIV vectors elicited and maintained robust and 
highly polyfunctional TEM cell responses that were widely distributed at all potential 
SIV replication sites and recognized a broad range of MHC class I and II restricted 
epitopes. Remarkably, RhCMV-SIV vaccinated animals manifested an unprecedented 
long term pattern of protection or elite virus control without need for anamnestic 
stimulation [98-100]. 
However, the high seroprevalence rate of CMV among people raises concerns 
about the potential risk for tolerance to CMV-based vaccines due to pre-existing host 
immunity to the virus [101]. CMV has however the capacity to re-infect the same hosts 
[102]. Thus, the ability of CMV to re-infect encourages the use of CMV vector vaccines in 
CMV seropositive individuals as well as the potential for re-use of CMV vectors encoding 
the same or different target antigen in the same individuals. In addition, the ability of 
CMV to arrest and clear overtime residual SIV infection suggests that CMV vector based 
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vaccines can be used in therapeutic vaccine settings against HIV-1 or other chronic 
infectious diseases [103]. 
Finally, CMV-based vector vaccines could synergize with other vaccine platforms 
and potentially enhance overall vaccine efficacy. For instance, vaccines that are 
designed to elicit humoral immune responses could be combined and work together in 
a complementary fashion with CMV vectors designed to elicit robust cytotoxic TEM-based 
cellular responses. Induction of acquisition blocking antibodies and highly effective 
long lasting TEM responses could manage early and long term control of infections and 
cancer [103,104]. Important considerations in the use of wild-type human CMV vectors 
is the persistence and potential pathogenicity of the virus. These issues need to be 
actively evaluated in the upcoming first-in-human clinical studies for CMV vectors. 
SYNTHETIC LONG PEPTIDE VACCINES
Vaccines consisting of multiple overlapping synthetic long peptides (SLPs) containing 
T cell epitopes constitute a very popular and promising prophylactic T cell-based 
immunization strategy. SLPs are chemically stable, can be easily synthesized, lack 
toxicity and oncogenic potential [105]. SLPs are usually designed as approximately 
30-mer peptides overlapping by 10 to 15 amino acids. There is compelling evidence 
that the length of the peptide vaccine regulates the magnitude of the induced T cell 
responses [106,107]. Vaccination with exact MHC-binding peptides, usually 8-10 
amino acids has been tested in many infectious diseases and following combination 
with adjuvants (i.e incomplete Freud adjuvant, montanide ISA-51) managed to protect 
against subsequent pathogen infection. However, a growing body of research evidence 
suggests that vaccination with short peptides is frequently not able to induce memory 
CD8+ T cell responses and immunological tolerance to the immunizing antigens may 
occur [108-111]. Direct comparison of whole protein and short peptide vaccines with 
SLP vaccines has shown that the latter are cross-processed by intracellular routing 
leading to superior CD8+ T cell stimulation [106,112]. Specifically, SLPs cannot bind 
directly to MHC class I molecule but are internalised and processed by specialised APCs 
(i.e DCs) before being presented to either CD4+ or CD8+ T cells. This process results in 
enhanced T cell activation and induction of more effective antigen-specific immune 
responses [107,113]. Hence, vaccination with SLPs is considered more efficient and 
an optimal approach for priming protective immunity compared to short peptides or 
protein vaccines.
Another important advantage of SLP vaccines is that they allow epitope selection 
in vivo based on the animal’s or patient’s own MHC profile. Additionally, multivalent 
SLP vaccines may facilitate simultaneous priming of T cells against multiple epitopes 
stimulating a broad immune response. Markedly, professional APCs can handle large 
pools of long peptides and are capable of properly exercising multiple MHC class I and 
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II peptide epitopes for presentation at the cell surface. Therefore, injection of pools 
of long peptides will lead at the induction of both CD4+ and CD8+ T cells, specific to 
all targeted epitopes, each of which can contribute to pathogen control. However, 
competition among SLPs may occur leading to lower responses.
Importantly, SLPs vaccines alone are poorly immunogenic and need to be combined 
with adjuvants or other immune modulators for sufficient innate immune stimulation 
and T cell induction. In several preclinical models, agonists of TLR3, TLR4, TLR7 and 
TLR9 significantly boosted the size and efficacy of virus/and or tumour-specific T cell 
responses when where combined with SLPs [114-116]. Similarly, in humans, the use 
of SLP vaccine formulations combined with adjuvants have managed to enhance not 
only the magnitude but also the activation status of the T cell response and provided 
promising benefits in preclinical and clinical cancer immunotherapy studies [117-
121]. Although the capacity of the SLP vaccines to induce CD8+ T cell responses is not 
CD4+ T cell ‘’helper’’ dependent, the presence of a helper peptide markedly improves 
the magnitude of the CD8+ T cell response [122]. Furthermore, co-administration 
of agonistic antibodies (anti-OX40, anti-CD40, anti-4-1BB) in vivo to stimulate DC 
activation significantly improved the efficacy of the SLP vaccines in both mice and 
patients [116,123]. 
In conclusion, SLP vaccines has shown promising clinical results in a number of 
published and ongoing clinical trials. Combination of SLPs with other methods, such 
as nanomaterials and chemotherapy, or improved delivery systems is investigated and 
their clinical efficacy remains to be evaluated.
SCOPE AND OUTLINE OF THIS THESIS
The overarching research question studied within this thesis is whether the SLP vaccine 
modality can form an efficacious vaccination strategy against CMV infection. 
In chapter 2, the preventive efficacy of a SLP vaccine comprising MHC class I MCMV 
epitopes that exclusively elicit cytotoxic MHC class I T cell responses against lytic MCMV 
challenge was examined. The quality of the vaccine induced CD8+ T cell responses was 
studied in depth and the vaccine efficacy was evaluated in two mouse strains of CMV 
infection (C57BL/6 and BALB/c mice). This study showed that the breadth of MHC class 
I SLP based vaccines determines the efficacy of the vaccine to significantly reduce 
the viral load. 
Next in chapter 3, an effort was undertaken to optimize the efficacy of the MHC class 
I SLP based vaccine by the addition of CD4+ T cell ‘’help’’ and/or OX40 costimulation. 
SLPs containing MHC class II epitopes from 5 immunodominant MCMV antigens were 
tested individually or in combination with the MHC class I SLPs for possible prophylactic 
effect against lytic MCMV infection in C57BL/6 mice. In addition, OX40 signalling was 
enhanced to optimise vaccine-induced CD4+ T cell responses and to enforce induction 
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of vigorous vaccine-specific CD8+ T cell responses. Vaccination with both MHC class 
I and II SLPs in combination with OX40 costimulation led to superior protection and 
a strong reduction in viral titers after challenge. Subsequently in the appendix section 
of chapter 3, the therapeutic efficacy of the combinatorial MHC class I and II SLP vaccines 
was examined in the C57BL/6 mouse strain.
In chapter 4, studies were undertaken to discover novel HCMV T cell epitopes 
and enlarge the choice of antigens for potential HCMV T cell-based SLP vaccines. In 
silico methods using public immune epitope databases and in vitro screening of T 
cell reactivity against the indispensable for virus replication IE2 HCMV protein was 
performed in PBMCs obtained from healthy CMV seropositive and seronegative mid 
age volunteers. Highly immunogenic areas with MHC class I and II T cell epitopes 
were identified and could be used for vaccination purposes. These results were 
complemented with in silico screening for previously published epitopes to design 
the most promising MHC class I and II IE2-based CMV vaccine. 
In chapter 5, the capacity of the CMV-based viral vector vaccines to protect and/
or treat virus inducing cancer was tested. MCMV-based vaccine vectors expressing 
immunodominant HPV antigens in either inflationary or non-inflationary T cell epitope 
regions were generated. The diversity of the inflationary versus non-inflationary HPV 
specific T cell responses induced was thoroughly examined over time and the vaccine 
effectiveness was evaluated and showed that the level of pre-existing immunity 
determines the efficacy of MCMV-based vaccine vectors.  
Chapter 6 provides a critical narrative overview of literature focused on 
the importance of T cell-based eliciting vaccines in counteracting chronic viral 
infections. The main determinants and mechanistic factors required to shape immunity 
and maximize prophylactic T cell vaccine efficacy were discussed. 
Finally, a general discussion of the core research findings, the main strengths and 
weaknesses and fruitful future research directions are outlined in chapter 7. Important 
emphasis is also placed on whether the knowledge obtained from this thesis can be 
clinically utilised and translated into the design of more potent prophylactic T-cell 
based vaccines.
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ABSTRACT
There is an ultimate need for efficacious vaccines against human cytomegalovirus 
(HCMV), which causes severe morbidity and mortality among neonates and 
immunocompromised individuals. In this study, we explored synthetic long peptide 
(SLP) vaccination as a platform modality to protect against mouse CMV (MCMV) infection 
in preclinical mouse models. In both C57BL/6 and BALB/c mouse strains, prime-booster 
vaccination with SLPs containing MHC class I restricted epitopes of MCMV resulted in 
the induction of strong and polyfunctional (i.e., IFN-γ+, TNF+, IL-2+) CD8+ T cell responses, 
equivalent in magnitude to those induced by the virus itself. SLP vaccination initially 
led to the formation of effector CD8+ T cells (KLRG1hi, CD44hi, CD127lo, CD62Llo), which 
eventually converted to a mixed central and effector-memory T cell phenotype. Markedly, 
the magnitude of the SLP vaccine-induced CD8+ T cell response was unrelated to the T 
cell functional avidity but correlated to the naive CD8+ T cell precursor frequency of each 
epitope. Vaccination with single SLPs displayed various levels of long-term protection 
against acute MCMV infection, but superior protection occurred after vaccination 
with a combination of SLPs. This finding underlines the importance of the breadth of 
the vaccine-induced CD8+ T cell response. Thus, SLP-based vaccines could be a potential 
strategy to prevent CMV-associated disease.
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INTRODUCTION
Human cytomegalovirus (HCMV) contributes substantially to morbidity in 
immunocompromised individuals. Organ or hematopoietic stem cell transplant 
recipients, people infected with HIV and patients with lymphocytic leukaemia 
are particularly vulnerable to HCMV-associated disease [1]. Moreover, congenital 
HCMV infection of unborn and new born children can lead to severe and permanent 
neurological symptoms [2]. Although currently available antivirals for HCMV are able 
to decelerate viral progression, thereby reducing the odds for major side effects, 
they require prolonged treatment periods and are accompanied with significant 
toxicity. Adoptive transfer of HCMV-specific T cells is an alternative treatment modality 
but is costly and laborious. The apparent burden of HCMV-associated disease and 
the paucity of cost-effective measures without side-effects have led to major efforts to 
develop effective HCMV vaccines but unfortunately no licensed vaccines are currently 
available [3, 4].
There is accumulating evidence that effective control of persistent viral infections 
requires the induction of a balanced composition of polyfunctional T cell responses [5]. T 
cell immunity against CMV plays a critical role in controlling the primary viral infection and 
latency [6]. Whereas CMV-specific CD4+ T cells are important during the primary infection 
phase, CD8+ T cells are associated with greater benefits at the persistent infection phase 
and confer superior protection during reactivation and re-exposure [7-9]. Upon CMV 
infection, extra-ordinary large CD8+ T cell responses of diverge phenotype arise. CD8+ T 
cell response kinetics specific to most antigens follow the traditional course comprised 
by expansion after antigen encounter, rapid contraction, long-term maintenance at 
low levels and acquisition of a central-memory phenotype. Interestingly, CD8+ T cell 
responses to certain CMV antigens do not dwindle post-infection but inflate and exhibit 
a polyfunctional effector-memory phenotype [10-13]. In immunocompromised hosts, 
the balance between CMV and cellular immunity is apparently underdeveloped or lost, 
and therefore instigating the development and/or restoration of the T cell compartment 
specific for CMV would be particularly informative.
The overarching aim of this study was to test a potential prophylactic vaccine platform 
against CMV based on synthetic long peptides (SLPs) containing immunodominant T 
cell epitopes. Previously, we reported that in therapeutic settings SLP-based vaccines 
can be successfully designed to stimulate effector and memory T cells against human 
papilloma virus-associated disease in mice and human [14-16]. As the efficacy of 
SLP-based vaccines is directly linked to the phenotypical and functional characteristics 
of the vaccine-induced CD8+ T cell response, we rigorously evaluated SLP-induced T cell 
responses. MCMV-specific SLP vaccines, assessed in two different mouse strains (C57BL/6 
and BALB/c mice), lead to strong polyfunctional T cell responses, and combined SLP 
vaccines targeting different antigens provide a successful vaccine modality to control 
MCMV infection. 
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RESULTS
Prime-boost vaccination with MHC class I-restricted SLPs leads to the induction of 
robust CD8+ T cell responses
To assess the potential of SLP-based vaccines in eliciting protecting CD8+ T cell 
responses against MCMV infection, we designed SLPs containing immunodominant 
MHC class I T cell epitopes from MCMV encoded proteins, and evaluated this vaccine 
platform in two different immunocompetent mouse strains with different susceptibility 
to MCMV; the C57BL/6 strain (MHC haplotype H-2b) and the more MCMV-susceptible 
mouse strain BALB/c (MHC haplotype H-2d) (S1 Table). C57BL/6 mice are less susceptible 
to MCMV infection compared to BALB/c mice because C57BL/6 mice express the NK 
cell-activating receptor Ly49H, which recognizes the MCMV protein m157 at the surface 
of infected cells [17-20].
Mice were vaccinated subcutaneously with SLPs along with the TLR9 ligand CpG as 
adjuvant. The SLP vaccine administration was well tolerated without adverse events. 
At day 7 after SLP immunization, epitope-specific CD8+ T cell responses were detected 
in the blood but a booster vaccination was required for induction of vigorous CD8+ T 
cell responses (Figure 1A and 1B). Prime-boosting with SLP vaccines induced very high 
frequencies of circulating CD8+ T cells against the noninflationary epitopes M45985-993 and 
M57816-824 in C57BL/6 mice, and were even higher than the percentages of the circulating 
MCMV-induced CD8+ T cells at the peak of infection (day 7). Also the response against 
m139419-426, known to be non-inflationary during the early phase after MCMV and at later 
time points as inflationary, is strong. The response against the non-inflationary M45507-515 
epitope in BALB/c mice was even much higher in the SLP-vaccinated group as compared 
to the MCMV infected mice. The frequencies of the circulating CD8+ T cells against 
the inflationary M38316-323 and IE3416-423 epitopes in C57BL/6 mice and the inflationary 
m164257-265 and IE1168-176 epitopes in BALB/c mice were comparable (Figure 1A and 1B). 
SLP vaccines containing MHC class I epitopes may comprise unidentified class II 
epitopes and linear B cell epitopes leading to CD4+ T cell and antibody responses. To 
exclude this possibility, we performed polychromatic intracellular cytokine staining 
with the SLPs and performed SLP-specific antibody ELISAs, respectively (S1 and S2 
Figures). Neither MCMV-specific CD4+ T cells nor peptide specific Abs were detected in 
these assays, indicating that the designed SLPs lead exclusively to antigen-specific CD8+ 
T cell responses and that epitope-specific responses induced by SLP or MCMV can only 
be compared for CD8+ T cells. 
Longitudinal analysis of the antigen-specific CD8+ T cell responses revealed that 
all SLP-induced T cell responses in both mice strains contracted gradually over time 
after the booster immunization (Figure 1B). Two months after the booster vaccination, 
the SLP-induced responses to most epitopes were still clearly detectable in blood. 
During MCMV infection, the epitope-specific CD8+ T cell responses followed a different 
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Figure 1. Prime-boost SLP vaccination provokes the induction of robust CD8+ T cell responses 
analogous to MCMV infection. (A) The magnitude of the CD8+ T cell responses specific to 
the indicated epitopes was determined in blood by MHC class I tetramer staining at day 7 post 
booster vaccination with SLPs and at day 7 post MCMV infection in C57BL/6 mice and in BALB/c 
mice. Representative flow cytometry plots show MHC class I tetramer (Tm) staining within 
the CD8+ T cell population. Numbers represent the percentage of Tm+ cells within the total CD8+ T 
cell population. (B) Longitudinal analysis of the epitope-specific CD8+ T cell responses induced by 
either SLP vaccination or MCMV infection in blood. Data represents mean values ± SEM (n=6 per 
group). (C) Percentages and total numbers of splenic SLP and MCMV-specific CD8+ T cells during 
the acute phase (at day 7 post booster vaccination and day 8 and after MCMV infection) and 
memory phase (at day 60 post booster vaccination and day 60 post MCMV infection) are shown. 
Data represents mean values + SEM (n=6 per group), and are representative of three independent 
experiments. *, P< 0.05; **, P<0.01; ***, P<0.001. 
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course, consistent with previous reports [10, 11]. T cell responses to the non-inflationary 
epitopes M45985-993, M57816-824, and M45507-515 rapidly contracted after the peak response 
and were stably maintained in time while T cell responses to the epitopes M38316-323, 
m139419-426, m164257-265, IE1168-176 and IE3416-423 inflated (Figure 1B). These data indicate that 
the context of epitope expression determines the kinetics of the T cell responses, which 
is uniform for diverse epitopes after SLP vaccination but in the case of MCMV infection 
this results in a dichotomy of responses related to the chronic nature of this infection.
At the peak after the booster SLP immunization (day 7-8), high frequencies of 
epitope-specific CD8+ T cells, analogous to the responses elicited by MCMV virus were 
observed in the spleen (Figure 1C). However, in absolute numbers, MCMV infection led 
to a higher T cell magnitude compared to SLP vaccination, which can be attributed to 
virus-associated inflammation leading to splenomegaly. At the memory phase (day 60), 
MCMV-specific T cell responses to the non-inflationary epitopes were significantly lower 
than the equivalent SLP vaccine-induced responses (Figure 1C). The MCMV-induced 
CD8+ T cell responses to the inflationary epitopes were of higher magnitude compared 
to those induced by SLP vaccination.
Taken together, these results show that prime-boost vaccination with SLP vaccines 
containing MHC class I MCMV epitopes elicit in mouse strains with different susceptibility 
to MCMV high percentages of effector and memory CD8+ T cells that contract gradually 
in time. 
The T cell precursor frequency determines the magnitude of SLP vaccine-induced 
CD8+ T cell responses 
Next, we aimed to dissect the underlying mechanisms of the relatively low responses 
to some of the SLPs (i.e. M38 and IE3 in C57BL/6; M45 in BALB/c) compared to the other. 
First, we endeavoured to alter the SLP sequences by altering the C-terminal cleavage, 
which may improve the immunogenicity (S3 Figure). However, the altered M38316-323 
SLP did not exhibit a significant improvement in the SLP-induced T cell response whilst 
the altered SLP containing the IE3416-423 epitope elicited responses were actually reduced. 
Then we questioned if the differences in the magnitude of the T cell responses 
triggered by the various single SLP vaccines might be related to the functional avidity 
of the T cells, which is determined by the affinity of the peptide for MHC and the TCR 
affinity for the peptide-MHC complex (Figure 2A and 2B). The SLPs elicited T cells with 
different levels of functional avidity but no correlation was found with the strength of 
the CD8+ T cell response. Moreover, in both C57BL/6 and BALB/c mice the functional 
avidity of the T cells, elicited either by SLP vaccines or MCMV infection, were remarkably 
similar and remained stable in time as they were similar during the acute and memory 
phase of response. Thus, differences in TCR affinity are not involved in the observed 
difference in the magnitude of the T cell responses. 
The data presented above illustrated that factors other than peptide-MHC/TCR 
affinity are implicated in shaping the strength of SLP-induced T cell responses. Recently, 
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it was shown that the precursor frequency of naive T cell populations can predict 
the immunodominance hierarchy of viral epitope specific CD8+ T cell responses [21]. To 
test whether the precursor frequency is predictive for the magnitude of SLP-induced T 
cell responses we determined the precursor frequency of all the epitopes included in 
this study in naive C57BL/6 and BALB/c mice (Figure 2C). In C57BL/6 mice, the precursor 
frequencies for the M45985-993 and M57816-824 epitopes were among the highest followed 
Figure 2. The T cell precursor frequency but not the functional avidity of the SLP vaccine-
induced CD8+ T cells predicts the magnitude of the response. (A) Splenocytes from SLP 
vaccinated (n=4-5 mice per epitope) and MCMV infected C57BL/6 mice (n=4-5 mice) were 
isolated during the acute (day 8 post booster SLP vaccination and MCMV infection) and memory 
(day 60 post booster SLP vaccination and MCMV infection) phase and were restimulated 
with various peptide concentrations in the presence of brefeldin A. The percentage of IFN-γ 
producing CD8+ T cells was measured and normalized to the response at the highest peptide 
concentration. (B) Similar description as in (A) for experiments performed with BALB/c mice. Note 
that the M45507-515 CD8
+ T cell response during MCMV infection was too low to obtain accurate 
results. Shown are the functional avidity curves and are representative of at least 2 independent 
experiments. Data represents mean values. (C) Absolute numbers of epitope specific T cell 
precursors present in spleen and lymph nodes of naive C57BL/6 and BALB/c mice were determined 
by tetramer staining. Each symbol represents an individual mouse. Data represents mean values ± 
SEM (n = 4-6 per group). Experiments were performed twice with similar outcome.
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by the precursor frequencies to the m139419-426 epitope. The lowest precursor frequencies 
were detected to the M38316-323 and IE3416-423 epitopes, confirming a previous report 
[22]. In BALB/c mice, the highest precursor frequencies were observed for the m164257-
265 and IE1168-176 epitopes whereas the frequency of M45507-515 specific T cells was lower 
(Figure 2C). Markedly, the average level of the precursor frequency of each epitope-
specific CD8+ T cell population was proportional to the expansion of the antigen-specific 
populations found in mice following either SLP immunization or MCMV infection. 
Together, these results indicate that naive precursor frequencies rather than TCR avidity 
determine the magnitude of SLP vaccine-mediated CD8+ T cell responses.
Phenotypical and functional characteristics of SLP-induced CD8+ T cells 
To assess the phenotypical and functional quality of MCMV-specific CD8+ T cells induced 
by either the SLPs or the virus, we determined the formation of the diverse T cell subsets 
that develop after antigenic challenge. Early after the booster, SLP vaccination resulted in 
the induction of a highly activated CD8+ T cell subset exhibiting an effector-like phenotype 
(CD62Llo, CD44hi, CD127lo, KLRG1hi), which completely resembled the MCMV-specific T 
cell phenotype during the acute phase of the infection (Fig 3A and 3B). In the memory 
phase, both SLP- and MCMV-induced T cell phenotypic traits diverged (Figure 3C and 
D). All SLP-induced CD8+ T cells exhibited a fairly mixed phenotype sharing features 
of both central-memory T cells (CD62Lhi, CD44lo, CD127hi, KLRG1lo), effector-memory 
T cells (KLRG1hi, CD44hi, CD127lo, CD62Llo) but also an intermediate phenotype (i.e. 
KLRG1hi, CD127hi). As expected, during MCMV infection, the non-inflationary M45985-993, 
M45507-515 and M57816-824-specific CD8
+ T cells gained a predominant central memory-like 
phenotype while the inflationary M38316-323, m139419-426, IE3416-423, m164257-265 and IE1168-176-
specific T cells appeared mostly effector-memory like. 
To assess the cytokine profiles of the SLP-induced CD8+ T cells, we performed 
intracellular cytokine staining for IFN-γ, TNF and IL-2 and compared these to MCMV-
induced T cells. At the peak response after booster vaccination, SLP-induced T cells 
consisted mainly of single IFN-γ and double IFN-γ/TNF producing populations (Figure 
4A and S4 Figure). The cytokine producing traits of the MCMV-induced effector CD8+ 
T cells matched in general with the SLP-elicited T cells. Except relatively more single 
IFN-γ producing CD8+ T cells after MCMV infection compared to SLP vaccination were 
found in the T cell populations reactive to the epitopes IE3416-423, IE1168-176, M45507-515 and 
m164257-265.
At the memory phase, the SLP-specific CD8+ T cells gained the ability to co-produce 
the three cytokines, at the expense of single cytokine producing cells (Figure 4B and S4 
Figure). This gain in triple cytokine production (IFN-γ/TNF/IL-2) during MCMV infection 
is mainly observed in the non-inflationary CD8+ T cells. Both during the acute and 
memory phase, the percentage of the total CD8+ T cell population producing IFN-γ, 
either in case of SLP vaccination or MCMV infection, corresponded to the percentage of 
MHC class I tetramers, indicating full differentiation of the elicited T cells. 
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Figure 3. Phenotypic heterogeneity of SLP vaccine-induced CD8+ T cells. (A) Peripheral blood 
from either SLP immunized (day 7 after booster peptide vaccination) or MCMV infected C57BL/6 
and BALB/c mice (day 7 post infection) were stained with MHC class I tetramers and for cell surface 
molecules. Representative plots show CD127 versus KLRG1 expression on tetramer-positive CD8+ 
T cells. (B) Cell-surface characteristics of tetramer-positive CD8+ T cells in blood and spleen at 
day 8 post booster SLP vaccination and day 8 after MCMV infection. (C) Peripheral blood from 
either SLP immunized (day 60 after booster peptide vaccination) or MCMV infected C57BL/6 and 
BALB/c mice (day 60 post infection) were stained with MHC class I tetramers and for cell surface 
molecules. Representative plots show CD127 versus KLRG1 expression on tetramer-positive CD8+ 
T cells. (D) Cell-surface characteristics of antigen-specific CD8+ T cells in blood and spleen at day 
60 post booster SLP vaccination and day 8 after MCMV infection. Data represents mean values, 
and are representative of three independent experiments (n=6 per group). 
38 | Chapter 2
A hallmark of memory T cells is the ability to undergo secondary expansion upon 
antigenic challenge [23]. To assess this property of vaccine-induced memory T cells, 














































































































































































































Figure 4. SLP vaccination elicits polyfunctional CD8+ T cells. Following SLP vaccination or MCMV 
infection the cytokine polyfunctionality of splenic CD8+ T cells was determined after peptide 
restimulation. Representative plots show IFN-γ versus TNF production at (A) day 8 (acute phase) 
and (B) day 60 (memory phase) post booster vaccination and post MCMV infection. Pie charts 
depict the percentages of the single (IFN-γ), double (IFN-γ/TNF) and triple (IFN-γ/TNF/IL-2) 
cytokine producers of each antigen-specific T cell population upon peptide stimulation. Data 
represents mean values, and are representative of three independent experiments (n=4-5 per 
group). Statistics of the results depicted in these pie charts are reported in S4 Fig. 
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memory M45985-993 and m139419-426-specific CD8
+ T cells from SLP vaccinated and MCMV 
infected mice were isolated and transferred into naive recipient mice, which were 
subsequently challenged with MCMV (Figure 5). SLP-induced M45985-993 and m139419-426-
specific T cells expanded; albeit to a lesser extend as compared to the MCMV-induced 
(Figure 5). The MCMV-elicited M45985-993-specific T cells exhibited, corresponding to 
their central-memory phenotype, a superior capacity in expansion as compared to 
the MCMV-elicited m139419-426-specific T cells with an effector-memory phenotype. 
Of note, the expansion of the SLP-induced M45-specific T cells was comparable to 
the m139-specific T cells induced by MCMV, although the phenotype of SLP-induced 
cells were more central-memory like. This indicates that the instruction that T cells 
receive in different settings can result in cells with a different expansion potential 
despite a seemingly similar phenotype based on markers for central/effector memory 
cells. All together we conclude that SLP-based vaccines induce a heterogeneous pool 
of memory T cells with a secondary expansion potential that is somewhat lower as 
compared to memory T cells elicited by virulent virus. 
Combinatorial SLP vaccination confers superior efficacy against CMV infection
The various SLP vaccine formulations were evaluated for their capacity to confer 
protection against MCMV challenge (at day 60 after booster vaccination). In C57BL/6 
Figure 5. Secondary expansion potential of SLP-induced CD8+ T cells upon MCMV challenge. 
M45985-993 and m139419-426 epitope specific CD8
+ T cells were isolated from the spleen at day 60 after 
booster vaccination and infection of SLP vaccinated and MCMV infected CD45.1 mice. 1 × 104 
antigen-specific CD8+ T cells were adoptively transferred into naive C57BL/6 (CD45.2) recipient 
mice. Recipient mice were subsequently infected i.p. with 5 × 104 PFU MCMV-Smith. The total 
numbers of the donor derived M45985-993 and m139419-426 CD8
+ T cells were determined in the spleen 
at day 5 post challenge. Data represent mean values + SEM (n=5). Experiments were performed 
twice with similar outcome. *, P<0.05; **, P<0.01.
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Figure 6. Efficacy of single SLP vaccines against acute MCMV infection. Unvaccinated (naive), 
SLP vaccinated and MCMV infected C57BL/6 and BALB/c mice were challenged at day 60 post 
vaccination/infection with 5 × 104 PFU and 5 × 103 PFU salivary gland-derived MCMV Smith, 
respectively. At day 5 post challenge, spleen, liver, and lungs were isolated and the viral genome 
copies were determined by qPCR. The viral titres of individual (A) C57BL/6 and (B) BALB/c mice are 
depicted (n=5-8 per group). Mean ± SEM is indicated. Dashed line represents the detection limit 
as measured in naive mice. Experiments were performed twice with similar outcome. *, P< 0.05; 
**, P<0.01; ***, P<0.001; ns, not significant.
mice, the viral load of unvaccinated (naive) mice challenged with MCMV was found 
to be significantly higher in spleen, liver and lungs, when compared to the viral load 
of MCMV re-challenged mice that successfully controlled a previous MCMV infection, 
indicating that pre-existing immunity to MCMV can clearly reduce the viral load upon 
re-infection (Figure 6A). All the different SLP vaccines resulted in a reduction in viral 
load in the spleen compared to unvaccinated mice, albeit less effective when compared 
to MCMV infected mice. Mice vaccinated with the SLPs containing the M38316-323 and 
m139419-426 epitopes display a significant reduction in viral titres in the liver and lungs. 
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Also, the M57816-824 and IE3416-423 epitope containing SLPs were capable in reducing 
the viral replication in the liver after MCMV challenge, albeit to a lesser extent 
(Figure 6A). 
Re-challenge of MCMV infected BALB/c mice resulted in substantial protection 
of the m164257-265 epitope containing SLP vaccine in spleen and liver (Figure 6B). 
The M45507-515 and IE1168-176 epitope containing SLPs however did not induce protective 
immunity in vaccinated mice. These results indicate that certain SLPs but not all have 
the potency to elicit protective immunity against virus challenge, and that this protection 
is not necessarily correlating to the size of the SLP-induced CD8+ T cell response.
Since vaccination with the m139419-426 and M38316-323 epitope containing SLPs was 
accompanied with some reduction of the viral load, we examined in C57BL/6 mice 
whether vaccination with these two, or even more, SLPs combined were able to exceed 
the protection efficacy of single SLP immunization. Strong and long-lived peptide-
specific CD8+ T cell responses were measured in mice vaccinated with the mixture of 
the m139 SLP plus the M38 SLP and with a mixture of all 5 SLP vaccines (Figure 7A). 
Notably, the T cell response against each peptide epitope with the combined SLP 
vaccines was lower as compared to single SLP vaccination (except for the m139-specific 
response), indicating that competition among antigen-specific CD8+ T cell populations 
can occur in multivalent vaccines. Especially, altered were the responses to the epitopes 
in M57 and IE3 because these were not boosted (Figure 7A). Such competition among 
T cells during boosting has also been observed after viral infection [24]. The kinetics of 
the combined SLP vaccine-induced T cell responses were found similar to single SLP 
vaccines, and the phenotype (Figure 7B) and the cytokine polyfunctionality of the T 
cells as well (S5 Figure). 
At day 60 post booster vaccination, mice were challenged with MCMV and 5 days 
later viral titres were measured in different organ tissues. The efficacy of the combined 
SLPs to protect upon acute MCMV challenge was remarkably improved compared 
to the single SLP vaccines, as all mice that received a mixed SLP vaccine exhibited 
significant reduction in the viral load, especially in the liver (Figure 7C), suggesting 
that the breadth of the response or the magnitude of the total anti-viral response is 
important. Remarkably, the combination of the m139 SLP with the M38 SLP was as 
efficacious as the combination with all 5 SLPs. To assess if superior viral control was 
related to the breadth of the response, we adoptively transferred 1 × 104 m139 SLP-
induced CD8+ T cells, 1 × 104 M38 SLP-induced CD8+ T cells, or an equal total number 
of a pool of both m139 (0.5 × 104) and M38 (0.5 × 104) SLP-induced CD8+ T cells in naive 
recipient mice (Figure 7D). The transfer of SLP-induced CD8+ T cell populations with 
a dual specificity resulted in a significant reduction in viral titres, while the transfers of 
equal amounts of T cells with single specificity did not. Thus, combinations of at least 
two distinct SLP vaccines have an increased potency to protect compared to single SLP 
vaccines, indicating that the breadth of the vaccine-induced CD8+ T cell responses plays 
a crucial role in anti-viral immunity. We conclude that vaccination with single SLPs can 
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Figure 7. Enhanced efficacy against CMV infection by combinatorial use of distinct SLP vaccines. 
C57BL/6 mice were vaccinated with single m139 and M38 SLPs, a combination of these SLPs, and 
a mixture of five different (M45, M57, m139, M38, IE3) SLPs a mixture of five different SLPs. (A) 
Kinetics of the antigen-specific CD8+ T cells in the blood at day 7 post booster vaccination. Data 
shown are mean values ± SEM (n=8) (B) Phenotypic profile of the (combinatorial) SLP vaccine-
induced CD8+ T cells in blood at day 7 (acute) and day 60 (memory) post booster vaccination. 
Data represent mean values (n=8). Experiment was performed twice with similar outcome. 
(C) Unvaccinated (naive), (combined) SLP vaccinated and MCMV infected C57BL/6 mice were 
challenged 65 days post booster-vaccination/infection with 5 × 104 PFU salivary gland-derived 
MCMV Smith. At day 5 post challenge, liver, lungs and spleen were isolated and the viral genome 
copies were determined by qPCR. The viral titres of individual mice are depicted (n=6-8 per group). 
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be applied as a prophylactic vaccine strategy against CMV infection, but vaccination 
with combinations of different SLPs serve as a superior vaccine technology platform 
against viral challenge. 
DISCUSSION
In this study, we report that SLP-based vaccines are an effective modality against CMV 
infection. In a prime-boost vaccine regimen, SLPs containing single MCMV epitopes 
are highly immunogenic in both C57BL/6 and BALB/c mice, and generate long-lasting 
polyfunctional CD8+ T cell responses. Our study revealed three key findings. First, 
the magnitude and phenotype of the SLP-induced T cell responses initially resemble 
those evoked by a real viral infection. Second, the magnitude of the SLP-induced 
T cell response strongly correlated to the naive T cell precursor frequency, and third 
the protection against viral infection by SLP-induced memory CD8+ T cells was most 
pronounced when vaccination was performed with combinations of distinct SLPs 
leading to an increased breadth of the antigen-specific T cell response. 
In the last decades many vaccine strategies such as attenuated virus, DNA 
constructs, protein, and virally vectored vaccines targeting HCMV have been 
developed [3, 4]. The focus of most of these vaccines was to generate protective 
antibodies. Our finding that SLP-based vaccines that solely provoke CD8+ T cell responses 
are efficacious suggests that the design of more efficient vaccines against CMV should 
incorporate the induction of CD8+ T cell immunity. Although we observed some epitope 
competition among SLP vaccine-induced CD8+ T cell responses, we anticipate that 
inclusion of CD4+ T cell and B cell epitopes will further improve the vaccine efficacy 
given that CD4+ T cells and antibodies have also antiviral actions against CMV. Moreover, 
SLP-based vaccines allow further refinement by different prime-booster regimens and 
by combinations with adjuvants, immunomodulatory antibodies or other vaccine 
platforms [25]. Conceivably, this will positively impact the phenotype and effectivity of 
the vaccine-induced T cells. 
(D) Splenic antigen-specific CD8+ T cells were sorted at day 60 post booster-vaccination of single 
m139419-426 or M38316-323 SLP vaccinated CD45.1 mice.  1 × 10
4 m139419-426, 1 × 10
4 M38316-323 or 0.5 × 
104 m139419-426 plus 0.5 × 10
4 M38316-323 CD8
+ T cells were adoptively transferred into naive CD45.2 
recipient mice. Subsequently, recipient mice were infected i.p. with 5 × 104 PFU MCMV-Smith. At 
day 5 post infection spleen and liver were isolated and the viral genome copies were determined 
by qPCR. The viral titres of individual mice are depicted (n=6 per group). Mean ± SEM is also shown. 
The detection limit was below 1000 genome copies as measured in naive mice. Experiments were 
performed twice with similar outcome. Statistical difference is indicated (*, P<0.05; **, P<0.01; 
***, P<0.001; ****, P<0.0001; ns, not significant) as compared to the unvaccinated group unless 
otherwise indicated.
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As to date, the high CD8+ T cells responses elicited with the SLP vaccines encoding 
MCMV epitopes have not been observed before with other SLPs including those 
containing epitopes of human papilloma virus (HPV) [14], lymphocytic choriomeningitis 
virus (LCMV) [26], influenza [27] or model antigens [28]. This may be explained by 
the relatively high precursor frequency of T cells responding to some of the MCMV 
epitopes. Our study indicates that it is of interest for T cell-based vaccines to determine 
the antigen-specific T cell precursor frequencies as these correlate to the magnitude 
of the vaccine-induced antigen-specific response, allowing the selection of epitopes 
generating the most robust responses. This knowledge can be very useful for 
development of vaccines that are based on selection of epitopes. Nevertheless, 
the magnitude of the vaccine-induced T cell response appears not necessarily to 
correlate to protective immunity but seems to depend also on the specificity. For 
example, in C57BL/6 mice, the large vaccine-elicited responses to the M45985–993 and 
M57816-824 epitopes do not provide as good protection as the seemingly lower response 
to the M38316–323 epitope. Similarly, in BALB/c mice the m164 SLP confers immunity in 
liver and spleen whereas the IE1168-176  epitope containing SLP, which is analogous in 
magnitude, does not show protective effects. Previous studies using short peptide or 
DNA vaccination also reported that the strength of the vaccine-induced IE1-specific 
CD8+ T cell response does not necessarily correlate to protection [29-31], suggesting 
that the quality of the vaccine-induced T cell is more decisive.
Dissimilarities in transcription of viral genes [32], which may even vary in different 
tissues, as well as the efficiency of peptide processing and presentation at the cell 
surface, may also be implicated in the differential efficacy of the T cell response to each 
particular epitope to confer resistance to MCMV. In this respect, it is of interest to note 
that SLP vaccines containing “inflationary” epitopes (i.e., M38 and m139) elicit better 
protection as compared to the non-inflationary epitopes. This may relate to differences 
in the presentation of the inflationary epitopes as compared to the non-inflationary 
epitopes by infected cells and/or by (cross-presenting) APCs. 
An important requirement for memory inflation is chronic antigenic exposure [12]. 
The fact that SLPs do not elicit inflation suggests that SLPs are broken down in 
such a manner that epitopes are not presented over a long period of time as occurs 
during persistent CMV infection. Other factors important for memory inflation during 
CMV infection, such as dependence on certain T cell costimulatory interactions 
(e.g., CD27-CD70 [33]), are likely also not in place at late time points post SLP 
vaccination. In addition, a characteristic feature of inflationary T cells is their 
predominant effector-memory like phenotype. The SLP vaccine-induced T cells are not 
mostly effector-memory like, as may be expected because of the apparent absence of 
memory inflation. Although the expansion of the SLP-induced CD8+ T cells seems to be 
somewhat negatively influenced as compared to virus-induced T cells, it remains to be 
determined whether protection on a per-cell basis is influenced as well. Nevertheless, 
the SLP-induced T cells were well capable to reduce the viral load upon viral challenge, 
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especially when a mixture of distinct SLPs was used for vaccination. The somewhat lesser 
expansion potential of the SLP-induced T cells might relate to some of the differences 
in the phenotype of the SLP and MCMV-elicited T cells. Although the effector T cells 
induced by either SLP boost vaccination or MCMV infection had an analogous 
phenotype (KLRG1hi, CD44hi, CD127low, CD62Llow, IL2+/-) and cytokine profile, the memory 
T cells elicited by SLPs displayed a mixed profile of effector-memory (KLRG1hi, CD127lo), 
central-memory (KLRG1lo, CD127hi) and double-positive T cells (KLRG1hi, CD127hi). 
In contrast, MCMV infection induces a more polarized phenotype: either a central-
memory phenotype (mainly non-inflationary responses) or an effector-memory 
phenotype (mainly inflationary responses). Whether a lack of CD4+ T cell helper 
signals [34] or a lack of virus-associated inflammatory signals [26] is responsible for 
the observed SLP vaccine-associated phenotype and secondary expansion potential 
remains to be examined in future studies.
We showed that the efficacy of SLP vaccines to protect against MCMV is primarily 
driven by the breadth of the CD8+ T cell responses rather than the magnitude of 
the individual SLP vaccine-induced T cell responses. A possible explanation is that viral 
infected cells are to a certain degree resistant to CD8+ T cell mediated killing due to 
sophisticated immune evasion mechanisms including downmodulation of MHC class I 
molecules and prevention of apoptosis [35-37]. Accordingly, it has been estimated that 
one effector CD8+ T cell kills only 2-16 MCMV-infected cells per day and the probability 
of death of infected cells increases for those contacted by more than two CTLs, which 
is indicative of CTL cooperation [38]. Our study suggests that multiple encounters 
with cytotoxic CD8+ T cells with different specificity result in more effective killing of 
infected cells. 
Overall, this study provided evidence that SLP-based vaccines eliciting memory 
CD8+ T cell responses have protective effects against acute MCMV infection with 
respect to lowering the viral load in tissues. These promising results highlight 
the need for additional studies to elucidate the role of vaccine-induced T cells against 
CMV and other persistent viral infections. 
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MATERIALS AND METHODS
Mice
C57BL/6 mice and BALB/c mice were purchased from Charles River Laboratories 
(L’Arbresle, France). CD45.1 (Ly5.1) congenic mice on a C57BL/6 background were 
obtained from The Jackson Laboratory. Mice were maintained under specific-pathogen-
free conditions at the Central Animal Facility of Leiden University Medical Center 
(LUMC), and were aged 8-10 weeks at the beginning of each experiment. The mice did 
not undergo any immunosuppressive treatments and were fully immunocompetent.
Ethics Statement
All animal experimental protocols were approved by the LUMC Animal Experiments 
Ethical Committee in accordance with the Dutch Experiments on Animals Act and 
the Council of Europe (numbers 13156 and 14187). 
Virus production, infections and determination of viral load
MCMV virus stocks were prepared from salivary glands of BALB/c mice infected with 
MCMV-Smith (American Type Culture Collection (ATCC)). The viral titres of the produced 
virus stocks were determined by viral plaque assays with 3T3 mouse embryonic 
fibroblasts (MEFs) (ATCC). Age- and gender-matched C57BL/6 mice were infected with 
5 × 104 PFU MCMV, and age- and gender-matched BALB/c mice with 5 × 103 PFU MCMV. 
Viruses were administered intraperitoneally (i.p) in a total volume of 400 ml in PBS. 65 
days post-booster vaccination or infection, SLP vaccinated or MCMV infected mice were 
(re)-challenged with 5 × 104 PFU MCMV. Determination of viral load was performed by 
real-time PCR as described previously [39].
Peptides synthesis and vaccination
Short (9-10 aa) and long (20-21 aa) peptides containing MHC class I-restricted T cell 
epitopes from MCMV encoded proteins in C57BL/6 and BALB/c mice were produced 
at the peptide facility of the LUMC (peptide sequences are described in S1 Table). 
The purity of the synthesized peptides (75-90%) was determined by HPLC and 
the molecular weight by mass spectrometry. Synthetic long peptide (SLP) vaccinations 
were administered subcutaneously (s.c.) at the tail base by delivery of 50 mg SLP and 20 
mg CpG (ODN 1826, InvivoGen) dissolved in PBS in a total volume of 50 ml. Booster SLP 
vaccinations were provided after 2 weeks. Vaccination with a mixture of SLPs was done 
with 50 mg of each SLP and 20 mg CpG.
Flow cytometry
Cell surface and intracellular cytokine stainings of splenocytes and blood lymphocytes 
were performed as described [40]. For examination of intracellular cytokine production, 
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single cell suspensions were stimulated with short peptides for 5 h in the presence of 
brefeldin A or with long peptides for 8 h of which the last 6 h in presence of brefeldin 
A (Golgiplug; BD Pharmingen). MHC class I tetramers specific for the following MCMV 
epitopes: M45985–993, M57816–824, m139419-426, M38316–323, and IE3416–423 in C57BL/6 mice and 
M45507–515, m164257-265 and IE1168-176 in BALB/c mice were produced as reported [41]. 
Fluorochrome-conjugated mAbs were purchased from BD Biosciences, Biolegend 
or eBioscience. Flow cytometry gating strategies are shown in S6 Fig. Samples were 
acquired with the LSRFortessa cytometer (BD Biosciences) and analysed with FlowJo-
V10 software (Tree star). 
T cell functional avidity assay
A peptide dose-response titration was performed to determine and compare the TCR 
avidity of the CD8+ T cells induced after SLP vaccination and MCMV infection at the acute 
and memory phase. In brief, spleenocytes were stimulated with various concentrations 
of short peptide in presence of 2 μg/ml brefeldin A for 5 h at 37°C. Subsequently, cell 
surface staining and an intracellular IFN-γ staining were performed. Responses were 
analysed using the same approach as described above.
Antibody detection by ELISA
Blood was collected from the retro-orbital plexus and after brief centrifugation, sera were 
obtained and stored at −20ºC. Specific immunoglobulin levels in serum were measured 
by ELISA as described [39]. Briefly, Nunc-Immuno Maxisorp plates (Fisher Scientific) 
were coated either with 2 μg/ml SLPs or with MCMV-Smith in bicarbonate buffer, and 
after blocking with skim milk powder (Fluka BioChemika) diluted sera were added. Next, 
plates were incubated with HRP-conjugated antibodies (SouthernBiotech) to detect 
different Ab isotypes. Plates were developed with TMB substrate (Sigma Aldrich) and 
the colour reaction was stopped by addition of 1M H2SO4. To serve as a positive control, 
a peptide from the M2 protein (eM2) of influenza A virus with identified ability to induce 
antibodies and corresponding serum was used. Optical density was read at 450 nm 
(OD450) using a Microplate reader (Model 680, Bio-Rad). 
Determination of the T cell precursor frequency 
To determine the endogenous naive precursor frequency of MCMV-specific CD8+ T 
cell populations in C57BL/6 and BALB/c mice, enrichment assays of antigen-specific 
CD8+ T cells were performed as described [42]. In short, single cell suspensions were 
generated from pooled spleen and lymph nodes (mesenteric, inguinal, cervical, 
axillary, and brachial) of individual mice. Cells were stained with PE and APC-labelled 
MHC class I tetramers for 0.5 h at RT, then washed, labelled with anti-PE and anti-APC 
microbeads (Miltenyi Biotec), and passed over a magnetized LS column (Miltenyi 
Biotec). The tetramer-enriched fractions were stained with fluorochrome labelled Abs 
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against CD3 (clone 500A2), CD4 (clone L3T4), CD8 (clone 53-6.7) for 30 min at 4°C, 
and subsequently analysed. Samples were acquired with the LSRFortessa cytometer 
(BD Biosciences).
Adoptive transfers
The expansion capacity and vaccine efficacy of SLP vaccine and/or MCMV-induced 
antigen-specific CD8+ T cells was determined by adoptive transfers. Splenic CD8+ T cells 
from chronically (day 60) infected and SLP vaccinated CD45.1+ mice were enriched with 
magnetic sorting using the CD8+ T cell isolation kit in accordance with the manufacturer’s 
protocol (Miltenyi Biotec). Next, cells were stained with MHC class I tetramers and with 
fluorochrome labelled antibodies against CD3 and CD8. Tetramer positive CD8+ T cells 
were sorted using a FACSAria II Cell Sorter (BD Biosciences) and 1 × 104 tetramer+ CD8+ T 
cells were transferred (retro-orbital in a total volume of 200μl in PBS) into naive CD45.2+ 
C57BL/6 recipients. Recipients were subsequently (2 h later) infected with 5 × 104 PFU 
MCMV.  At day 5 post viral challenge the viral titres were determined by qPCR and 
the number of donor-specific CD8+ T cells by flow cytometry. 
Statistical analyses
Statistical significance was assessed with Student’s t-test or ANOVA using GraphPad 
Prism software (GraphPad Software Inc., USA). The level of statistical significance was 
set at P<0.05.
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Supplementary Figure 1. MHC class I SLP vaccines do not elicit activation of CD4+ T cells. 
(A) C57BL/6 and (B) BALB/c mice were vaccinated SLPs, and at day 8 following vaccination 
the intracellular cytokine production by CD8+ and CD4+ T cells was determined after restimulation 
with long peptide. Representative plots show IFN-γ versus TNF production of CD8+ and CD4+ T 
cells of (A) M57816-824 and IE3416-423 epitope containing SLP vaccinated C57BL/6 mice, and of (B) 
m164257-265 and IE1168-176 epitope containing SLP-vaccinated BALB/c mice. No peptide controls and 
naive mice were used as negative controls. IFN-γ and TNF reactivity was only observed in CD8+ T 
cells. Similar data were observed for the other SLPs (i.e., M45, m139 and M38 SLPs in C57BL/6 mice 
and M45 SLP in BALB/c mice). Experiments were performed twice with similar outcome (n=3-4 
mice per group).
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Supplementary Figure 2. Vaccination with MHC class I restricted SLPs does not lead to 
the induction of peptide-specific Abs. At day 60 post booster SLP vaccination or MCMV infection 
serum samples were obtained from C57BL/6 and BALB/c mice. ELISA plates were coated with 
either SLP (A, C) or MCMV (B, D) and detection of peptide specific Ab (including IgG, various 
IgG subtypes, and IgE) in the serum was assessed. To serve as a positive control, a peptide with 
known ability to induce antibodies and corresponding serum was used. Optical density values 
were measured at 450nm. Each symbol represents an individual mouse. Mean value ± SEM (n=3-4 
mice per group) is indicated. Experiments were performed twice with similar outcome. 
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Supplementary Figure 3. Epitope alteration at the C-terminus did not improve 
the immunogenicity. Alterations of the C-terminus sequence residues of the M38316-323 and 
IE3416-423 epitope containing SLPs was performed and their capacity to induce epitope-specific 
CD8+ T cell responses was tested and compared to the unaltered SLPs. MHC class I tetramer 
staining on blood was performed to assess the immunogenicity of the M38316-323 and IE3416-423 
peptides on C57BL/6 mice (n=4). Data represent mean values ± SEM (n=4 mice/group). *, P<0.05; 
**, P<0.01; ns, not significant.
Supplementary Figure 4. SLP vaccination elicits polyfunctional CD8+ T cells. Statistical analysis 
of the results depicted in the pie charts of Fig. 4. The cytokine polyfunctionality of the splenic 
CD8+ T cells elicited after SLP vaccination or MCMV infection was determined after 5 hours in 
vitro restimulation with short peptides. Graphs show the percentages of the single (IFN-γ), double 
(IFN-γ/TNF) and triple (IFN-γ/TNF/IL-2) cytokine producers of each antigen-specific T cell population 
upon peptide stimulation. Data represents mean values + SEM, and are representative of three 
independent experiments (n = 4-5 per group). *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001; ns, 
not significant.
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Supplementary Figure 5. Analysis of the magnitude and functionality of the multivalent SLP 
vaccine-induced CD8+ T cells. C57BL/6 mice were prime-boost vaccinated with a mixture of 5 SLPs. 
The cytokine production capacity of the splenic SLP vaccine-induced CD8+ T cells was examined 
by intracellular cytokine staining at day 8 (acute phase) and 60 (memory phase) after booster 
vaccination. Pie charts depict the percentages of the single (IFN-γ), double (IFN-γ/TNF) and triple 
(IFN-γ/TNF/IL-2) cytokine producers of each antigen-specific T cell population after 5 hours in vitro 
restimulation with short peptide. Data represents mean values, and are representative of three 
independent experiments (n = 6 mice per group). 
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Supplementary Figure 6. Flow cytometry gating strategy. (A) Representative plots show 
the gating strategy to detect MHC class I tetramer positive cells in blood and spleen. In sequential 
gating, cells were first gated on lymphocytes (forward scatter vs. side scatter), then singlets 
(FSC-A vs. FSC-H), followed by viability (FSC-A vs. 7-AAD). Next, live cells were analysed for 
the expression of CD3 and CD8 while cells positive for CD4 were excluded. MHC class I tetramer 
positive cells (CD8 vs. Tm) were analysed for the expression of KLRG1, CD44, CD127 and CD62L 
surface markers. (B) Gating strategy for intracellular cytokine staining. Utilizing a sequential 
gating analysis, cells were initially gated on lymphocytes (FCS-A vs. SCS-A) and singlets (FCS-A vs. 
FSC-H). Next, cells were analysed for the expression of CD3 and CD8 while cells positive for CD4 
were excluded. IFN-γ producing CD8+ T cells were further analysed for expression of TNF and IL-2.
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ABSTRACT
There is an imperative need for effective preventive vaccines against human 
cytomegalovirus (HCMV) as it poses a significant threat to the immunologically 
immature, causing congenital disease, and to the immune compromised including 
transplant recipients. In this study we examined the efficacy of synthetic long peptides 
(SLPs) as a CD4+ and CD8+ T cell-eliciting preventive vaccine approach against mouse 
CMV (MCMV) infection. In addition, the use of agonistic OX40 antibodies to enhance 
vaccine efficacy was explored. Immunocompetent C57BL/6 mice were vaccinated in 
a prime-boost vaccination regiment with SLPs comprising various MHC class I and II-
restricted peptide epitopes of MCMV-encoded antigens. Enforced OX40 stimulation 
resulted in superior MCMV-specific CD4+ as CD8+ T cell responses when applied during 
booster SLP vaccination. Vaccination with a mixture of SLPs containing MHC class II 
epitopes and OX40 agonistic antibodies resulted in a moderate reduction of the viral 
titers after challenge with lytic MCMV infection. Markedly, the combination of SLP 
vaccines containing both MHC class I and II epitopes plus OX40 activation during 
booster vaccination resulted in polyfunctional (i.e., IFN-γ+, TNF+, IL-2+) CD4+ and CD8+ T 
cell responses that were even higher in magnitude when compared to those induced by 
the virus, and this resulted in the best containment of virus dissemination. Our results 
show that the induction of strong T cell responses can be a fundamental component in 
the design of vaccines against persistent viral infections.
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INTRODUCTION
It is estimated that 60-80% of people worldwide are infected by the prototypic 
β-herpesvirus human cytomegalovirus (HCMV). CMV establishes low level viral 
persistence within immunocompetent hosts without clinical symptoms. However, 
it can cause life-threatening disease in the immunological immature (unborn babies 
and newborns) and immunocompromised individuals (e.g. bone marrow and organ 
transplant recipients) [1,2]. Although new antiviral drugs against CMV are in clinical 
development, the most commonly used agents display toxicity. Importantly, no licensed 
prophylactic or therapeutic vaccines exist for CMV at present. Consequently, there is an 
imperative need to identify potent vaccine modalities to prevent HCMV infection [3-5].
CD4+ and CD8+ T cell responses play a critical role in controlling CMV infection in 
both mouse and human. While CD4+ T cells seem to be more crucial in the early phase 
after infection, CD8+ T cells are imperative during latency and harbor superior protective 
properties upon re-challenge [6-9]. Moreover, adoptive transfer approaches established 
the pivotal role of CMV-specific CD4+ and CD8+ T cells in orchestrating virus replication 
control [10-12]. During CMV infection, CD4+ and CD8+ T cell responses either follow 
the traditional course comprised by massive expansion followed by rapid contraction 
and maintenance at low levels or instead do not undergo contraction but remain at 
high frequency or even expand gradually. The latter has been described as memory 
T cell inflation, and has been observed for a restricted set of immunodominant CMV 
antigens [13-16]. Memory inflation is thought to occur due to low-level persistent 
antigenic priming and requires certain costimulatory receptor-ligand pairs of which 
CD27-CD70 and OX40-OX40L interactions are important [17,18]. Phenotypically 
inflationary T cells exhibit effector-like properties without signs of exhaustion [14,16,19]. 
The comparable nature of the T cell response to MCMV and HCMV is also found for 
B cell and NK cell responses, and is likely related to the similarities of both viruses in 
tropism, pathology and the establishment of latent infection that reactivates upon 
immunosuppression [20,21].
Recently, we demonstrated that synthetic long peptide (SLP) vaccines, designed 
to exclusively induce MHC class I-restricted CD8+ T cells, were able to elicit robust and 
polyfunctional T cell responses that led to reduced MCMV replication in C57BL/6 and 
BALB/c mouse strains after challenge [22]. However, live MCMV vaccines were more 
efficient which prompted us to further improve the SLP vaccine efficacy. Since CD4+ 
helper T cells promote long-term maintenance of memory CD8+ T cells, also during 
MCMV infection [23,24], and display direct anti-viral capabilities [12,25], the induction of 
CD4+ T cells may improve the efficacy of the SLP vaccine. Here we analyzed the potency 
of SLP vaccines inducing MCMV-specific CD4+ T cells, either alone or in conjunction 
with SLPs eliciting MCMV-specific CD8+ T cells. Enforced OX40 signaling was used to 
enhance the expansion of both CD4+ and CD8+ T cell subsets. We show that combined 
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administration of SLPs eliciting CD4+ and CD8+ T cells and OX40 stimulation during 
booster vaccination leads to a startling increase of both the T cell magnitude and 
polyfunctionality, ultimately leading to efficient control of lytic MCMV infection. 
RESULTS
Prime/boost vaccination with SLPs inducing MCMV-specific CD4+ T cell responses
MHC class II epitopes from MCMV encoded proteins have previously been identified 
by us in the C57BL/6 mouse strain (MHC haplotype H-2b) [11], and five immunogenic 
epitopes (i.e., m18872–886, M25409–423, m139560–574, m14224–38 and m09133–147) were selected for 
the SLP vaccine platform (Table 1 in Supplementary Material). Initially, the potential of 
single SLP-based vaccines in eliciting CD4+ T cell responses was assessed in a prime/
boost vaccination setting (2 weeks apart) with the TLR9 ligand CpG as adjuvant. At day 8 
after the first SLP vaccination, CD4+ T cell responses were not detected by polychromatic 
intracellular cytokine staining (data not shown) but they became detectable in the spleen 
at day 8 after the booster SLP vaccination (Figure 1A). However, these responses were 
relatively low when compared to SLP-induced CD8+ T cell responses [22]. Analysis of 
the cytokine profile revealed the presence of single IFN-γ, double IFN-γ/TNF and triple 
IFN-γ/TNF/IL-2 cytokine producing CD4+ T cell populations (Figure 1B).
For clinical applications multiple SLPs need to be combined in order to deal 
with MHC heterogeneity. Moreover, the breadth of SLP vaccines is important for 
the efficacy [22]. Hence, mice were vaccinated with a mixture of the 5 SLPs and 
the CD4+ T cell response for each individual peptide epitope was measured. CD4+ T cell 
reactivity to all MHC class II epitopes was detected (Figure 1C), albeit that the response 
to each individual peptide was lower when compared to single SLP vaccination, 
suggesting that competition among CD4+ T cell peptide epitopes occurs in multivalent 
vaccines. Moreover, in comparison to the CD4+ T cell response observed after MCMV 
infection, vaccination with a mixture of MHC class II SLPs resulted in lower numbers 
of MCMV-specific T cells (Figure 1C). Nevertheless, the cytokine polyfunctionality 
of the SLP-elicited CD4+ T cells was augmented compared to MCMV-induced CD4+ T 
cells (Figure 1D). Taken together, these results show that prime/boost vaccination with 
a mixture of MHC class II epitope-containing SLPs elicits polyfunctional MCMV-specific 
CD4+ T cell responses, but in magnitude these are lower as compared to those induced 
by the virus itself. 
Enforced OX40 triggering during booster vaccination shows superior induction of 
SLP-elicited CD4+ T cell responses
Next, we attempted to augment the magnitude of the SLP-induced CD4+ T cell 
responses. As OX40-mediated signals are important for enhancing CD4+ T cell expansion 
and survival [26], we decided to use an agonistic OX40 antibody that provides in vivo 
OX40 stimulation. First, we investigated the scheduling of the agonistic OX40 antibody 
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Figure 1. Prime-boost SLP vaccination with combined MHC class II SLPs provokes the induction 
of strong and polyfunctional CD4+ T cell responses. (A) At day 8 post booster vaccination with 
single SLPs containing MHC class II epitopes, the magnitude of the CD4+ T cell responses specific 
to the indicated epitopes was determined by intracellular cytokine staining after restimulation 
with peptide. Representative plots show percentages of IFN-γ versus TNF cytokine production 
of the vaccine-elicited CD4+ T cells. (B) Pie charts depict the percentages of the single (IFN-γ), 
double (IFN-γ/TNF) and triple (IFN-γ/TNF/IL-2) cytokine producers of each antigen-specific CD4+ 
T cell population at day 8 post booster vaccination with single MHC class II SLPs. (C) Percentages 
(left) and total numbers (right) of splenic SLP and MCMV-specific IFN-γ+ CD4+ T cells at day 8 post 
booster vaccination with a mixture of all 5 MHC class II SLPs are shown. (D) Pie charts depict 
the percentages of the single (IFN-γ), double (IFN-γ/TNF) and triple (IFN-γ/TNF/IL-2) cytokine 
producers of each antigen-specific CD4+ T cell population at day 8 after booster vaccination 
with a mixture of all 5 MHC class II SLPs. Data represent mean values, and are representative of 3 
independent experiments (n=4-5 per group). *, P< 0.05; **, P< 0.01; ns, not significant.
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administration (i.e. during priming only, during booster only or during priming and 
booster) in order to obtain the most optimal CD4+ T cell stimulation (Figure 2A). 
The magnitude of the T cell response elicited by the SLP containing the M25409–423 
epitope was measured 8 days post booster vaccination in the spleen. OX40 stimulation 
clearly increased the magnitude of the M25409–423-specific CD4
+ T cell responses, and 
remarkably this was most prominent when the mice received agonistic OX40 antibody 
during the booster vaccination only (Figures 2B, C). Markedly, a >100-fold increase in 
IFN-γ+ CD4+ T cells was observed when compared to SLP vaccination without enforced 
OX40 stimulation, whereas the response was 17-fold and 5-fold higher than in mice 
receiving OX40 antibody during priming only or during both priming and booster 
vaccination, respectively (Figure 2C). In addition, there was a striking gain in cytokine 
polyfunctionality when agonistic OX40 antibody was provided during booster 
vaccination only (Figures 2D-F). Compared to SLP vaccination, the increase in absolute 
numbers of triple IFN-γ/TNF/IL-2 producers was even >200 fold (Figure 2E). 
Next, we examined whether the strong increase in MCMV-specific CD4+ T cells by 
administration of agonistic OX40 antibody during booster vaccination was also evident 
in case of a mixture of SLPs. Clearly, at day 8 post booster vaccination a strong increase in 
both percentages and absolute numbers of the peptide-specific IFN-γ+ CD4+ T cells was 
observed for all epitopes in the mixture (Figure 3A). In addition, administration of OX40 
antibody dramatically improved the cytokine polyfunctional traits (Figure 3B). Most 
profoundly, OX40 stimulation augmented the IL-2 production capacity of the vaccine-
induced CD4+ T cells (Figure 3B, C). Together, these results demonstrate that activation 
of the OX40 axis during booster SLP vaccination leads to superior CD4+ T cell expansion 
and induction of cytokine polyfunctionality.
Having established a powerful means to augment SLP vaccines containing MHC class 
II epitopes, we tested if the used SLPs may comprise unidentified class I epitopes and/
or linear B cell epitopes leading to CD8+ T cells and antibody responses, respectively. 
However, intracellular cytokine staining did not reveal any induction of MCMV-
specific CD8+ T cells and SLP-specific antibody ELISAs were negative (Figures S1A, B 
in Supplementary Material). Furthermore, increased percentages of activated NK cells 
were also not detected after SLP vaccination (Figure S1C in Supplementary Material), 
indicating that the intended MHC class II epitope-containing SLPs with enforced OX40 
stimulation exclusively activate antigen-specific CD4+ T cell responses. 
Provision of OX40 stimulation during booster vaccination also advances SLP-induced 
CD8+ T cell responses 
To improve our previously reported CD8+ T cell eliciting SLP vaccine modality [22], 
we here envisaged to combine both MHC class I and II epitope containing SLPs. We 
therefore, also analysed the impact of OX40 engagement on vaccine-induced CD8+ T 
cells in a similar scheduling experiment using a SLP exclusively containing the CD8+ 
T cell peptide epitope M57816-824 (Figure S2A in Supplementary Material). Consistent 
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Figure 2. Activation of the OX40 axis during booster vaccination with a single MHC class II 
SLP vaccine propels increment of the vaccine-induced CD4+ T cell response. (A) Scheme of 
the experimental procedure and the vaccination timeline. Wild type C57BL/6 mice were vaccinated 
(i) s.c with M25409–423 MHC class II SLP alone or (ii) with M25409–423 MHC class II SLP (s.c.) along with 
anti-OX40 mAb (i.p.). 2 weeks after prime vaccination mice from group (i) and (ii) were divided into 
two groups respectively and a booster immunization was administered. Half mice received only 
the M25409–423 SLP and the other half were injected anti-OX40 mAb in addition to the M25409–423 
SLP. (B) The total size of the splenic M25409–423 SLP vaccine induced CD4
+ T cells from each group 
was measured by intracellular cytokine staining. Representative plots depict percentages of IFN-γ 
versus TNF cytokine producing CD4+ T cell populations at day 8 post booster vaccination. (C) Total 
numbers of splenic IFN-γ+ producing M25409–423 antigen-specific CD4
+ T cells at day 8 post booster 
SLP vaccination and differential anti-OX40 mAb treatment are shown. (D) Total double (IFN-γ/
TNF) and (E) triple (IFN-γ/TNF/IL-2) cytokine producers of M25409–423 vaccine-specific CD4
+ T cells 
measured in spleen at day 8 post booster vaccination. Fold differences among each population 
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are also depicted (F) Pie charts show the percentages of the single (IFN-γ), double (IFN-γ/TNF) and 
triple (IFN-γ/TNF/IL-2) cytokine producers of each M25409–423-specific CD4+ T cell population 
upon vaccination with M25409–423 SLP and anti-OX40 mAb. Data represent mean values, and 
are representative of three independent experiments (n=5-6 per group). *, P< 0.05; **, P< 0.01; 
ns, not significant.
Figure 3. OX40 activation during booster vaccination with combinatorial MHC class II SLP 
vaccines leads to the induction of robust and polyfunctional CD4+ T cell responses. (A) 
Percentages (left) and total numbers (right) of the splenic epitope-specific IFN-γ+ CD4+ T cell 
responses elicited at day 8 post booster vaccination with a mixture of SLPs containing MHC class 
II epitopes alone (CD4 SLP mixture; white bars) or with SLPs containing MHC class II epitopes 
and anti-OX40 mAb (CD4 SLP mixture + anti-OX40 boost; black bars). (B) Pie charts show 
the percentages of the single (IFN-γ), double (IFN-γ/TNF) and triple (IFN-γ/TNF/IL-2) cytokine 
producers of each antigen-specific CD4+ T cell population at day 8 post booster vaccination 
with a mixture of MHC class II SLPs alone or with MHC class II SLPs plus anti-OX40 mAb. (C) Total 
triple (IFN-γ/TNF/IL-2) cytokine producers of each antigen-specific CD4+ T cell population were 
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with the results described for CD4+ T cells, mice that were vaccinated and treated with 
agonistic OX40 antibody during booster vaccination displayed the strongest SLP-
induced CD8+ T cell response in both blood and spleen (Figures S2B-F in Supplementary 
Material). The number of SLP-induced CD8+ T cells, determined either by IFN-γ reactivity 
or by MHC class I tetramer binding, at the peak after the boost were similar, indicating 
that OX40 stimulation during SLP vaccination (provided either during priming, during 
booster or during prime/boost) induces functional (non-exhausted) CD8+ T cells (Figures 
S2C,D in Supplementary Material). The cell-surface phenotype based on KLRG1 and 
CD127 of the vaccine-induced CD8+ T cells at the peak of the response after the booster 
was comparable (Figure S2G in Supplementary Material).
Next, the impact of OX40 stimulation during booster vaccination was evaluated 
for a mixture of MHC class I epitope-containing SLPs. Longitudinal analysis of the SLP-
specific CD8+ T cell response revealed that OX40 stimulation during booster vaccination 
clearly amplifies the expansion of all SLP vaccine-induced CD8+ T cells measured in blood 
and spleen (Figures 4A, B), although this effect was relatively lower when compared 
to that seen for CD4+ T cells. At the peak of the response, 8 days after booster SLP 
vaccination, the magnitude of the IFN-γ+CD8+ T cell response specific for each MHC class 
I-restricted epitope was again proportional to the MHC class I tetramer response (data 
not shown). However, the polyfunctional cytokine profile was improved upon OX40 
stimulation (Figures 4C, D). In particular OX40 stimulation augmented the percentages 
and absolute number of the triple cytokine producers in particular (Figures 4C, D). 
To gain insight into the mechanisms underlying the apparent impact of OX40 
stimulation during booster vaccination, we examined the expression of the pro-
apoptotic protein BCL-2, a known target of OX40 triggering and implicated in T cell 
survival [27]. BCL-2 expression was up-regulated by the vaccine-specific CD8+ T cells 
when OX40 stimulation was provided during booster vaccination compared to no OX40 
stimulation (Figure 4E). Moreover, when agonistic OX40 antibody was administered 
during both primary and booster vaccination, BCL-2 expression was down-regulated. 
These results indicate that stimulation of OX40 can bolster vaccine-induced CD8+ 
T cell expansion through a BCL-2 dependent mechanism, if this stimulation is 
correctly scheduled.  
Over time, the SLP-induced CD8+ T cell responses contracted, yet the OX40 boosted 
epitope-specific CD8+ T cell responses to M38, M45 and M57 were maintained at higher 
levels (Figures 5A). At the memory phase (60 days after booster vaccination), there were 
higher percentages and numbers of triple (IFN-γ/TNF/IL-2) cytokine producing vaccine-
measured in spleen at day 8 post booster vaccination with a mixture of MHC class II SLPs and 
anti-OX40 mAb or with SLPs alone. Fold difference is indicated. Data represent mean values, and 
are representative of 3 independent experiments (n=6 per group). *, P< 0.05; **, P< 0.01.
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Figure 4. OX40 ligation during booster vaccination with a mixture of MHC class I-epitope 
containing SLPs leads to the induction of strong and polyfunctional CD8+ T cell responses. 
(A) Longitudinal analysis of the epitope-specific CD8+ T cell responses in blood induced by 
combinatorial MHC class I epitope containing SLP vaccines without (CD8 SLP mixture) and with 
anti-OX40 mAb administration (given only during booster vaccination) (CD8 SLP mixture + 
a-OX40 boost). Data represents mean values ± SEM (n=12 per group). (B) Total IFN- γ+ cytokine 
producing CD8+ T cells for each antigen-specific population detected in spleen at day 8 post 
booster vaccination with CD8 SLP mixture (white bars) or with CD8 SLP mixture + anti-OX40 boost 
(black bars). (C) Pie charts show the percentages of the single (IFN-γ), double (IFN-γ/TNF) and 
triple (IFN-γ/TNF/IL-2) specific cytokine producers of the antigen-specific CD8+ T cell populations 
at day 8 post booster vaccination. (D) Total numbers of IFN-γ/TNF/L-2 cytokine producing CD8+ 
T cells for each antigen-specific population detected in spleen at day 8 post booster vaccination. 
(E) At day 8 after booster vaccination with combined MHC class I SLPs and/or anti-OX40 mAb 
(during booster or during both prime/boost), the BCL-2 protein expression was measured within 
the antigen specific CD8+ T cells in spleen by flow cytometry. Fold changes between groups are 
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depicted. Data represents mean values + SEM (n=6 mice per group), and are representative of 3 
independent experiments. *, P< 0.05; **, P< 0.01; ***, P< 0.001; ****, P< 0.0001.
Figure 5. Agonistic OX40 mAb administration during booster vaccination leads to improved 
memory SLP-elicited CD8+ T cell responses. (A) Total single IFN-γ+ cytokine producing CD8+ T 
cells for each antigen-specific population detected in spleen at day 60 post booster vaccination 
with combinatorial MHC class I SLPs and anti-OX40 mAb (provided during booster vaccination) 
(CD8 SLP mixture + anti-OX40 boost) or with MHC class I SLPs alone (CD8 SLP mixture). Fold 
changes between groups are depicted. Data represents mean values + SEM (n=6 per group). 
(B) Pie charts show the percentages of the single (IFN-γ), double (IFN-γ/TNF) and triple (IFN-γ/
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induced CD8+ T cells in mice that received agonistic OX40 antibody during booster 
vaccination (except for m139419-426) (Figures 5B, C). 
We also tested the impact of the in vivo OX40 stimulation on the secondary 
expansion potential, a hallmark of memory T cells. We performed adoptive transfer 
experiments in which congenically marked  (CD45.1+) memory CD8+ T cells from SLP 
vaccinated mice were isolated and transferred into naïve recipient mice, which were 
subsequently challenged with MCMV (Figure S3A in Supplementary Material). Overall, 
the SLP-induced memory CD8+ T cells isolated from mice that also received OX40 
stimulation during booster vaccination expanded better compared to the vaccine only 
group (Figure S3B, C in Supplementary Material). 
Subsequently, we examined whether OX40 stimulation is able to further improve 
the prophylactic efficacy of the combined MHC class I SLP vaccine. At day 60 post 
booster vaccination, mice were virally challenged and the titres were quantified in 
spleen, liver and lungs. Similar to our previous study [22], vaccination with a mixture of 
MHC class I SLPs resulted in reduction of the virus titres (Figure 5D). Mice that received 
OX40 stimulation during the booster showed increased potency to control the virus 
compared to mice that received no extra stimulation of OX40 (Figure 5D). All together, 
these data suggest that enforced OX40 stimulation during booster SLP vaccination 
does not only impact the expansion of activated CD8+ T cells but also has a long-lasting 
constructive influence on the magnitude and the functional profile of the vaccine-
elicited CD8+ T cells leading to more effective viral control.
SLP vaccines inducing both CD4+ and CD8+ T cells confer superior protection against 
MCMV infection
To evaluate if the provision of CD4+ T cells would benefit the CD8+ T cell response, 
C57BL/6 mice were vaccinated with a mixture of either all 5 MHC class I epitope-
TNF/IL-2) cytokine producers of each antigen-specific CD8+ T cell population in spleen at day 60 
post booster vaccination with a mixture of MHC class I SLPs and anti-OX40 mAb (administered 
only during booster vaccination) or with MHC class I SLPs alone. (C) Total triple IFN-γ+/TNF+/
IL-2+ producing CD8+ T cells for each antigen-specific population detected in spleen at day 60 
post booster vaccination. Fold changes between groups are depicted. Data represents mean 
values + SEM (n=6 per group). (D) Different groups of mice (unvaccinated (naive), MCMV infected 
(live virus vaccine), vaccinated with a mixture of all 5 MHC class I SLPs, vaccinated with a mixture of 
all 5 MHC class I SLPs and anti-OX40 mAb (given only during booster vaccination) or treated with 
a-OX40 mAb only) were challenged at day 60 post vaccination/infection with 5 × 104 PFU salivary 
gland-derived MCMV Smith. At day 5 post challenge spleen, liver and lungs were harvested and 
the viral genome copies were determined by qPCR. The viral titers of individual mice are depicted 
(n=5-8 mice per group). Mean ± SEM is indicated. The detection limit was below 1000 genome 
copies as measured in naive mice. Experiments were performed twice with similar outcome. 
*, P< 0.05; **, P< 0.01; ***, P< 0.001; ns, not significant as compared to the unvaccinated group 
unless otherwise indicated.
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containing SLPs or with a mixture of all 5 MHC class I and all 5 class II epitope-containing 
SLPs (Table 1 in Supplementary Material). Agonistic OX40 mAb was provided during 
the boost only. The CD8+ T cell response after the prime vaccination was higher when 
the SLP vaccine contained a mixture of MHC class I and II peptide epitopes (Figure 6A 
and Figure S4A in Supplementary Material), stressing the importance of CD4+ T cell 
help during the priming. Also, the phenotype of the vaccine-induced CD8+ T cells after 
prime vaccination revealed slightly more effector-type (KLRG-1+CD127-) CD8+ T cells 
when CD4+ T cell help was provided (Figure S4B Supplementary Material), whereas 
the polyfunctionality of the vaccine-induced CD8+ T cells remained unchanged (data not 
shown). However, at day 7/8 after booster SLP vaccination, the effect of CD4+ T cell help 
on the magnitude of the vaccine-induced CD8+ T cell response was no longer detectable 
in blood (Figure 6A) and spleen (Figure 6B). At this time-point, also no difference in 
the CD8+ T cell cytokine polyfunctionality and phenotype was found (Figures 6C, D). 
Furthermore, the size and polyfunctionality of the CD4+ T cells responses induced at 
the peak response after combined MHC class I and II SLP vaccination was similar as 
vaccination with MHC class II SLPs only (Figures S5A, B in Supplementary Material). 
Taken together, vaccination with a mixture of MHC class I and II epitope-containing 
SLPs resulted in enhanced primary CD8+ T cell expansion compared to vaccination with 
class I epitope-containing SLPs only, but no additional effects of the helper T cells were 
observed after the enforced OX40 stimulation provided during booster vaccination.
Ultimately, we analysed the prophylactic efficacy of the SLP-induced MCMV-specific 
CD4+ and CD8+ T cells to control viral replication. At day 60 post booster SLP vaccination, 
mice were infected with MCMV and 5 days later the viral titers were quantified. The viral 
load of unvaccinated (naive) mice challenged with MCMV was found significantly 
higher in spleen, liver and lungs compared to the viral load of mice that received earlier 
a virulent virus as a vaccine. This result suggests that pre-existing immunity to MCMV 
can inhibit virus replication during subsequent infection (Figure 7). Furthermore, 
the viral titers of mice that had received the virulent virus-based vaccine were similar 
to those measured during chronic MCMV infection, indicating that this is the maximum 
of immune control that can be achieved. Mice vaccinated with the mixture of SLPs 
containing MHC class II epitopes plus OX40 triggering during booster vaccination 
displayed significant reduction in viral load in all tested organs (Figure 7), indicating 
that the SLP-induced MCMV-specific CD4+ T cells display direct antiviral properties. 
Vaccination with the mixture of MHC class I SLPs plus anti-OX40 during booster resulted 
in a more efficient reduction of viral load in all organs. Strikingly, mice that received 
a mixture of MHC class I and II epitope-containing SLPs and OX40 stimulation during 
booster vaccination displayed the strongest reduction in viral load (Figure 7). Notably, 
the SLP vaccine-induced reduction in viral load in the spleen and liver was almost as 
effective as to what is observed after vaccination with virulent virus. Thus, SLP vaccines 
comprising a mixture of MHC class I and II SLPs has the highest protection potency 
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Figure 6. Combinatorial MHC class I and class II epitope-containing SLP vaccines and OX40 
agonistic mAb during booster vaccination leads to robust induction of both CD4+ and CD8+ T 
cell responses. C57BL/6 mice were vaccinated s.c. with a combination of all MHC class I epitope-
containing SLPs (CD8 SLP) or with a combination of all MHC class I and MHC class II-epitope 
containing SLPs (CD4 + CD8 SLP). In both groups agonistic OX40 mAb was administered i.p. 
during booster vaccination. (A) Kinetics of the antigen-specific CD8+ T cells measured by MHC 
class I tetramer staining in blood. Data shown are mean values ± SEM (n=18 mice/group) (B) Total 
MHC class I tetramer-specific CD8+ T cells induced by combinatorial MHC class I or MHC class I 
plus MHC class II SLP vaccination compared to MCMV infection at day 8 post booster vaccination 
in spleen. Data represent mean values (n=5 mice/group). (C) The cytokine production capacity 
of the splenic SLP vaccine-induced CD8+ T cells was examined by intracellular cytokine staining 
at day 8 after booster vaccination. Pie charts depict the percentages of the single (IFN-γ), double 
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(IFN-γ/TNF) and triple (IFN-γ/TNF/IL-2) cytokine producers of each antigen-specific CD8+ T cell 
populations at day 8 post booster vaccination. (D) Phenotypic analysis of the combinatorial SLP 
vaccine-induced CD8+ T cells in spleen at day 8 post booster vaccination. Data represent mean 
values (n=5 mice/group) and are representative of three independent experiments. 
Figure 7. Prime-boost vaccination with combinatorial MHC class I and class II epitope-
containing SLPs exhibits increased potency to protect against lytic MCMV infection. 
Unvaccinated (naive), MCMV (live-virus vaccine), combined MHC class II SLPs (CD4 mixture), 
combined MHC class I SLPs (CD8 mixture), combined MHC class I and II SLPs (CD4+CD8 mixture) 
and anti-OX40 mAb only treated C57BL/6 mice were challenged 60 days post booster-vaccination/
infection with 5 × 104 PFU salivary gland-derived MCMV Smith. At day 5 post challenge, liver, 
lungs and spleen were harvested and the viral genome copies were quantified by qPCR. To further 
evaluate the efficacy of the vaccines, the viral titers of chronically infected (MCMV chronic/day 
60) mice were also measured. The viral titers of individual mice are depicted (n=4-8 per group). 
Statistical significance between the unvaccinated group and the rest of the groups is indicated 
with asterisks above each group. A statistical comparison between the CD4 + CD8 mixture 
group and the MCMV (live virus vaccine) and MCMV chronic group was also performed (vertical 
statistical bar). For both comparisons the statistical difference was found the same (**, P< 0.01). 
The detection limit was below 1000 genome copies as measured in naive mice. Experiment 
was performed twice with similar outcome. Statistical difference is indicated **, P< 0.01; ***, 
P< 0.001; ****, P< 0.0001; ns, not significant as compared to the unvaccinated group unless 
otherwise indicated.
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compared to similar vaccines that elicit merely MCMV-specific CD4+ or CD8+ T cell 
responses. All together, we conclude that OX40 activation during booster vaccination 
empowers SLP-induced memory CD4+ and CD8+ T cells to efficiently counteract lytic 
MCMV infection. 
DISCUSSION
In this study, we show that SLP-based vaccine strategies eliciting vigorous 
polyfunctional CD4+ and CD8+ T cell responses are highly effective against MCMV 
infection. While SLP-based vaccines that evoke solely CD8+ T cell responses display 
already efficacy against lytic MCMV infection [22], vaccination with a mixture of various 
immunodominant MHC class II and MHC class I MCMV epitopes and the combination 
with enforced OX40 stimulation results in superior vaccine efficacy. Former explored 
CMV vaccines focused mainly on the induction of neutralizing antibodies and thus far 
did not show substantial efficacy [3-5]. Our finding that SLP-based vaccines that merely 
provoke CD4+ and CD8+ T cell responses are almost as efficient as a virulent vaccine 
suggests that the inclusion of T cell stimulating antigens should facilitate the design of 
more efficient vaccines against CMV. 
Signals through the OX40 costimulatory receptor are known to regulate expansion 
and survival of both CD4+ and CD8+ T cells after antigen encounter [26,28]. Consistent 
with this, OX40 had a robust effect on the magnitude of the effector SLP vaccine-
induced CD4+ and CD8+ T cells and on their capacity to induce “Th1” cytokine responses 
(especially IL-2). This effect of OX40 costimulatory signals was stronger when agonistic 
antibody to OX40 was provided during booster SLP vaccination. We hypothesize that 
primed T cells more rapidly and stronger upregulated OX40 leading to greater benefit 
during enforced OX40 stimulation. OX40 ligation seems to work better on CD4+ T cells 
as compared to CD8+ T cells, which may be related to the higher expression of OX40 on 
CD4+ T cells [29,30]. Due to its capacity to regulate both CD4+ and CD8+ T cells, OX40 is 
a promising candidate in immunotherapy of chronic viral infections and cancer [28]. 
In this study we did not detect toxicity of OX40 agonistic antibodies but a better 
understanding of potential side-effects is required. 
CD4+ T cell responses in CMV infection have been long known as important 
contributors to control primary infection [9,31]. In MCMV infection, CD4+ T cells direct 
the quality and persistence of inflationary CD8+ T cells and B cell responses [23,24,32]. 
Here we show that vaccine-induced CD4+ T cells solely can confer moderate protection 
against acute MCMV infection. These results are consistent with other reports showing 
CD4+ T cell effectivity against MCMV and HCMV [9,12,25,33-35]. Furthermore, we 
observed that addition of CD4+ T cell help during vaccination with MHC class I SLP 
vaccines promoted priming of naïve CD8+ T cells. After booster vaccination in settings 
wherein OX40 costimulation was enhanced, no additional effects of CD4 help on 
the magnitude and phenotype of the CD8+ T cells were observed, suggesting that 
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enforced OX40 stimulation during booster vaccination may replace the need for CD4 
help signals. On this basis, the improved prophylactic vaccine efficacy of the combined 
MHC class I and II SLP vaccines appears to be more additive rather than synergistic. 
Another interesting observation was that the vaccine efficacy was somewhat better 
in liver and spleen than in lungs. A possible explanation for this discrepancy is that 
the SLP-induced CD8+ T cells are better capable to control the virus (lowering the viral 
titers) in the spleen and liver than the SLP-induced CD4+ T cells. A marked difference in 
the efficacy of SLP-induced CD4+ and CD8+ T cells as observed in liver and spleen is not 
found in the lungs, and can thus be dictated by the tissue environment. Differences in 
site-specific control of MCMV-specific CD4+ and CD8+ T cells is known to be especially 
important in the salivary glands but for other tissues this may be important as well [36]. 
Nevertheless, the combined SLP vaccines inducing both CD4+ and CD8+ T cell responses 
clearly improved the efficacy of the vaccine in all organ tissues. In this respect it is of 
interest to note that SLP-based vaccines can be further refined by different prime-
booster regimens, inclusion of B cell epitopes and by combinations with adjuvants, 
immunomodulatory antibodies or other vaccine platforms [37].
This study provided evidence that SLP-based vaccines eliciting broad CD4+ and CD8+ 
T cell responses can effectively control lytic MCMV infection without contribution by 
humoral responses. The use of OX40 as an adjuvant for MCMV peptide immunization 
strongly bolstered the development of effective CD4+ and CD8+ T cells. Future studies to 
examine the ability of the SLP vaccine-induced T cells and OX40 costimulation to boost 
immune responses in immunocompromised settings of CMV infection or other chronic 
viral infections are strongly encouraged by these promising findings. Taken together, 
our data highlight the importance of designing CMV vaccines that elicit effective CD4+ 
and CD8+ T cell responses.
MATERIALS AND METHODS
Mice
Wild-type female C57BL/6 mice (8-10 weeks) were purchased from Charles River 
Laboratories (L’Arbresle, France) and Ly5.1 (SJL; CD45.1) congenic mice on a C57BL/6 
genetic background were obtained from The Jackson Laboratory. Mice were bred and 
housed under specific-pathogen-free (SPF) conditions at the Central Animal Facility 
of Leiden University Medical Center (LUMC). Experimental procedures were approved 
by the LUMC Animal Experiments Ethical Committee and conducted according to 
the Dutch Experiments on Animals Act and the Council of Europe (#13156 and #14187).
Viral infections 
Virus stocks were prepared from salivary glands of BALB/c mice infected with MCMV-
Smith (American Type Culture Collection (ATCC)). The viral titres of the produced virus 
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stocks were determined by viral plaque assays with mouse NIH-3T3 Embryonic Fibroblasts 
(ATCC). C57BL/6 mice were infected intraperitoneally (i.p) with 5 × 104 PFU MCMV in 
400 μl of PBS. 60 days post-booster vaccination or infection, mice were (re)-challenged 
with 5 × 104 PFU MCMV. Viral loads in spleen, liver and lungs were determined by 
real-time PCR at day 5 post challenge as described previously [38]. Due to differences in 
peak viral replication, the viral load in the salivary glands was not measured.
Peptides and vaccination 
Short (9-10 aa) and long (20-21 aa) peptides containing MHC class I-restricted T 
cell epitopes [22] and 15 aa long peptides containing MHC class II epitopes [39] 
were produced at the GMP-peptide facility of the LUMC. The purity (75-90%) of 
the synthesized peptides was determined by HPLC and the molecular weight by mass 
spectrometry. All peptide sequences used in this study are listed and described in S1 
Table in Supplementary Material. Both single and mixed synthetic long peptide (SLP) 
vaccines were administered subcutaneously (s.c) at the tail base by delivery of 50 μg of 
each SLP and 20 μg CpG (ODN 1826, InvivoGen) in a total volume of 50 μl in PBS. Booster 
SLP vaccinations were provided after 2 weeks. At the indicated times (during prime and/
or booster vaccination), mice were injected i.p. with 150 μg agonistic OX40 mAb (clone 
OX86) dissolved in 150 μl of PBS. All SLP vaccine administrations were well tolerated 
without adverse events and signs of hypersensitivity.
Flow cytometry
To evaluate CD4+ and CD8+ T cell responses, cell surface and intracellular cytokine 
staining in splenocytes and blood lymphocytes were performed as previously 
described [40]. In brief, to determine the cytokine production capacity, single-cell 
suspensions from spleens were stimulated with short MHC class I peptides (2 μg/ml) 
for 5 h in the presence of brefeldin A (Golgiplug; BD Pharmingen) or with long MHC 
class II peptides (5 μg/ml) for 8 h of which the last 6 h in presence of brefeldin A. MHC 
class I tetramers specific for the M45985–993, M57816–824, m139419-426, M38316–323, and IE3416–423 
MCMV epitopes were used. Fluorochrome-conjugated mAbs were obtained from BD 
Biosciences, Biolegend or eBioscience. Flow cytometry gating strategies are shown in 
S6 Fig. All data were acquired on a LSRFortessa cytometer (BD Biosciences) and analysed 
with FlowJo-V10 software (Tree star). 
Antibody detection by ELISA
Total IgG, IgG2b, IgG2c, IgG3, IgE and IgA concentrations were determined by ELISA in serum 
samples as previously described [38]. Briefly, Nunc-Immuno Maxisorp plates (Fisher 
Scientific) were coated overnight with 2 μg/ml MHC class II SLPs in bicarbonate buffer, 
and after blocking (skim milk powder, Fluka BioChemika) sera from mice i) chronically 
infected, ii) long term vaccinated with MHC class II SLP vaccines and anti-OX40 mAb 
treated (i.p. during booster vaccination only) or iii) uninfected were added. Next, plates 
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were incubated with various HRP-conjugated antibodies (SouthernBiotech) to detect 
different immunoglobulin isotypes. Plates were developed with TMB substrate (Sigma 
Aldrich) and the colour reaction was stopped by the addition of 1 M H2SO4. To serve as 
a positive control, a peptide from the M2 protein (eM2) of influenza A virus with known 
ability to induce antibodies and corresponding serum was used. Optical density was 
read at 450 nm (OD450) using a Microplate reader (Model 680, Bio-Rad). 
Adoptive T cell transfers
The secondary expansion potential of the SLP vaccine-induced antigen-specific CD8+ T 
cells receiving agonistic OX40 mAb only during booster vaccination was determined by 
adoptive transfers. Splenic memory (day 65) CD8+ T cells from SLP vaccinated CD45.1+ 
congenic mice were negatively enriched with magnetic sorting using the CD8+ T cell 
isolation kit (Miltenyi Biotec). 2 × 106 total CD8+ T cells were retro-orbitally injected 
(in a total volume of 200 μl in PBS) into naive CD45.2+ recipients. Recipient mice were 
rested for 2 hours and concomitantly infected with 5 × 104 PFU MCMV. Subsequently, 
in order to quantify the number of the vaccine-antigen specific CD8+ T cells that was 
transferred, a representative amount of cells was stained with MHC class I tetramers and 
with fluorochrome labelled antibodies against CD44, CD3, CD4 and CD8. The number 
of the donor’s vaccine-specific T cells transferred was ranging between 8×103- 2.5×104 
cells for the group that did not receive OX40 mAb and between 1.8×104- 4.5×104 cells 
for the OX40 mAb boosted group.  6 days later the number of vaccine-specific CD8+ T 
cells of the donor was measured (based on the expression of the CD45.1 marker) by flow 
cytometry, and the fold expansion was calculated. 
Statistical analyses
Statistics were calculated using the unpaired Student’s t-test or ANOVA in GraphPad 
Prism software (GraphPad Software Inc., USA). *p < 00.5, **p < 0.01, ***p < 0.001, and 
****p <0.00001. 
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Supplementary Figure 1. MHC class II SLP vaccines do not induce peptide-specific Abs and do 
not activate CD8+ T cells and NK cells.  (A) At day 60 post booster MHC class II SLP vaccination and 
anti-OX40 mAb administration (i.p. during booster vaccination only) or MCMV infection serum 
samples were obtained from C57BL/6 mice. ELISA plates were coated with SLP and detection of 
peptide specificAb (including IgG, various IgG subtypes, IgE and IgA) in the serum was assessed. To 
serve as a positive control, a peptide with known ability to induce antibodies and corresponding 
serum was used. Optical density values were measured at 450 nm. Each symbol represents an 
individual mouse. Mean value ± SEM (n=3-4 mice per group) is indicated. (B) At day 8 following 
booster MHC class II SLP vaccination and a-OX40 mAb administration the intracellular cytokine 
production by CD8+ and CD4+ T cells was determined after restimulation with long peptide (5μg/
ml) for 8 h and of which the last 6 h in presence of brefeldin A at 37°C. Representative plots show 
percentages of IFN-γ versus TNF production of CD8+ and CD4+ T cells of each peptide specific 
population in spleen. No peptide stimulation and naive mice were used as negative controls. 
IFN-γ and TNF reactivity was only observed in CD4+ T cells. Experiments were performed twice 
with similar outcome (n=5 mice per group). (C) Potential NK cell activation following vaccination 
with combinatorial MHC class II SLP vaccines and different doses of anti-OX40 mAb administration 
was investigated. At day 7 after booster vaccination cell surface staining for NK cell marker NK1.1 
was performed in blood. No NK cell proliferation was triggered by the vaccines. Each symbol 
represents an individual mouse. Mean value ± SEM (n=3-6 mice per group) is indicated.
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Supplementary Figure 2. Agonistic OX40 mAb administration during booster MHC class II-
restricted SLP vaccination provokes accrual of the vaccine-induced CD4+ T cell responses. (A) 
Scheme of the experimental procedure and the vaccination timeline. Wild type C57BL/6 mice 
were vaccinated (i) s.c with M57816-824 MHC class I SLP alone or (ii) with M57816-824 MHC class I SLP 
(s.c.) along with anti-OX40 mAb (i.p.). 2 weeks after prime vaccination, mice from group (i) and 
(ii) were divided into two groups respectively and a booster immunization was administered. 
Half mice received only M57816-824 SLP and the other half were injected anti-OX40 mAb in addition 
to M57816-824 SLP. (B) Percentages and (C) total size of the M57816-824 SLP vaccine induced CD8
+ 
T cells from each group was measured by tetramer staining in blood and spleen at day 7 and 8 
after booster vaccination respectively. (D) Total single (IFN-γ+), (E) double (IFN-γ+TNF+) and (F) 
triple (IFN-γ+TNF+IL-2+) cytokine producers of vaccine-antigen-specific CD8+ T cell populations 
measured in spleen at day 8 post booster vaccination with M57816-824 SLP and different doses 
of anti-OX40 mAb. Fold differences among each population is shown (E) Phenotypic profile of 
the SLP vaccine-induced CD8+ T cells in spleen at day 8 post booster vaccination. Data represent 
mean values, and are representative of three independent experiments (n=5 mice per group). 
*, P< 0.05; **, P< 0.01; ***, P< 0.001; ns, not significant.
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Supplementary Figure 3. OX40 activation during booster combinatorial MHC class I SLP 
vaccination improves the secondary expansion potential of the memory vaccine-elicited CD8+ 
T cells. (A) Scheme of the experimental setup and the vaccination schedule followed. Briefly, 
CD45.1+ congenic mice were vaccinated s.c. in a prime boost vaccination schedule with a mixture 
of all 5 MHC class I SLPs solely or along with anti-OX40 mAb (one dose administered only during 
booster vaccination). 65 days post booster vaccination splenic CD8+ T cells were negatively 
enriched and 2 × 106 total CD8+ T cells were retro-orbitally transferred into naive C57BL/6 recipient 
mice. Recipient mice were subsequently challenged (i.p.) with 5 × 104 PFU MCMV and 6 days 
later the expansion capacity of the donor’s CD45.1+ Tet+ CD8+ T cells was measured by tetramer 
staining in spleen. (B) Fold expansion of the donor’s antigen-specific CD8+ T cells transferred was 
measured in spleen at day 6 after viruschallenge. Data represents mean values + SEM, and are 
representative of 2 independent experiments (n= 9 mice per group). *, P< 0.05; **, P< 0.01; ns, 
not significant.
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Supplementary Figure 4. Inclusion of CD4+ T cell responses during prime vaccination with 
combinatorial MHC class I SLP vaccines improves the magnitude of the vaccine-induced 
CD8+ T cells. C57BL/6 mice were vaccinated s.c. with a mixture of all MHC class I SLPs or with 
a combination of all MHC class I and II SLPs (S1 Table). (A) Graph shows total numbers of the tetramer 
epitope-specific CD8+ T cells responsesdetected in spleen at day 8 post prime vaccination. 
(B) Phenotypic traits of the vaccine antigen-specific CD8+ T cells in spleen at day 8 post prime 
vaccination. Note that anti-OX40 mAb was not injected during prime vaccination. Data represents 
mean values (n=5 mice per group), and are representative of 3 independent experiments. 
*, P< 0.05; **, P< 0.01.
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Supplementary Figure 5. The magnitude and polyfunctionality of the CD4+ T cell responses 
elicited by booster combinatorial MHC class II SLP vaccination is not altered by the presence of 
CD8+ T cell responses. (A) Total size of antigen-specific CD4+ T cell population measured in spleen 
at day 8 post booster combinatorial MHC class II SLP vaccination (light grey bars) or a mixture 
of both MHC class II and MHC class I SLPs (back bars). Anti-OX40 mAb was administered in both 
groups during booster vaccination.  (B) Cytokine profile of the vaccine induced CD4+ T cells in 
spleen at day 8 post booster vaccination. Same group description as above. Data represents 
mean values (n=5 mice per group), and are representative of 3 independent experiments. ns, 
not significant.
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Supplementary Figure 6. Flow cytometry gating strategy. (A) Representative plots show 
the gating strategy to detect MHC class I tetramer positive cells in blood and spleen. In 
sequential gating, cells were first gated for singlets (FSC-A vs. SSC-A), then for lymphocytes 
(FSC-A vs. FSC-H), followed by viability (FSC-A vs. 7-AAD). Next, live cells were analysed for 
the expression of CD3 and CD8 while cells positive for CD4 were excluded. MHC class I tetramer 
positive cells (CD8 vs. Tm) were analysed for the expression of KLRG1, CD44, CD127 and CD62L 
surface markers. (B) Gating strategy for intracellular cytokine staining to detect CD4+ and CD8+ 
vaccine elicited T cell responses. Utilizing a sequential gating analysis, cells were initially gated for 
singlet’s (FSC-A vs. SSC-A) and then for lymphocytes (FSC-A vs. FSC-H). Next, cells were analysed 
for the expression of CD3 and CD4 while cells positive for CD8 were excluded. IFN-γ producing 
CD4+ T cells were further analysed for expression of TNF and IL-2. A similar gating strategy was 
followed to identify CD8+ T cell responses.
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ASSESSING THERAPEUTIC SLP VACCINATION TO TREAT PERSISTENT 
MCMV INFECTION 
A therapeutic CMV vaccine may be of clinical benefit in immunocompromised 
individuals that are otherwise unable to cope with CMV infection. Evidently in 
congenital infection, allogeneic hematopoietic stem-cell transplantation (allo-HCT), 
solid organ transplantation, but also in other immunocompromised settings the host 
immune system is frequently found to be unable to control CMV infection leading to 
severe morbidity and mortality. A therapeutic CMV vaccination strategy that is able to 
elevate (pre-existing) immunity to CMV in presence of an ongoing CMV infection, may 
potentially also reduce  CMV-associated morbidity . A plethora of studies performed in 
MCMV have confirmed the importance of T cell-mediated immunity in resolving acute 
infection and limiting latent virus reactivation. CD8+ T cells appeared to be able to block 
virus spread and CD4+ T cells were crucial for virus clearance from the salivary grands 
[1-4]. Despite significant progress in the area of prophylactic CMV vaccines as evidenced 
by the number of current candidate vaccines [5-8], only a very limited number of studies 
with a primary focus on therapeutic CMV vaccination have been conducted [8-11]. 
In Chapters 2 and 3 prophylactic vaccination with a combination of MHC class I and/
or MHC class II SLPs containing immunodominant epitopes managed to reduce viral 
titers upon primary MCMV infection. Administration of anti-OX40 agonistic antibodies 
further improved the vaccine efficacy and a remarkable reduction in the viral titers 
was observed in the organs tested (spleen, liver, lungs). Guided by these promising 
results, the therapeutic potential of the SLP vaccination platform during established 
MCMV infection was investigated. The experimental procedure followed is presented 
in Figure 1A. Briefly, immunocompetent C57BL/6 mice were infected with 5 x 104 
PFU salivary gland-derived MCMV Smith strain, and 2 weeks after infection a prime-
boost SLP vaccination with 2 weeks interval was provided. Candidate vaccines tested 
included a combination of all the MHC class I SLPs, a combination of all MHC class II 
SLPs and a mixture of both (Chapter 3, Table S1 in Supplementary Material). Agonistic 
OX40 mAb was provided during the boost in all tested groups. 
Since the ability of a vaccine to enhance immunogenicity of self-antigen T cell 
responses has been associated with control of viremia [11,12], the capacity of the SLP 
vaccines to activate the immune system and boost virus induced CD8+ T cell responses 
was evaluated by MHC class I tetramer assays in blood 10 days after the booster 
vaccination (Figure 1B). The non-inflationary MCMV M45-specific CD8+ T cell response 
was markedly amplified following immunization with a mixture of MHC class I and II 
SLPs. However, no significant difference in the magnitude of the post-vaccination m139, 
M38 and IE3 inflationary MCMV epitope-specific CD8+ T cells responses compared to 
the control group (unvaccinated) was observed. Consistent with previous reports, viral 
titers in spleen and liver tissues during the persistent phase of MCMV infection (here 
day 39 post infection) were found severely reduced, although still clearly detectable in 
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Figure 1. Combination of MHC class I and II epitope-containing SLP vaccines and OX40 
agonistic mAb stimulation during booster vaccination exhibits no therapeutic efficacy 
against established MCMV infection. (A) C56BL/6 mice were infected (i.p.) with 5 x 104 PFU 
salivary gland-derived MCMV Smith strain. At day 14 post infection mice were divided in several 
groups and subsequently vaccinated (s.c. in the tail) in a prime-boost vaccination schedule 
with a combination of all i) MHC class I epitope-containing SLPs (CD8 SLPs), ii) MHC class II 
epitope-containing SLPs (CD4 SLPs) and iii) with both MHC class I and II epitope-containing 
SLPs (CD4 + CD8 SLPs). In all groups, agonistic anti-OX40 mAb (150 μg/ml) was provided (i.p.) 
during the booster vaccination. In parallel, unvaccinated (naïve) and anti-OX40 mAb only treated 
C57BL/6 mice were also challenged to serve as controls. (B) Percentages of virus epitope-specific 
CD8+ T cell responses measured in blood at day 10 post booster vaccination. (C) At day 11 post 
boost mice were sacrificed and the viral genome copies were measured in spleen, liver and 
salivary glands by qPCR. The viral titers of individual mice are depicted (n = 4–5 mice per group). 
Dash lined indicate the detection limit as measured in naive mice. Experiment was performed 
twice with similar outcome. Statistical difference is indicated *P < 0.1; **P < 0.01; ****P < 0.0001; 
ns, not significant as compared to the unvaccinated group.
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all tested groups (Figure 1C). In contrast, high viral titers were measured in the salivary 
glands, the major site of CMV persistence and replication. Interestingly, for all tested 
vaccine combinations no difference in the viral titers was observed indicating that none 
of the candidate SLP vaccines is potent to control persistent MCMV infection. 
A possible explanation for this finding is that the viral infection already activated 
and boosted CMV-specific T cells to a level that could not be increased anymore by 
the tested SLP vaccines. The response that was most strongly enhanced was against 
the non-inflationary M45 CD8+ T cell epitope. The observation that the increase in 
this response did not translate into reduced viral titers was to be expected since we 
previously showed that vaccine-induced M45-specific CD8+ T cells exhibited minor 
cytotoxic function and prophylactic vaccine efficacy [13]. Viral CD8+ T cell responses 
against the m139 and M38 inflationary epitopes were previously found by us to be 
the most efficacious in prophylactic settings [13], yet these were only slightly boosted 
following therapeutic vaccination. Amplifying these inflationary responses may be key to 
show therapeutic efficacy. This however raises a significant challenge as the inflationary 
T cells may already be maximally tickled by the (reactivated) virus. A particularly 
informative future direction is to stringently test whether the SLP vaccines increase 
only the virus-preexisting T cell responses or are also able to prime a new repertoire 
of anti-viral T cell responses. Moreover, it is of interest to test the efficacy of the SLP 
vaccines in immunocompromised settings (i.e irradiation or chemotherapy-induced 
myelosuppression). A therapeutic CMV vaccine that will succeed to boost the host’s 
antiviral T cell immunity in e.g. allo-HCT settings has a great potential to complement 
or even replace costly T cell adoptive transfer treatments and high toxicity antiretroviral 
therapies currently used to contain CMV spread. 
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ABSTRACT
Human Cytomegalovirus (HCMV) is an omnipresent pathogen that is associated with 
increased morbidity and mortality of immunocompromised individuals. Studies of 
T-cell immunity to HCMV primarily reflect anti-HCMV pp65 or immediate early 
(IE) antigen 1 (IE1) activity. Recent evidence highlights the importance of the major 
immediate-early 2 (IE2) protein, which is expressed early after HCMV infection and 
reactivation, for triggering the lytic cycle of HCMV infection. In this study, we assessed 
IE2 HCMV T-cell responses in the peripheral blood of 15 HCMV-seropositive and 6 
HCMV-seronegative healthy donors using IE2 synthetic long peptide (SLP) pools and 
cytokine flow cytometry. The response was dominated by CD4+ T cells as IE2-specific 
CD8+ T-cell reactivity was measured in only 3 donors. Surprisingly, an IE2 HCMV specific 
T-cell response was detected in 3 out of 6 donors who were screened negative for 
HCMV antibody. Most of the donors recognised chiefly the IE2351-434 residues, revealing 
a remarkably immunogenic area of the protein. Numerous HLA class I- and II-restricted 
IE2 T-cell epitopes were identified, which significantly advances the existing evidence. 
Functional characterization of the IE2 T-cell responses uncovered 5 highly immunogenic 
IE2 SLPs, which induced polyfunctional Th1 cytokine (IFN-γ+/ TNF +/ IL-2+) responses. 
The testing of these 5 highly immunogenic IE2 SLPs as potent candidates for T-cell 
based vaccine platforms aiming to inhibit CMV infection by targeting the expression of 
IE genes is warranted.
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INTRODUCTION 
The β-herpesvirus Human Cytomegalovirus (HCMV) is a widespread pathogen that 
infects a large proportion of the population worldwide. After primary infection, 
the virus establishes lifelong latency within its host. HCMV infection is usually benign, 
with no clinical disease manifestations in immunocompetent individuals but it can 
lead to severe complications in susceptible individuals including newborns, allograft 
recipients, and HIV patients [1-4]. 
Despite extensive research, a licensed vaccine intervention to treat or prevent 
CMV infection remains elusive [5,6]. Studies in patients concur on the importance of 
T cells for establishment of immunity and long-lasting memory against HCMV [7-11] 
Recently, T-cell based vaccines designed to induce CD4+ and/or CD8+ T-cell responses 
have received significant research attention. Evidence from various models of mouse 
CMV infection (MCMV) suggests that vaccine-induced T-cell responses may successfully 
control CMV replication without the aid of antibodies [12-14].
Many of the HCMV proteins are recognized by CD4+ and CD8+ T cells in healthy 
HCMV-seropositive subjects [15]. While T cells most frequently target the antigens pp65 
and immediate-early 1 (IE1), the dominance and magnitude of the T-cell response to 
IE1 is associated with protection from HCMV-induced disease [16,17]. Interestingly, 
IE1 but also the major immediate-early 2 (IE2) protein are abundantly expressed 
and play a key role in initiating lytic cycle virus gene expression and replication [18]. 
Deletion of the IE1 gene partially inhibits viral DNA replication [19], whereas IE2 gene 
is indispensable for expression of early lytic genes and virus replication [20,21]. This 
makes the IE antigens promising HCMV immune targets for vaccine approaches that 
aim to attack viral infection at an early phase and prevent wide dissemination [22]. 
While vaccines against IE1 are already tested [23-26], less is known about the immune 
response to IE2. Characterization of IE2-specific T-cell immunity in protected healthy 
individuals will reveal its immunogenicity and may foster the development of vaccines 
targeting indispensable proteins of CMV. 
In this study, we aimed to identify novel HLA class I- and II-restricted IE2 T-cell 
epitopes. We mined the Immune Epitope Database (IEDB) to record previously identified 
IE2 epitopes and examined IE2-specific T-cell reactivity, directly ex-vivo, in the peripheral 
blood of 15 HCMV seropositive and 6 seronegative healthy donors, using overlapping 
synthetic long peptides (SLPs) covering the entire IE2 amino acid sequence. Interestingly, 
IE2-specific T-cell reactivity could be detected directly ex-vivo in more than half of all 
screened individuals. The response was dominated by CD4+ T cells and IE2-specific CD8+ 
T-cell reactivity was found in only 3 donors. A number of previously identified but also 
new T-cell epitopes were found. Among all immunogenic SLPs there were five, which 
were frequently recognized among healthy donors, containing epitopes recognized by 
CD4+ T cells and/or CD8+ T cells, and considered to be useful in vaccine development.
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RESULTS 
Ex vivo detection of CD4+ and CD8+ T-cell responses against various HCMV IE2 peptide 
pools
To identify new HCMV IE2 MHC class I and MHC class II restricted T-cell epitopes 
a traditional high-throughput and well established screening strategy using overlapping 
SLPs was performed [27]. Importantly, the use of overlapping SLPs accelerates prediction 
of the exact peptide sequence recognized when a positive response is monitored. 
Synoptic illustration of the approach is presented in Figure 1. 
A cohort of 21 healthy human volunteers (15 HCMV-seropositive and 6 HCMV-
seronegative), aged between 34-65 years, were recruited irrespective of gender, ethnic 
and educational background criteria (Table 1). To capture virus-primed T-cell reactivity, 
the directly ex vivo detectable IE2-specific cellular response against each of the peptide 
pools, was evaluated based on the percentage of antigen-specific IFN-γ and TNF  
producing CD4+ and CD8+ T cells.
Figure. 1. Overview of the screening strategy to discover IE2-specific T cell epitopes. Forty-one 
‘28-mer SLPs overlapping by 14 aa and covering the whole IE2 HCMV protein were synthesized. 
Eight pools each consisted of 5-6 SLPs. PBMCs from 21 healthy adult human individuals of which 
15 were HCMV-seropositive and 6 HCMV-seronegative were screened by ex vivo ICS for direct 
recognition of IE2 SLP pools. Next, T cells that recognized peptide pools were cultured in vitro for 
10 days and subsequently expanded T cells were analysed for IE2-specific CD4+ and CD8+ T cells 
using ICS and flow cytometric analysis. Positive responses against individual SLPs were confirmed 
and IE2-specific MHC class I and II epitopes were identified. A set of 5 IE2 peptides that were 
frequently recognized by CMV seropositive healthy donors was identified.
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Interestingly, IE2-specific CD4+ T-cell responses were detected in 11 of the 15 HCMV-
seropositive donors and IE2-specific CD8+ T cell responses were detected in 3 of these 
donors (Table 1, Figures 2A and B). Surprisingly, IE2-specific CD4+ T-cell reactivity was 
also detected in 3 HCMV-seronegative donors (donor 16, 17 and 20). Peptide pool 6 
(IE2351-434) was the most frequently recognized immunogenic region (9/21 positive 
responders), followed by pool 1 (IE21-84) and pool 7 (IE2421-504). Peptide pools 3, 4 and 5 
(IE2141-364) were barely recognized (Figures 2A and B). Notably, the magnitude of the ex 
vivo detected response was low and a phenotypic analysis was difficult. 
Typical examples of HCMV-seropositive subjects (donor 1 and 6) and HCMV-
seronegative subjects (donor 16) who displayed IFN-γ+/TNF + CD4+ T-cell reactivity 
upon stimulation with IE2 peptide pools are provided in Figure 3.
In parallel, the response to the pp65 peptide pool was measured as this allowed 
us to compare and interpret the magnitude and impact of the IE2 T-cell immune 
response during HCMV infection. Although the level of the responses fluctuated 
among donors, most of the HCMV seropositive donors showed CD4+ T-cell reactivity 
against both antigens (Table 1, Figure 2 and Figure 4A). The size of the pp65 CD4+ T-cell 
responses, however, did not exhibit a direct correlation with the equivalent IE2 peptide 
pool responses (Figure 4B). Furthermore, while IE2-specific CD8+ T-cell reactivity was 
infrequently detected, the pp65 SLP pool was recognized by CD8+ T cells in 8 out of 
15 seropositive donors and none of the seronegative donors (Figure 4C, Table 1 and 
Figure 2B).
Taken together, ex-vivo immune reactivity testing showed that the HCMV IE2 protein 
has a high propensity to activate CD4+ T cells comparable to pp65. Especially, the amino 
acid sequence covered by the IE2 peptide pool 6 is recognized by the majority of 
the donors responding to IE2, revealing a remarkably immunogenic area of the protein. 
In contrast to pp65, the IE2 protein does not efficiently stimulate ex vivo detectable 
CD8+ T-cell reactivity. 
Identification of MHC class I- and II- restricted IE2 T-cell epitopes 
Responding donor PBMCs were stimulated with each of the individual peptides present 
in the pool to confirm the ex vivo detected IE2-specific T-cell responses and to identify 
the peptides recognized in each of the recognized IE2 peptide pools. The responding 
T cells were first expanded for 10 days in vitro, then stimulated with each individual 
Figure. 2. Ex vivo IFN-γ+/TNFα+ CD4+ (A) and CD8+ (B) T-cell responses measured in each donor 
following stimulation with different peptide pools. Donor’s identification number (ID) and HCMV 
status are depicted. Responses to the pp65 and IE2 pools are also shown. Unstimulated samples 
(negative) response measured present the background response. Cellular cytokine responses >2 
fold higher than the background responses were considered positive (light grey) and the peptide 
response was further evaluated. Positive CD4+ T-cell responses were measured in 14 donors and 
positive CD8+ T-cell responses in 3 donors.
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SLP followed by polychromatic ICS. Peptide-specific CD4+ and CD8+ T-cell reactivity was 
detected in 11 and 3 donors, respectively, confirming the ex vivo measured responses. 
Representative examples of robust reactivity detected in the peptide-expanded PBMC 
of HCMV-seropositive and seronegative donor’s T cells are depicted in Figure 5. Few 
donors displayed reactivity to one SLP but most of them reacted to 2 or more SLPs with 
donor 6 showing a CD4+ T-cell response to 13 different SLPs (Supplementary Table 2).
 In the end, the in vitro culture revealed many more IE2-specific T-cell epitopes than 
appreciated from the ex vivo ICS where IE2 peptide pools were tested. A summary of 
all CD4+ and CD8+ T-cell responses measured against individual SLPs is provided in 
Tables 2 and 3, respectively. 
The Immune Epitope Database (IEDB) site was used to search for all known MHC 
class I and MHC class II T-cells epitopes of the IE1 (UL123) and IE2 (UL122) HCMV viral 
proteins till June 2016. A chart depicting the exact position and HLA restriction of 
all the previously identified IE1 and IE2 T-cell epitopes (including the T-cell epitopes 
identified in this study) is given in Supplementary Fig. 2.  Importantly, we were able to 
confirm most of the previously reported MHC class I- and class II-restricted IE2 specific 
Figure. 3. CD4+ T-cell recognition of IE2 SLP pools in HCMV-seronegative and seropositive 
subjects. Donor’s PBMCs were stimulated with 8 different IE2 peptide pools (each pool consists of 
5-6 SLPs) and T-cell reactivity was measured by ICS assay and analysed by flow cytometry. Typical 
examples of ex vivo IFN-γ+/ TNF + CD4+ T-cell reactivity captured in HCMV-seropositive (donor 1 
and 6) and HCMV-seronegative individuals (donor 16) are displayed. The background response 
was measured in unstimulated PBMCs (medium) and SEB served as positive control. The x-axis 
of the fluorescent intensity plots indicates percentages of IFN-γ and the y-axis TNF  cytokine 
production within CD4+ T cells.
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Figure. 4. Characterization of the total IE2 and pp65 HCMV-specific CD4+ and CD8+ T-cell 
responses measured in HCMV-seropositive and seronegative subjects. Donor PBMCs were 
screened by ex vivo ICS for direct detection of IE2 and pp65 pool specific CD4+ and CD8+ 
T-cell reactivity. In total 21 donors were tested, of whom 15 were HCMV-seropositive and 6 
HCMV-seronegative (A) Percentages of the total pp65 and IE2 pool IFN-γ+/ TNF + CD4+ T-cell 
responses detected across the whole population sample are shown. (B) No correlation between 
the magnitude of the pp65 and IE2 pool CD4+ T-cell responses was observed in responder donors 
(n=12 and p > 0.055). (C) Frequency of IFN-γ+/ TNF + cytokine producing CD8+ T-cell responses 
measured ex vivo against the pp65 and IE2 peptide pools I (n=21). CD8+ T-cell reactivity against 
the IE2 peptide pool was detected only in donor 10, whereas pp65 specific CD8+ T-cell reactivity 
was measured in 8 out of 15 HCMV-seropositive donors.
108 | Chapter 4
Figure. 5. CD4+ and CD8+ T-cell epitope identification in HCMV-seropositive and seronegative 
subjects.  Ex vivo positive peptide pools for CD4+ and CD8+ T-cell reactivity PBMCs were expanded 
following 10 days in vitro culture and subsequently stimulated with each SLP contained in 
the relevant pools. Characteristic plots of T-cell epitope validation ICS results are shown for 2 
HCMV-seropositive individuals (donor 1 and 6) and a HCMV-seronegative donor (donor 16). 
For donor 1, CD4+ and CD8+ T-cell reactivity to SLPs 29 and SLP 30 was measured indicating 
the presence of MHC class I and II epitopes. Responses to individual SLPs, peptide pools and 
the IE2 pool are depicted. As a negative control, unstimulated PBMCs (medium) were used and as 
a positive control SEB. The x-axis of the fluorescent intensity plots indicates percentages of IFN-γ 
and the y-axis TNF  cytokine production within CD4+ or CD8+ T-cell populations.
T-cell epitopes [28-37], but we also identified a total of 6 new CD4+ T-cell epitopes and 
1 new CD8+ T-cell epitope. 
Polyfunctional cytokine profiling of T-cell responses against the most immunogenic 
IE2 epitopes 
The number of individuals responding to a peptide is a reflection of its immunogenicity. 
From the 41 individual IE2 SLPs there were 5 of which a unique sequence is present that 
was recognized by the CD4+ T cells (SLPs #3, 26, 28, 30 and 32) or CD8+ T cells (SLP #27/28) 
of the majority of tested donors (peptide sequences marked in bold in Table 2 and 3). As 
the functional traits of the T-cell response responding to such a peptide is an important 
determinant for its potential protective efficacy against HCMV infection, the cytokine 
profile of all the IE2-specific T-cell epitopes was examined. All selected peptide epitopes 
elicited a polyfunctional cytokine response as indicated by the percentage of T cells 
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co-secreting all three, IFN-γ+/ TNF +/ IL-2+, antiviral cytokines. In conclusion, 5 highly 
immunogenic IE2 SLPs, capable of inducing polyfunctional type 1 cytokine T-cell 
responses (Figures 6A-F) were identified. 
DISCUSSION
Controlling viral infection at an early phase may prevent wide dissemination and full 
blown infection. Reinforcement of the T-cell response to highly immunogenic antigens 
expressed immediately after infection could be key in the development of protective 
vaccines. The IE2 protein, which is expressed early after HCMV infection and reactivation, 
is likely to be a particularly valuable target for vaccine strategies against HCMV. In this 
study, we assessed the immunogenicity of the HCMV IE2 protein to identify amino acid 
stretches that were frequently targeted by T cells of healthy HCMV-protected donors. 
This led to the identification of numerous new and previously found [28-37] MHC class 
I- and II-restricted epitopes, to which T-cell reactivity could be detected directly ex vivo. 
The majority of the identified epitopes are located across the IE2351-434 residues, stressing 
that this is a very immunogenic area. Furthermore, we could single out five particularly 
interesting SLPs that were frequently recognized by donors with different HLA restriction 
elements. These SLPs contained epitopes recognized by CD4+ T cells and/or CD8+ T cells 
[28,34-37] and could form the core of a IE2-targeting T-cell based vaccine.
Unexpectedly, IE2 specific CD4+ T cell responses were detected ex vivo and in the 10 
day cultures from 3 out of 6 HCMV seronegative donors. This is not uncommon among 
individuals who are immune against viral infections. For instance, HIV-specific memory 
T cells accompanied with a complete lack of humoral immunity has also been observed 
in seronegative highly HIV-1-exposed individuals [38,39]. This finding supports 
the idea that CMV exposure does not inevitably lead to persistent infection and that 
heterogeneity in infection susceptibility could be due to natural protective immunity to 
CMV. One potential contributor to this difference may be the size of the initial infectious 
inoculum as it dramatically influences the antibody and T-cell response to the virus 
[40,41]. Phenotypic and functional characterization of cellular responses in HCMV 
resistant individuals or donors, who elicit merely virus-specific T-cell reactivity but 
lack humoral immune responses, might reveal distinct T-cell features and biomarkers 
of protection. However, the very low response rate in this study did not allow us to 
determine the T-cell activation status and to distinguish between effector or memory 
T-cell populations. 
Analysis of the T-cell response against IE2 revealed a predominance of ex vivo 
detectable CD4+ T-cell mediated reactivity (11 out of 15 seropositive donors) whereas 
CD8+ T-cell reactivity was seen in 3 donors only. This is consistent with a recent study 
[28] and not a technical problem since pp65-specific reactivity was readily detected 
ex vivo in the CD8+ T-cell population in parallel. A concomitant induction of CD4+ 
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Figure. 6. Functional profiling of the most immunogenic MHC class I and II IE2 T-cell epitopes 
identified. (A-E) Percentages of IFN-γ+ producing CD4+ and (F) CD8+ T cells elicited by responder 
donors following re-stimulation with relevant peptide. Cytokine production was measured in (in 
vitro) expanded donor T cells by polychromatic ICS assay. Pie charts show the percentages of 
the single (IFN-γ+), double (IFN-γ+/ TNF +) and triple (IFN-γ+/ TNF +/ IL-2+) cytokine producers 
within each antigen-specific CD4+ or CD8+ T-cell population and across all the responder donors. 
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and CD8+ T-cells responses of a good magnitude, breadth and functional profile are 
crucial preconditions of vaccine efficacy [42-45]. Indeed, in the mouse model for 
CMV prophylactic vaccination with a mixture of SLPs comprising MHC class I- and II-
restricted T-cell epitopes derived from different immunogenic proteins resulted in 
the best containment of virus dissemination after a challenge with lytic MCMV [12,14]. 
The detection of several immunodominant T-cell epitopes in the most immunogenic 
HCMV open reading frames (ORFs proteins) makes the translation of these findings in 
human clinical vaccine applications a valid and promising research target. Interestingly, 
while IE2 predominantly activates a strong ex vivo detectable CD4+ T-cell response, 
the IE1 protein largely triggers an ex vivo measurable response to CD8+ T cells [28]. 
These data would argue that an optimal SLP vaccine targeting the early phase of 
HCMV infection might require a mixture of IE1 and IE2 SLPs to achieve induction of 
a balanced CD4+ and CD8+ T-cell response. Of note, the SLP3 is shared between IE1 and 
IE2. Potentially the processing and presentation of this epitope is stronger in infected 
cells, however, whether such an epitope is more protective remains to be elucidated.
The development of efficient immunotherapeutic approaches against HCMV disease 
is an important research priority. The IE2 protein has never been explored in antibody 
or T-cell based vaccine platforms.  We here showed that the spontaneous immune 
response to IE2 is characterized by highly polyfunctional CD4+ T-cell reactivity that can 
be measured directly ex vivo. Moreover, the similar detection frequency of IE2- and 
pp65-specific T-cell reactivity validates IE2 as a strongly immunogenic HCMV target and 
identifies IE2 as a potential vaccine candidate. With that in mind, our study identified 
5 highly immunogenic regions containing clusters of IE2 T-cell epitopes which could 
be exploited in vaccine development strategies but also in adoptive transfer therapies.
MATERIALS AND METHODS
Donors and sample
PBMCs from 15 HCMV-seropositive and 6 HCMV-seronegative subjects were isolated 
from buffy coats obtained after informed-consent (Sanquin, The Netherlands) by Ficoll 
(Ficoll-Amidotrizoaat, pharmacy LUMC) density gradient centrifugation. PBMC were 
cryopreserved in 80% Fetal Calf Serum (FCS; PAA laboratories) and 20% DMSO (Sigma) 
and stored in the vapour phase of the liquid nitrogen until further use. Handling and 
storage of donor PBMCs were performed according to the standard operating procedure 
(SOP) of the department of Medical Oncology at the Leiden University Medical 
Center [46].  
Peptides and preparation of peptide pools 
The IE2 amino acid sequence of the laboratory strain AD169 was used to synthesize 
41 peptides of 28 amino acids in length and overlapping by 15 amino acids, together 
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covering the entire IE2 sequence, at the GMP-peptide facility of the LUMC. The purity 
(75-90%) of the synthesized peptides was determined by HPLC and the molecular 
weight by mass spectrometry. Additionally, a pool of peptides spanning the whole 
pp65 protein and a HLA A*0201-restricted pp65495-503 (NLVPMVATV) peptide were 
included in the T-cell detection assays. The peptides were dissolved in DMSO at 
a stock concentration of 50 mg/ml and then further diluted to a concentration of 2 
mg/ml and stored in -20°C. Subsequently, 8 peptide pools, each comprising either 5 or 
6 SLPs, were made and stored under the same conditions as the individual peptides. 
All individual IE2 peptides, and IE2 peptide pools used in this study are listed in 
Supplementary Table 1.
Ex vivo detection of antigen-specific T cells
Direct ex vivo detection of HCMV-specific T cells was performed as described before 
[27]. Briefly, autologous plastic adherent monocytes were cultured in X-vivo 15 medium 
(Lonza) supplemented with granulocyte-macrophage colony-stimulating factor (800 
IU/ml GM-CSF; Invitrogen) for 2-4 days at 37°C, 5% CO2 in a humidified incubator. Then, 
cells were incubated for 5 h with each of the IE2 peptide pools, a pool of all IE2 peptides, 
a pool of all pp65 peptides or the pp65 short peptide (SP) in a final concentration of 
50 μg/ml and for 24 h in the presence of poly (I:C) (25 μg/ml; Invivogen). A medium 
control sample served as negative control and Staphylococcal enterotoxin B (SEB; final 
concentration of 2 μg/ml; Sigma) was used as a positive control. Autologous donor 
PBMCs at a final concentration of 2-4 × 106 cells/well and Roferon (interferon-alpha 2a, 
3 × 106 U/0.5 ml; Roche) were added to the cultured monocytes. An hour later, Brefeldin 
A (Sigma) was added and cells were incubated for 16-20 h (37°C, 5% CO2) to allow 
the accumulation of intracellular cytokines. Subsequently, the cells were stained for 
live/dead marker (Yellow ARD, Life Technologies), CD3 (clone UCHT1), CD4 (clone SK3), 
CD8 (clone SK1), CD14 (M5E2), IFN-γ (B27), IL-2 (clone 5344.111), CD137 (clone 4B4-1), 
CD154 (TRAP1) all from BD and TNF  (clone MAb11), CD45RA (clone HI100) both from 
Biolegend according to SOP of the department of Medical Oncology. Samples were 
acquired at a LSRFortessa cytometer (BD Biosciences) and analysed using FlowJo-V10 
software (Tree star). Flow cytometry gating strategies are shown in Supplementary 
Fig. 1. An immune response was considered positive when donor T cells produced both 
IFN-γ and TNF  and the response was ≥ 2 than the background (medium control). 
In vitro expansion of low frequency antigen-specific T cells
To confirm the ex vivo detected T-cell responses against the IE2 SLP pools and to 
determine the reactivity to the individual SLPs within each pool, PBMC were subjected 
to a 10 day antigen-specific T-cell stimulation culture [47]. Briefly, donor PBMCs were 
thawed, resuspended in IMDM + 10% human AB serum (HAB, Life Technologies) and 
seeded in triplicate wells (3 ml/well) in a 6-wells plate (Costar). Tested peptide pools 
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were added to the PBMCs in a final concentration of 2.5 μg/ml and cells were cultured 
overnight at 37°C, 5% CO2. The following day, 5 ng/ml IL-15 (Peprotech) and T cell growth 
factor (TCGF, Zepto Metrix) to a final concentration of 10% were added to the cultured 
T cells (referred to as bulk cultures) and cells were maintained for 10 days. In parallel on 
day 7, autologous donor PBMCs were thawed, seeded in 24-wells plates and monocytes 
were cultured for 2 days and loaded with indicated peptide pools and all individual 
SLPs that the pool contained in a concentration of 5 μg/ml. On day 10, bulk cultured T 
cells were harvested and 7 × 105 – 1 × 106 cells/ml were added to the loaded monocytes. 
An hour later, Brefeldin A was added and cells were incubated for 16-20 h (37°C, 5% 
CO2). The same positive and negative controls as in the ex vivo detection assay were 
also included. Subsequently, an intracellular cytokine staining (ICS) was performed and 
samples were measured and analysed as described above. An immune response was 
considered positive when donor T cells produced IFN-γ and the response was ≥ 2 than 
the background (medium control). 
Statistical analysis
Statistical significance was calculated using the unpaired Student’s t-test or ANOVA in 
GraphPad Prism software version 6 (GraphPad Software Inc., USA). Statistical significance 
levels were *p < 0.05, **p < 0.01 and ***p < 0.001.
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SUPPORTING INFORMATION
Supplementary Table 1. List of the IE2 SLP pools and individual SLPs used in this study. 
SLP # Peptide residues (aa) SLP Sequence
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Supplementary Table 2. Summary of IE1 and IE2 CD4+ and CD8+ T cell responses identified per 
donor. 21 donors were evaluated for CD4+ and CD8+ T-cell recognition of 28-mer IE2 peptides by 
ICS assay. Because the initial 85 amino acids of the IE1 and IE2 proteins are identical, the responses 
have been divided into three segments: shared IE1 and IE2 and unique IE2. The total number of 
the combined single and shared CD4+ and CD8+ T-cell responses measured is depicted. CD4+ T-cell 
responses were confirmed in 11 donors, including 3 HCMV-seronegative (donors 16, 17 and 20). 
CD8+ T-cell responses were detected in 3 HCMV-seropositive donors. 
Donor #
IE1/IE2 shared segment* Unique IE2 segment IE2 total
CD4 CD8 CD4 CD8 CD4 CD8
1 5 2 5 2








10 10 2 10 2
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Supplementary Figure 1. Gating strategy for intracellular cytokine staining to identify 
CD4+ and CD8+ IE2 T-cell responses. In sequential gating, cells were initially gated for singlet’s 
(SSC-A vs. FSC-H) and then for viability (FSC-A vs. live/dead) and lymphocytes (FSC-A vs. SSC-A). 
Next lymphocytes were gated on CD3+ CD14- to exclude monocytes and subsequently analysed 
for the expression of IFN-γ+ producing CD4+ and CD8+ T cells. CD4+ and CD8+ T-cell subsets 
were further analysed for expression of TNF  and IL-2 cytokines and several activation markers 
(CD154, CD137).
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Supplementary Figure 2. 
Chart of all the IE1 
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ABSTRACT
Cytomegalovirus (CMV) infection elicits long-lasting strong T cell responses. This 
property along with the ability to engineer the genome of this DNA virus, and 
the capacity of CMV to re-infect hosts despite pre-existing immunity has led to studies 
on the potential of CMV as vaccine vector. Pre-existing immunity, however, is known 
to reduce the infectious effect of CMV. Given the high variability in the magnitude of 
CMV-specific T cell responses in the human population, we here determined whether 
the level of pre-existing immunity influences the efficacy of CMV-based vaccine vectors 
in tumor mouse models. Immunization with CMV-based vaccines via the intraperitoneal 
or subcutaneous route eliciting strong vaccine-induced CD8+ T cell responses that 
fully protected mice against lethal challenge with subcutaneous tumors expressing 
the model tumor antigen E7 of human papillomavirus type 16 (HPV16). Previous 
exposure to CMV via low dose or intranasal infection elicited weak CMV-specific 
immunity and did not result in an altered efficacy of the anti-tumor response following 
subsequent immunization with the CMV-based vaccine vector. In contrast, strong pre-
existing immunity due to high dose CMV infection prevented vaccine-induced T cells to 
control tumor outgrowth. Together, our studies highlight the prospective of CMV-based 
vaccines, yet warrant that the level of pre-existing immunity should be considered 
when aiming for optimal efficacy of such vaccines.
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INTRODUCTION
The role of the immune system in cancer eradication has been firmly established, 
and immunotherapy of cancer has set itself as a mainstream therapy among 
the conventional therapies comprising chemotherapy, radiotherapy and surgery. 
Immunotherapeutic approaches in which the inhibitory pathways are blocked to 
rejuvenate tumor-specific T cells (immune checkpoint blockade) and adoptive cell 
therapy (ACT) with tumor-specific T cells have shown efficacy in a significant number 
of patients [1,2]. Vaccination, is another promising form of immunotherapy that has 
been extensively explored, yet currently not many vaccines show clear clinical benefit. 
The latter has been contributed to the lack of inducing substantial long-lasting 
functional T cell responses able to overcome the immunosuppressive environment [3].
Cytomegalovirus (CMV) is unique among other viruses as this common betaherpesvirus 
is characterized by a strong induction of so-called memory inflation [4]. This process is 
characterized by virus-specific T cell responses and antibody levels that do not decline 
after primary infection but remain high or even increase over time [5,6]. Inflationary T 
cells are mostly effector-memory like, remain life-long polyfunctional, and are found in 
both lymphoid organs and tissues [7]. Despite the induction of host immune responses, 
CMVs are still able to re-infect [8]. Based on these properties, together with the ability to 
engineer the genome of CMV to attenuate the pathogenicity and/or to express foreign 
genes/epitopes that are of interest for vaccination, CMV-based vaccines have recently 
been explored. In mice and non-human primates the efficacy has been greatly valued 
against pathogens including SIV and Ebola [9,10]. Moreover, CMV-based vaccines 
containing tumor antigens have also shown anti-tumor efficacy in prophylactic and 
therapeutic settings [11-13]. 
Although CMV has the capacity to re-infect the host despite the presence of CMV-
specific T and B cell responses that were elicited upon primary infection, experimental 
and epidemiological data indicated that pre-existing immunity is lowering 
the pathogenicity of the virus [14]. For example, mothers previously exposed to CMV have 
a lower prevalence of transmitting congenital CMV infection compared to unexposed 
mothers [15]. Given the promising results of CMV-based vaccine vectors to elicit 
responses with persistent immune activity against cancer, we studied here the efficacy 
of such vaccines on protection against tumor progression but also addressed the impact 
of pre-existing immunity. This is highly relevant in light with the large prevalence of 
this virus world-wide, and the fact that there is a great diversity in the level of pre-
existing immunity based on the large difference in the magnitude of CMV-specific T 
cell responses in the population, ranging from nearly detectable to 40% of the memory 
compartment [16]. Here we found that CMV-based vaccines eliciting strong vaccine-
induced CD8+ T cell responses fully protected mice against lethal tumor challenge. 
Previous exposure to CMV eliciting weak immunity did not impact vaccine efficacy, 
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however, strong pre-existing immunity prevented vaccine-induced T cells to control 
tumor outgrowth. The results highlight the potential of CMV-based vaccines, yet 
warrant that the level of pre-existing immunity should be taken into account when an 
optimal vaccine-induced immune response is required. 
RESULTS 
Recombinant MCMV induces large inflationary T cell responses to inserted antigens
To assess the immune protection induced by CMV-based vaccine vectors against cancer, 
we first measured the kinetics of the vaccine-induced response after immunization 
with MCMV-based vectors containing tumor-specific antigens. Mice were infected i.p. 
with recombinant MCMV (MCMV-IE2-E7) expressing a single tumor-specific CD8 T cell 
epitope RAHYNIVTF (E749-57) derived from the E7 oncogene of HPV16. This epitope was 
fused to the carboxyl terminus of the MCMV IE2 gene because epitopes at this position 
are known to induce strong inflationary responses [17]. The non-inflationary response 
to the M45985-993 epitope present in the recombinant MCMV and in MCMV-Smith showed 
the classical response of rapid expansion till day 8 followed by swift contraction and 
stable memory formation (Figure 1A and 1B). The E7-specific CD8+ T cell response in 
the blood showed similar inflationary response kinetics as the response to the MCMV 
M38316-323 epitope in the same vector or in wild-type MCMV (Figure 1A and 1B). 
Characteristic of inflationary T cells is their effector-memory (EM) like (CD44+CD62Llow, 
CD127+/-, KLRG1+ appearance [4]. In the acute phase of infection, the percentage of T 
cells with a naïve phenotype (CD44- CD62L+ KLRG1-) dropped to 50%, and remained 
stable during memory phase. In contrast, the percentage of EM-like cells within the total 
CD8+ T cell population increased to 15-20%. Detailed analysis of the phenotype of 
antigen-specific CD8+ T cell populations indicated that 40% of the M45-specific CD8+ 
T cells showed an EM phenotype throughout the memory phase. M38-specific CD8+ T 
cells displayed a gradual increment of the EM phenotype up to 70-80 %. The E7-specific 
CD8+ T cells acquired a similar high level of EM-like cells, albeit already early after 
immunization, which remained high throughout the memory phase. Taken together, 
these data show that immunization with MCMV-IE2-E7 vector induces inflation of 
the E7-specific CD8+ T cells with an EM-like phenotype.
The magnitude of inflationary T cell responses is influenced by the route of infection
To investigate the impact of the route of infection for the application of MCMV-based 
vaccine vectors, we compared the kinetics of the antigen-specific CD8+ T cell responses 
upon i.p., i.n. and s.c. infection. Infection via i.p. and s.c. routes with MCMV-IE2-E7 elicited 
up to 3.5% non-inflationary M45-specific T cell responses within the total CD8+ T cell 
pool at day 7 post infection, and during the memory phase of infection around 1% was 
stably lasting (Figure 2). However, i.n. infection induced only 0.1% M45-specific T cells, 
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Figure 1. Recombinant MCMV vectors induce potent T cell responses resembling wild-type 
MCMV infection. Mice were infected with 1x105 PFU (i.p.) MCMV-Smith or MCMV-IE2-E7, and at 
the indicated times, the CD8 T cell responses were examined in blood. (A) Representative flow 
cytometry plots for MHC class I tetramer (Tm) staining to M45, M38 and E749–57 epitopes in blood of 
MCMV-IE2-E7 infected mice or naïve mice (control) during acute phase (day 8 post virus infection) 
and memory phase (day 64 post virus infection). Numbers represent the percentage of Tm+ cells 
within the total CD8+ T cell population. Flow cytometry plots show similar numbers of cells in 
each plot. (B) The frequency of MCMV- and tumor antigen-specific CD8+ T cells in blood for each 
epitope, identified using MHC class I tetramers in mice infected with 1x105 PFU (i.p.) MCMV-Smith 
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and during the memory phase this response was close the detection limit. The M38-
specific CD8+ T cell response after both i.p. and s.c. infection was 1% and 3% of the total 
CD8+ T cell population, respectively, at the acute phase of infection (Figure 2). During 
the persistent phase, i.p. infection resulted in a gradual increase of the M38-specific 
CD8+ T cells (up to 6%), whereas the responses upon s.c. infection remained relatively 
robust, yet steadily declined. Similarly, E7-specific T cell responses raised gradually up 
to 6% upon i.p. infection while after s.c. infection responses remained high but did not 
inflate. Upon i.n. infection, the MCMV and E7-specific CD8+ T cell responses were small 
(Figure 2). Taken together, these data show that i.p. and i.n. infection induces prominent 
T cell responses, albeit with different kinetics, while i.n. infection resulted in weak 
responses at best.
The strength of the vaccine-induced immune response determines the anti-tumor 
efficacy of MCMV-based vaccine vectors
Next, we investigated the influence of the route of infection and the resulting T cell 
response of the MCMV vectors on their vaccine efficacy in tumor challenge experiments. 
We prophylactically vaccinated mice with MCMV-IE2-E7 via the i.p., i.n. or s.c. routes and 
subsequently challenged them with TC-1 tumor cells expressing the HPV-16 E6 and E7 
oncoproteins. While TC-1 tumors grew out progressively in all naïve mice, immunization 
with MCMV-IE2-E7 via the i.p. and s.c. route induced complete protection against TC-1 











































Figure 2. Impact of the route of administration of MCMV-IE2-E7 vaccination on the elicited CD8 
T cell response. Mice were infected with 1x105 PFU i.p., 1x105 PFU i.n. and 5x105 s.c. MCMV-IE2-E7 
at day 0. The antigen-specific CD8+ T cell responses were followed in blood for more than 60 days. 
Frequency of MCMV- and antigen-specific CD8+ T cells to M45 (A), M38 (B) and E7 (C) epitopes. 
Data represents mean values ± SEM (n = 7-8 mice per group). Data represents mean values + SEM 
(n = 7-8 per group), and are representative of two independent experiments.
or MCMV-IE2-E7. Data represents mean values ± SEM (n = 5-7 mice per group). (C) Percentages 
of EM cells (CD44+ CD62L- KLRG-1+ CD127-) within the total CD8+ T cells and within the E749–57 Tm
+ 
population. Data represents mean values + SEM (n = 7 mice per group), and are representative of 
two independent experiments.
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Figure 3. Different routes of infection with recombinant MCMV vaccine vectors induce various 
levels of protection against tumors. Mice were infected with 1x105 PFU i.p., 1x105 PFU i.n. and 
5x105 s.c MCMV-IE2-E7 at day -35 or kept uninfected (A-B). CD8 depleting antibody was given in 
the group of mice infected with MCMV-IE2-E7 via i.p. at the day -4. On day 0, all the mice were 
challenged with 1x105 TC-1 tumor cells. The tumor outgrowth and survival of the mice was 
followed for 60 days. A) TC-1 tumor growth graphs of mice challenged with different routes of 
infection with MCMV-IE2-E7 compared to untreated mice. The number of tumor-free mice from 
the total mice is indicated above each graph. B) Survival graph of TC-1 tumor challenged mice 
shown in A. C) Tumor outgrowth kinetics of mice immunized with 5x105 PFU MCMV-IE2-OVA via 
the i.p. or i.n. route. After 60 days, mice were challenged with TC-1 tumor cells. The number of 
tumor-free mice from the total mice is indicated above each tumor out growth graph. 
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tumor challenge (Figure 3A and 3B). However, intranasal immunization with MCMV-
IE2-E7 only protected 50% of the mice (Figure 3A and 3B). Remarkably, all the mice which 
remained tumor free till day 60 were also protected against tumor rechallenge with 
unrelated C3 tumor cells expressing the E7 oncoprotein (data not shown), indicating 
the induction of immunological memory. 
To assess if MCMV-based vaccine vector induced tumor protection is determined by 
CD8+ T cells, we depleted these cells 4 days before TC-1 tumor challenge in mice infected 
earlier with MCMV-IE2-E7 via the i.p. route. Clearly, all the tumors grow out similar to 
untreated mice, suggesting the importance of vaccine-elicited tumor antigen-specific 
CD8+ T cells (Figure 3A and 3B).  To exclude possible bystander effects of virus infection 
on protection against tumor outgrowth, mice were infected with recombinant MCMV 
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not expressing the tumor antigen E7 (MCMV-IE2-OVA via the i.n. and i.p. route and 
challenged with TC-1 tumor cells. Infection with MCMV-IE2-OVA induced inflationary 
T cell responses against H-2kb-restricted OVA257-264; SIINFEKL epitope and M38 and 
a non-inflationary response to the M45 epitope of the virus (Supplementary Figure 1). 
Importantly, TC-1 tumor cells grew out in all the mice immunized with MCMV-IE2-OVA 
via i.n. and i.p. route, suggesting that a vaccine-induced specific T cell response against 
antigens expressed by the tumor is required to induce protective immunity (Figure 3C). 
Thus, immunization with MCMV-IE2-E7 via the i.p. and s.c. routes of infection induces 
large tumor-specific T cell responses which are better capable of controlling tumor 
out growth.
To evaluate the impact of the magnitude of the elicited vaccine-specific CD8+ T cell 
response by MCMV-based vaccine vectors in the same setting (i.e., route of infection), 
we immunized mice with different inoculum dosages (Figure 4A). Immunization of 
mice with 5 × 105 PFU MCMV-IE2-E7 via the s.c. route could protect all the mice from 
tumor outgrowth (Figure 4A, Group 2). However, immunization with 1000 fold less virus 
(500 PFU) could protect only 3 out of 12 mice (Figure 4A and 4B, Group 5). Similarly, i.n. 
immunization with 1 × 105 PFU MCMV-IE2-E7 resulted in 40% survival (Figure 4A, Group 
3) whereas all the mice succumbed when a 200 fold lower vaccine dose (500 PFU) was 
provided (Figure 4A and 4B, Group 6). Also, i.p. infection with a lower dose led to loss of 
the vaccine-mediated protection (Figure 4A and 4B, Group 7). 
To analyse the association between the strength of the vaccine-induced CD8+ T 
cell response and tumor outgrowth, we determined the magnitude of the CD8+ T cell 
response in blood. Infection with a high dose of MCMV-IE2-E7 via the i.p. and s.c. route 
induced stronger T cell responses against the E7 epitope compared to infection via i.n. 
route or lower dosages regardless of the infection route (Figure 4C). Taken together, 
these data suggest that the magnitude of the vaccine-induced CD8+ T cell response is 
a key determinant for the efficacy of MCMV-based vaccine vectors against tumors.
The level of pre-existing immunity impacts the anti-tumor efficacy of MCMV-based 
vaccines
To investigate if pre-existing immunity can impact the induction of protective immunity 
by CMV-based vaccine vectors, we immunized mice with recombinant MCMV-IE2-
OVA via the i.p. route. After 35 days, mice were inoculated with recombinant MCMV 
expressing the E7 tumor antigen via i.p, i.n and s.c. routes and subsequently challenged 
with TC-1 tumor cells (Figure 5A). Remarkably, tumor out growth was observed in all 
the mice which were previously infected with MCMV-IE2-OVA, despite the prophylactic 
vaccination with MCMV-IE2-E7 (Figure 5A and 5B), indicating that previous i.p. infection 
with MCMV hinders the anti-tumor immunity irrespective of the route of vaccine 
administration. 
Next, we tested whether previous infections via routes that stimulate lower levels 
of MCMV reactivity can hamper the efficacy of the MCMV-based vaccine vectors. 
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Group 1: no treatment
Follow tumor outgrowthTC-1 tumor challenge
Group 2: MCMV-IE2-E7 s.c 5x105 PFU/mouse




Group 4: MCMV-IE2-E7 i.p 1x105 PFU/mouse
Group 5: MCMV-IE2-E7 s.c 500 PFU/mouse
MCMV-IE2-E7 i.n 500 PFU/mouseGroup 6:
MCMV-IE2-E7 i.p 100 PFU/mouseGroup 7:






























































Figure 4. Efficacy of MCMV based vector vaccine depends on doses of immunization. A) Mice 
were infected with indicated doses and routes or kept uninfected as shown in the scheme of 
the experiment. After 35 days, all the mice were challenged with 1x105 TC-1 tumor cells. The tumor 
outgrowth and survival of the mice was followed for 60 days. TC-1 tumor growth graphs of mice 
challenged with different doses and routes of infection with MCMV-IE2-E7. The number of tumor-
free mice from the total mice is indicated above each tumor out growth graph. B) Survival graph 
of TC-1 tumor challenged mice shown in A. C) Percentage of E7 Tm+ CD8+ T cells of the vaccinated 
mice shown in A and B. 
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Figure 5. Previous MCMV infection can affect the efficacy of the anti-tumor efficacy of MCMV-
based vaccine vectors. Mice were infected with 1x105 PFU i.p. or i.n. MCMV-IE2-OVA at day 0 or 
kept uninfected. After 35 days, the mice were challenged with 1x105 PFU MCMV-IE2-E7 via i.p. 
or i.n. route or with 5x105 MCMV-IE2-E7 via the s.c. route. All the mice were challenged with TC-1 
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Interestingly, mice infected with MCMV-IE2-OVA via the i.n. route and subsequently 
challenged with MCMV-IE2-E7 via the i.p. and s.c. route, did not develop tumor out 
growth but remained tumor-free (Figure 5C). 
To address whether pre-existing MCMV immunity hindered the vaccine-induced 
CD8+ T cell responses against MCMV and E7, we examined the antigen-specific T cell 
responses. Consistent with our earlier observation of the inflationary T cell response 
against E7, infection with MCMV-IE2-OVA via the i.p. route induced a strong and 
inflationary CD8+ T cell response against OVA257-264 epitope while via the i.n. route 
resulted in a low and non-inflationary response (Figure 6). The M38-specific CD8+ T cell 
response was stronger following i.p. injection of MCMV-IE2-OVA than when given i.n. 
and after challenge with MCMV-IE2-E7 this response was less boosted than the M38-
specific responses induced by i.n. injection followed by s.c. injection of the MCMV 
vectors. The E7-specific T cell response was higher after vaccination with MCMV-IE2-E7 
via the i.p. and s.c. route in the mice previously infected with MCMV-IE2-OVA via 





















































Follow T cells response in blood
Figure 6. The strength of the T cell response induced by MCMV-based vaccine vectors depends 
on the levels of pre-existing immunity. Mice were infected with 1x105 PFU i.p or i.n MCMV-IE2-
OVA at day 0. After 35 days, the mice were challenged with 1x10
5 PFU MCMV-IE2-E7 via i.p. or 
with 5x105 MCMV-IE2-E7 via s.c. Blood was taken at different time points to follow the antigen-
specific CD8+ T cell response. Top: Scheme of the experiment. Below: Frequency of OVA, E7 and 
M38-specific CD8 T cells, identified using MHC class I tetramers. Data represents mean values ± 
SEM (n = 6 mice per group). 
tumor cells 35 days after the second infection. The tumor outgrowth and survival of the mice 
was followed for 60 days. A) and C) top: Scheme of the experiment. A) and C) below: TC-1 tumor 
outgrowth graphs of the mice. The number of tumor-free mice from the total mice is indicated 
above each tumor out growth graph. B) Survival graph of TC-1 tumor challenged mice shown 
in A. 
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MCMV-IE2-OVA via the i.p. route. Together, these results suggest that the level of pre-
existing immunity impacts the development of vaccine-induced CD8+ T cell response 
induced by MCMV-based vector vaccine, and consequently the vaccine efficacy against 
tumor outgrowth.
DISCUSSION
Here we interrogated the impact of the pre-existing immunity on the efficacy of 
CMV-based vaccines against cancer. Such vaccines have the capacity to provide long-
lasting robust tumor-specific T cell responses that protect against tumors. We found 
that the efficacy is however decreased in case of high-level pre-existing immunity, 
which warrants for the use of CMV-based vaccines without pre-screening for CMV 
immunity. Alternatively, recombinant CMV vectors that are still able to induce strong 
responses despite pre-existing immunity might be engineered in the future. Such 
vectors do exist for Rhesus macaques. RhCMV vectors containing SIV antigens provide 
strong immunity despite that the Rhesus macaques were all CMV positive. However, 
the used vaccine vector was unusual as it lead to the induction of unconventional CD8+ 
T cells recognizing SIV epitopes presented by MHC class II and HLA-E molecules due to 
evasion of MHC class I and a limited tropism [18]. Testing HCMV-based vaccines with 
the same limited tropism leads however to conventional responses [19]. It remains to be 
determined whether efficacious HCMV vectors can be engineered for hosts with strong 
pre-existing immunity.
Inflating CMV-specific T cell populations are characterized by their EM-like 
phenotype and such responses seem to be qualitatively different with respect to their 
immediate effector functions and homing properties to tissues [20]. The latter is likely of 
importance to protect against viruses infecting mucosal areas, and may as well be crucial 
for clearance of tumors arising e.g. from epithelial or endothelial cells. Still, there may 
be settings in which vaccine-induced cells with an CM-like appearance, are beneficial. 
For example, the  superior expansion capacity of CM-like cells upon challenge, may be 
crucial to fight-off systemic viral infections with highly replicating viruses [21]. 
In contrast to CMV-based vaccines, the majority of vaccines do not induce sustained 
high quantities of T cells with an EM phenotype. However, recently it became evident 
that memory inflation is not entirely restricted to CMV-induced responses. A relevant 
example of this are responses induced by adenoviral vectors.  In mouse models, such 
vectors can lead to induction of inflationary responses resembling those induced by 
MCMV [22,23]. Interestingly, adenoviral vectors have been tested against human 
pathogens, including HCV, malaria and Ebola, and the vaccine-elicited responses are 
sustained over time and phenotypically resemble those induced by CMVs [24-26]. 
Whether CMV or adenovirus-based vaccines provide superior efficacy over each other 
in therapeutic settings remains to be determined.
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Overall, our study shows the importance of determining the level of pre-existing 
immunity for CMV-based vaccines, and suggest to include stratification based on 
the magnitude of CMV-specific T cell responses in pre-vaccinated individuals. The route 
and dose of immunization may then even be adjusted to improve the vaccine efficacy. 
We conclude that further studies will be needed to clarify these questions with 
the anticipation to improve the efficacy of CMV-based vaccines.
MATERIALS AND METHODS
Mice
C57BL/6 mice were obtained from Charles River Laboratories (L’Arbresle, France). At 
the start of the experiments, mice were 6 to 8 weeks old. Mice were housed in individually 
ventilated cages (IVC) under specific pathogen-free conditions in the animal facility of 
the Leiden University Medical Centre (LUMC, The Netherlands). All animal experiments 
were approved by the Animal Experiments Committee of LUMC and were executed 
according to the animal experimentation guidelines of LUMC and were in compliance 
with the guidelines of Dutch and European committees.  
Virus preparation, quantification, and infection
MCMV-Smith was obtained from the American Type Culture Collection (Manassas, VA, 
Unites States). Stocks were derived from salivary glands of infected BALB/c mice as 
described elsewhere [27]. Viral titers of virus stocks or infected tissues were determined 
by plaque assays as previously described [28]. MCMV-IE2-E7 (RAHYNIVTF) and MCMV-
IE2-OVA (SIINFEKL) were generated as described [17].
Tumor challenge models and anti-tumor vaccination 
The tumor cell line TC-1 (a kind gift from T.C. Wu, John Hopkins University, Baltimore, 
MD) was generated by retroviral transduction of C57BL/6 lung epithelial cells with 
the HPV16 E6/E7 and c-H-ras oncogenes [29] and cultured as previously described 
[30]. The tumor cell line C3 was developed by transfection of mouse embryonic cells 
with the HPV16 genome and an activated-ras oncogene and maintained as previously 
described [31]. The MC38-OVA tumor cell line is generated by a retroviral infection of 
the MC38 parental cell-line with PMIG/MSCV-IRES-GFP plasmid encoding cytoplasmic 
bound OVA [32]. Iscove’s Modified Dulbecco’s Media (IMDM) (Lonza, Basel, Switzerland) 
supplemented with 8% fetal calf serum (FCS) (Greiner), 2 mM L-glutamine (Life 
Technologies, Carlsbad, CA, Unites States), 50 IU/ml Penicillin (Life Technologies) and 50 
μg/ml Streptomycin (Life Technologies) was used to culture tumor cell lines. Cells were 
cultured in a humidified incubator at 37°C and 5% CO2. Mycoplasma tests that were 
frequently performed for all cell lines by PCR were negative.  
Treatment schedule of each experiment is indicated in the respective figures 
and legends. Mice were infected with 1 × 105 PFU MCMV intraperitoneally (i.p.) or 
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intranasally (i.n.) or with 5 × 105 PFU MCMV subcutaneously (s.c.) unless otherwise 
mentioned. In tumor experiments, mice were inoculated subcutaneously in right flank 
with 1 × 105 TC-1 or 5 × 105 C3 tumor cells in 200 μl PBS containing 0.2% BSA on day 
0. Tumor size was measured two times a week using a calliper. Mice were euthanized 
when tumor size reached >1000 mm3 in volume or when mice lost over >20% of their 
total body weight (relative to initial body mass). 
In vivo antibody usage
CD8 T cell depleting monoclonal antibodies (clone 2.43) were purchased from Bio X Cell 
(West Lebanon, NH, United States) and administered i.p. twice weekly (200 μg/mouse) 
for 2-3 weeks. CD8 T cell depletion was started 4 days before tumor challenge. Depletion 
was checked by staining for CD3 and CD8 followed by flow cytometric analysis. 
Flow cytometric analysis of blood immune cells
For analysis of blood immune populations, blood cells were collected at different time 
points. Erythrocytes were lysed in a hypotonic ammonium chloride buffer. Cells were 
resuspended in staining buffer (PBS + 2% FCS + 0.05% sodium azide) and incubated 
with various fluorescently labelled antibodies against CD8 (clone 53-6.7), CD62L 
(clone MEL-14), CD44 (clone IM7), KLRG1 (clone 2F1), CD3 (clone 500A2), CD127 (clone 
A7R34). Antibodies were obtained from eBioscience (San Diego, CA, United States), BD 
Biosciences (San Jose, CA, United States) and Biolegend (San Diego, CA, United States). 
For dead cell exclusion, 7-Aminoactinomycin D (Invitrogen, Carlsbad, CA, United States) 
was used. To measure the MCMV-specific and tumor antigen-specific T cell response, 
the following class I-restricted tetramers were used: MHC class I Db restricted tetramers 
for the OVA257-264 epitope (SIINFEKL) and HPV E749-57 (RAHYNIVTF), the MCMV epitope 
M45985-993, and MHC class I Kb restricted tetramers for the MCMV epitopes M38316-323, and 
were produced as described [33]. Samples were analysed with a BD LSRII or LSRFortessa 
flow cytometer, and results were analysed using FlowJo software (Tree Star, Ashland, 
OR, United States). 
In vivo cytotoxicity assay
Splenocytes of naïve CD45.1 (Ly5.1) mice were isolated and loaded with MHC class I Db 
restricted-E749-57 or OVA257-264 for 1 hour at 37ºC at the final concentration of 1μg/ml. After 
extensive washing, cells which were pulsed with specific peptide or irrelevant peptide 
were labelled with high and low concentrations of CFSE (Invitrogen), respectively. Next, 
5 × 106 peptide pulsed cells were pooled and injected i.v. via the retro-orbital route 
into the mice that have been vaccinated 70 days earlier with MCMV-based vaccines. 
After 24 hours, spleens of the recipient mice were isolated, stained for CD45.1, and 
subjected to flow cytometry. The cytotoxic capacity was calculated relative to naïve 
mice by using the following formula: {100 – ((percentage of pulsed peptide in infected 
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mice/percentage of unpulsed peptide in infected mice)/(percentage of pulsed peptide 
in naive mice/percentage of unpulsed peptide in naive mice)} × 100.
Statistical analysis
Statistical analyses were performed using GraphPad Prism (La Jolla, CA, Unites States). 
Survival data were analysed by Kaplan-Meier and the log-rank (Mantel-Cox) test. 
Statistical significance was determined by Mann Whitney. P-values of ≤ 0.05 were 
considered statistically significant.
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Supplementary Figure 1. Immunization with MCMV-IE2-OVA induces vaccine-specific CD8+ 
T cell responses. Mice were infected with 1x105 PFU i.p. and i.n. MCMV-IE2-OVA. Frequency of 
antigen-specific CD8+ T cells for the M45 and M38 epitopes of MCMV and of the inserted OVA 
antigen were identified using MHC class I tetramers. Data represents mean values ± SEM (n = 6 
mice per group). 
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ABSTRACT 
For many years the focus of prophylactic vaccines was to elicit neutralizing antibodies 
but it has become increasingly evident that T cell-mediated immunity plays a central 
role in controlling persistent viral infections such as HIV, CMV, and HCV. Currently, 
a variety of promising prophylactic vaccines, capable of inducing substantial vaccine-
specific T cell responses, are investigated in preclinical and clinical studies. There is 
compelling evidence that protection by T cells is related to the magnitude, breadth and 
quality of the T cell response as well as the type of the activated T cell subsets, and their 
characteristic homing properties, cytokine polyfunctionality, and metabolic fitness. In 
this review, we evaluate the main factors that determine the qualitative and quantitative 
properties of CD4+ and CD8+ T cell responses in the context of chronic viral disease and 
prophylactic vaccine development. Elucidating the mechanisms through which T cells 
mediate protection against chronic viral pathogens will facilitate the development of 
more potent, durable and safe prophylactic T-cell based vaccines. 
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INTRODUCTION 
Our body is persistently exposed to a variety of pathogens present in the environment. 
The immune system is fortified with physical barriers and with diverse immune cell 
populations that play an integral role in protection from disease. Long-term immune 
protection is mediated by antigen-specific lymphocytes and antibodies that are formed 
upon pathogen entry. Memory B and T cells are numerically and functionally superior 
to their naïve-antigen precursors cells that are present prior to infection, and upon 
encounter with the same pathogen memory immune cells are able to induce a more 
rapid and powerful recall response (i.e., immunological memory) [1,2].
The majority of prophylactic vaccines against viral infections have focused on 
the induction of neutralizing antibodies. Indeed, potent antibody inducing vaccines 
against virally-induced diseases are available. Nevertheless, failures are demarcated 
in the case of providing long term efficacy and protection against certain complex 
chronic viruses. A series of studies in mice, non-human primates and humans provide 
evidence that effective prophylactic vaccines against chronic (low-level and high-level) 
replicating viruses (i.e. herpesviruses, HIV, HCV) should engage strong cellular T cell 
immunity [3,4,5]. The development of T cell-eliciting prophylactic vaccines has gained 
increasing attention despite that such vaccines are not always able to provide sterilizing 
immunity. The latter may relate to the fact that the immune mechanisms related to 
protection against chronic infections have not been clearly defined. There is still a lack 
of knowledge to be able to tailor vaccines to induce long-lasting CD4+ and/or CD8+ T 
cell responses of sufficient magnitude and phenotype that effectively contributes to 
pathogen clearance. Oftentimes, the memory cellular immune response provoked by 
vaccines is not sustained and frequently fades in time [6,7]. Elucidating the mechanisms 
through which antigen-specific T cell populations mediate long-term protection 
against viruses at body surfaces and (lymphoid) tissues remains an important goal, and 
will facilitate the development of more effective and safe prophylactic T cell-eliciting 
vaccines. Here we review determinants and mechanistic factors of T cell responses 
implicated in vaccine efficacy against chronic viral infections, and discuss how this 
knowledge can be utilised to maximize the possibility of creating effective vaccine 
platforms for persistent viral infections.
THE COMPLEXITY OF THE ANTIGEN-SPECIFIC T CELL RESPONSE 
DURING INFECTION
T cells acquire their activation signals as the interaction with the DCs becomes stable 
and reaches a duration of 12 h [8,9]. For proper activation of naïve CD4+ and CD8+ T cells, 
cognate antigenic signals through the TCR (signal 1), costimulatory signals (signal 2) 
and signals provided by inflammatory cytokines (signal 3) is required [10,11]. Expression 
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of particular chemokine receptors such as CCL19 and CCL21 by fibroblastic reticular 
cells (FRCs) enhance immune responses by stimulating the interactions between T 
cells and DCs during antigen presentation [12,13,14,15]. Additionally, the secretion of 
the CCL3 and CCL4 chemokines by activated DCs and CD4+ T cells enhances CD8+ T cell 
accumulation and help attract rare antigen-specific T cells [16,17]. The activation of T 
cells results in alteration of the expression of various molecules including integrins, 
selectins and chemokine receptors, resulting in modulating key intracellular signalling 
events that promote proliferation, differentiation and migration of T cells to inflamed 
tissues [18,19,20]. 
After resolution of the infection the majority (90-95%) of the effector T cells are 
eliminated by the immune system due to programmed cell death (PCD) and only a small 
diverse pool of memory cells remains [21,22]. Traditionally, memory T cells were classified 
into two major categories based on their proliferation capacity, phenotypic features 
and migration potential [23]. Specifically, effector-memory T (TEM) cells are identified 
based on combined expression and/or lack of certain cell surface markers including 
KLRG1hi/CD44hi/CD127lo/CD62Llo. These cells have limited proliferation capacity upon 
TCR triggering, yet rapidly produce effector molecules and cytokines such as IFN-γ and 
TNF [24,25]. Central-memory T (TCM) cells are distinguished by the expression of KLRG1
lo/
CD44hi/CD127hi/CD62Lhi surface markers, exhibit a superior proliferation capacity and 
produce cytokines that are directly associated with better secondary expansion such as 
interleukin (IL)-2. Secondary lymphoid organs are the main homing tissues of TCM cells 
whereas TEM cells are more dominantly present in tissues [26,27,28,29]. Both TCM and 
TEM cells can circulate, whereas a recently discovered new category of T cells present 
in tissues lacks migration capacities [30]. These cells, named tissue-resident memory T 
(TRM) cells, permanently reside in peripheral tissues after an infection is cleared and are 
present in most organs and tissues. TRM cells can be defined based on the expression of 
CD62Llo/CD44hi/CD69hi/CD103hi surface markers, yet the composition of these markers 
depends on the tissue-specific cues [31,32,33]. Furthermore, a small subset of memory 
T cells exhibit advanced stem-cell like qualities and proliferation capacities compared 
to the conventional T cells [34]. These memory T cells, which were designated stem cell 
memory T cells (TSCM cells), display a phenotype highly similar to naïve T cells (TN cells), 
KLRG1lo/CD44lo/CD127hi/CD62Lhi/CD69lo, but they co-express stem cell antigen (Sca-1), 
the β chain of the IL-2 and IL-15 receptor (CD122, IL-2Rβ), and the chemokine receptor 
CXCR3 [34,35,36,37,38,39]. 
Notably, T cell immunobiology is fundamentally similar between human and 
mice, and the concepts of TCM, TEM, TRM, and TSCM cells are matching. Evidently, both live 
attenuated and synthetic or subunit vaccines are able to elicit TCM, TEM, and TRM cells 
[30,33]. With respect to live attenuated vaccines, the vaccine-induced T cells subsets are 
in general similar to those subsets that develop upon infection [40]. However, the T cell 
subsets that develop upon immunization with synthetic or subunit vaccines is highly 
dependent on the route of administration and the adjuvant [41]. Whether sufficient 
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amounts of TSCM can be generated with live attenuated or synthetic vaccines needs 
further exploration.
THE MAGNITUDE OF THE T CELL RESPONSE IS IMPORTANT FOR 
OPTIMAL PROTECTION 
The magnitude of the viral-specific T cell responses is highly dictated by the infectious 
dose and route of infection [42]. Higher infectious dosages lead generally to higher 
peak values of effector T cells and correspondingly larger amounts of memory T cells 
in the circulation are found. However, if the immune system is overwhelmed and virus 
replication is uncontrolled this leads to immunopathology and subsequently this leads 
to exhaustion of T cells and poor memory formation [43]. 
Given the frequently observed correlation between the magnitude of T cell 
response and establishment of immunity during infections, in vaccination settings 
simply determining the magnitude of the vaccine-elicited T cell response may already 
serve as a predictor of efficacy. A number of studies have shown a direct association 
of the vaccine-elicited T cell response size and the ability for virus control [5,44,45,46]. 
Several parameters directly impact the magnitude of the vaccine-induced T cell response. 
Clearly, in case of live (attenuated) viruses the size of the initial dose of the inoculum 
correlates to the magnitude until a threshold is reached [47]. To reach the same level 
as compared to virulent virus, the inoculum sizes are, not surprisingly, higher for 
replication-deficient or single-cycle viral vectors. In case of synthetic vaccines, however, 
the saturation threshold may not be reached because of lack of sufficient inflammatory 
signals. However, recent discoveries in adjuvant development and synthetic (nano)
particles provide promising results [48,49,50]. Besides the initial inoculum dosage, 
booster vaccine regimens impact evidently the magnitude of the T cell response, and 
are likely essential for the majority of vaccines including live vaccines [51].   
MEMORY INFLATION AND THE MAGNITUDE OF RESPONSES TO 
RECOMBINANT VACCINES
An alternative mechanism which leads to an increased magnitude of memory T cells 
(especially CD8+ T cells) is observed for certain specific responses following infection by 
CMVs - described as memory “inflation” [52,53]. Here, antigen-specific T cell responses 
to a subset of peptides show an unusual dynamic, whereby they expand gradually 
over time and are maintained at high frequencies as TEM populations - as opposed to 
the classical expansion and contraction described above. These inflationary responses 
show maintained effector functions, tissue homing and can provide protection against 
challenge. Interestingly in the case of mouse cytomegalovirus (MCMV) there are two 
classes of response, a subset of inflationary responses and some which show classical 
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contraction and TCM phenotype [52,54]. Memory inflation has also been observed for 
CMV-specific antibodies, which levels gradually incline over time [55]. Although the rules 
that determine which kind of memory have not been fully defined, it is clear that for 
inflation to occur viral antigen must persist long term and since CMV is reactivating 
from latency this condition is clearly fulfilled. Inflation appears to be restricted by 
antigen presentation, since peptides which are dependent on the interferon-inducible 
molecule LMP7 to form the immunoproteasome are not apparently presented long term, 
although such responses may be primed [56]. Modifying the context of the peptide can 
convert a classical response to an inflationary one [57]. 
Recombinant CMVs may provide important  vectors for vaccines, although they are 
highly complex viruses, containing multiple immune evasion genes. In rhesus macaque 
experiments, the T cell responses induced against a recombinant CMV expressing 
SIV antigens include, in addition to CD8+ T cell inflationary responses, responses 
mediated by class II-restricted CD8+ T cells and also HLA-E restricted cells [58,59]. These 
unconventional responses likely arise because of the restrictions placed on normal 
antigen presentation by the attenuated CMV vectors used. More work is needed to 
identify which of these populations is critical for protection, and whether this additional 
protection – which can be very robust – is mediated via magnitude, function, breadth or 
targeting of particular peptides not normally presented. 
Memory inflation is not restricted to CMV-induced responses. Similar phenomena 
have been seen with other viruses, including vaccine vectors. The most relevant of 
these are responses induced by adenoviral vectors. In mouse models, adenovirus-based 
vectors can lead to induction of inflationary responses which closely resemble those 
induced by CMV [60,61]. In this vaccine platform it is possible to generate inflationary 
responses against otherwise non-inflationary epitopes by removing the requirements for 
processing and presenting it in the form of a “minigene” [62]. Human adenoviral vectors 
are in use in a range of settings, including HCV, malaria and Ebola vaccines[4,63,64]. 
Although these do not show numerical inflation, the responses are sustained over 
time and phenotypically and functionally resemble those seen in mice and also those 
induced by CMVs [61]. 
THE BREADTH OF THE INDUCED IMMUNE RESPONSE IMPACTS ON 
PROTECTION
An increased breadth of the vaccine-induced T cell response has been found beneficial 
against many chronic viral pathogens [5,65,66,67,68]. Development of T cells with 
multiple antigen-specificities correlated with advanced capacity for virus control or 
even complete eradication during primary infection with HCV and superior protection 
upon reinfection [69]. Similarly, the breadth of Gag-specific responses was linked with 
low viremia as shown by analysing the CD8+ T cell responses of untreated HIV-infected 
subjects [70].
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Successful induction of potent and broad T cell responses has been reported 
with DNA plasmid vaccines [71,72] and adenovirus serotype 26 vector-based 
vaccines [73]. The latter approach incorporated a combination of subdominant and 
dominant epitopes of rhesus macaques SIV, known as a HIV equivalent in monkeys, 
in a prime-boost vaccination schedules. In parallel with these findings, synthetic long 
peptide (SLP) T cell based vaccines, which induce memory CD8+ T cells, exhibited 
increased protection against mouse cytomegalovirus (MCMV), when vaccination was 
performed with combinations of several distinct SLPs. The efficacy of the SLP vaccines 
to protect against MCMV was mainly driven by the breadth of the antigen-specific T 
cell response rather than the magnitude of the individual SLP vaccine-induced T cell 
responses [5]. These findings indicate that cytotoxic CD8+ T cells with a broad repertoire 
of specificities are more capable for effective killing of virus infected cells than T cells 
of a single specificity. Possible explanations are that multiple encounters with T cells 
of diverse specificity results directly in enhanced killing of virus-infected cells or limits 
immune escape mechanisms. Moreover, an increase in epitope recognition may also 
contribute to protection against infection with heterologous viruses via cross-reactive 
responses [74]. Although the underlying mechanisms are still unclear the importance 
of the immune repertoire diversity should be taken into account while designing 
prophylactic T cell-based vaccines. As a consequence selection of the correct antigens 
that will steer the immune response at the correct direction is a very critical step of 
the vaccine development process. In this respect, it also of importance to mention that 
competition of antigens is apparent [5], warning that antigen selection is not simply 
the more the better. Overall, epitope-specific T cell repertoires elicited upon vaccination 
might serve as an evidence of vaccine efficacy, which will apply to many infections and 
not be limited to chronic viruses. Furthermore, not all antigen-specific T cell populations 
have the same efficacy. For example, T cell populations specific for CMV antigens that 
provoke inflationary responses show superior protective capacity [5]. Thus antigens 
provoking the most effective antigen-specific T cell populations should be selected to 
include in designing vaccine vectors or synthetic vaccines. 
While both magnitude and breadth of the T cell response is of importance there 
is no direct association between protection and the frequency of the T cells in 
the circulation [75]. In mouse models it is becoming increasingly clear that, depending 
on the route of infection, T cells present in the mucosal or in the tissues (Tem and/
or Trm) control the infection, and sufficient numbers are required [33]. Note, however, 
that besides the quantity and breadth also the quality of the T cell response is of 
crucial importance.
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CYTOKINE POLYFUNCTIONALITY OF T CELLS IS AN IMPORTANT 
PARAMETER FOR VACCINE EFFICACY
Cytokine production is an important effector mechanism of T cell mediated immunity. 
Upon most viral and bacterial infections protective immunity consists of CD4+ and 
CD8+ T cells  with a Th1 cytokine profile that is characterized by (co-)production of 
IFN-γ, TNF and IL-2 [76]. IFN-γ and TNF are pleiotropic cytokines with direct anti-viral 
properties [77,78,79]. Their receptors are broadly expressed, and signal via distinct 
pathways, which may explain why reciprocal production of IFN-γ and TNF leads to 
synergistic actions [80]. The predominant assessment method of vaccine-induced 
responses is the frequency of IFN-γ producing T cells. However, there are many examples 
showing that the magnitude of the IFN-γ secreting T cell response is not a sufficient 
immune correlate of protection. Single positive IFN-γ producing T cells can comprise 
a relatively large fraction of the total cytokine-producing CD4+ and CD8+ T cell population 
after immunization. Such T cells have a limited capacity to be sustained as memory T 
cells and are at the final stage of T cell differentiation [81]. Vaccines that elicit a high 
proportion of single, IFN-γ producing T cells would not be likely protective. On the other 
hand, studies characterizing vaccine elicited T cell responses against HIV, CMV and HBV 
revealed a strong correlation between the protection level of the vaccine regiments 
and their capacity to induce high frequencies of polyfunctional T cells (e.g. coproducing 
IFN-γ, TNF and IL-2 [4,82,83,84,85]. Similar results have been described in the course 
of infection with hepatitis C virus, CMV, influenza or M. tuberculosis [4,86,87,88,89]. 
Importantly, some of these studies showed that measuring the magnitude of IFN-γ 
producing CD4+ and CD8+ T cells alone was not sufficient to predict protection, and 
provided evidence that measuring the quality of the CD4+ and CD8+ T cell response, 
vis-à-vis polyfunctional T cells, is required. 
IL-2 signals through a trimeric receptor comprised of CD25 (IL-2Rα), CD122 
(IL-2Rβ) and the γc [90]. CD25 is not constitutively expressed but instead is transiently 
upregulated upon activation following exposure to certain inflammatory cytokines such 
as IL-12 [91]. Evidence examining he role  of CD4+ and CD8+ T cells in HIV infected showed 
increased levels of T cells expressing IL-2 and IFN-γ in long-term non-progressors, or 
those on anti-retroviral treatment, but increased levels of T cells producing IFN-γ only 
in individuals with high viral loads (processors)[92]. Although IL-2 has no direct anti-
viral function, it promotes proliferation and secondary expansion of antigen-specific 
T cells [93,94,95,96,97,98]. The ability of T cells to secrete IL-2 also relates to superior 
survival properties of these cells [81,99]. Additionally, IL-2 increases expression of 
the effector proteins perforin, granzyme B and IFN-γ that are all important for mediating 
cytolytic function [100,101]. IL-2 signals may also enhance NK cell activity that could 
contribute to the early control of infection following challenge [81,102,103,104,105]. 
In summary, the efficient vaccine protection medicated by CD4+ and CD8+ T cells 
is moderated by multiple mechanisms. First, CD4+ and CD8+ T cell have the highest 
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secretion rate of IFN-γ per-cell. Second, T cells that secrete both IFN-γ and TNF have 
enhanced effector activity compared with T cells that secrete IFN-γ alone. And third, 
autocrine IL-2 production promotes the secondary expansion of memory T cells, and is 
linked to other beneficial properties. Therefore, IL-2, TNF and IFN-γ comprise a simple 
set of cytokines that can be used to define the quality of the vaccine-elicited response 
against specific infections that require T cells for protection. As will be discussed 
hereafter, one way to improve the polyfunctionality of vaccine-induced T cells is by 
targeting of T cell costimulation It remains nevertheless necessary to better understand 
how the cytokine polyfunctionality is regulated during the programming of CD4+ and 
CD8+ T cell responses. Further dissecting these issues might provide fundamental 
insights into how T cell responses are controlled and may reveal potential strategies for 
superior vaccine-mounted T cell responses.
IMPROVING VACCINATION BY TARGETING T CELL METABOLISM?
The transition of naïve T cells to an active effector cell and to the formation of 
memory cells involves dynamic and coordinated metabolic modifications [106]. This 
reprogramming of the cellular metabolism is not a consequence of activation but is 
linked to the differentiation and activation processes, and reflect the fuel and substrates 
necessary to support the differentiation stages of a T cell [107,108]. Both naïve T cells 
and memory T cells rely primarily on oxidative phosphorylation (OXPHOS) and fatty 
acid oxidation (FAO) for fuel. This reflects the low level yet persistent need for energy 
as such cells are long-lived. Effector T cells on the other hand have extraordinarily 
high energetic and synthesis demands. These cells have enhanced glycolysis and 
employ the mitochondrial tricarboxylic acid (TCA) cycle to support their demand for 
de novo proteins, lipids and nucleic acids synthesis. It is becoming increasingly clear 
that metabolic reprogramming plays a critical role in T cell activation, differentiation 
and function. The distinct metabolic demands of different T cell subsets make them 
exquisitely sensitive to pharmacologic inhibitors of metabolism [109]. The different 
metabolic requirements of T cell subsets provide us with a promising therapeutic 
opportunity to selectively tailor (vaccine-induced) immune responses. Thus, targeting 
T cell metabolism affords the opportunity to additionally regulate vaccine-induced 
responses. 
Upon T cell activation, there is an immediate uptake of amino acids such as glutamine 
and leucine that is critical for proper metabolic reprogramming. This is accompanied 
with the upregulation of amino acid transporters involved in glutamine (SLC1A5) and 
leucine (SLC7A5/SLC3A2 heterodimer) [110,111]. It is essential that these processes 
operate well to avoid suppression of the differentiation of TH1 effector T cells while 
maintaining Treg differentiation. Whether this can be improved pharmacologically in 
vivo remains however to be further examined.
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CD28-mediated costimulation leads to PI3K-dependent upregulation of surface 
GLUT1 to facilitate enhanced glucose influx [112]. This upregulation of GLUT1 is critical 
for T cell function, as genetic deletion of GLUT1 markedly inhibits effector T cells [113]. 
Concomitant with increased expression of glucose transporters is the upregulation of 
key glycolytic enzymes [114]. This metabolic reprogramming occurs simultaneously 
with T cell activation and is facilitated by mTOR [115]. mTOR activation promotes 
glycolysis, fatty acid synthesis and mitochondrial biogenesis. As such, targets upstream 
and downstream of the mTOR signaling pathway are potential therapeutic targets. 
Rapamycin, although known as an ‘immunosuppressive’ drug due to its ability to slow 
down T cell proliferation, promote robust responses to vaccination by enhancing 
CD8+ T cell memory formation [116]. Correspondingly, deletion of the mTORC1 
inhibitory protein TSC2 leads to enhanced mTORC1 activity and increased effector 
function [117]. Targeting of TSC2 or other molecules in the mTOR pathway might 
accordingly enhance immunity. 
Targeting of glycolysis to inhibit immune responses in the setting of autoimmune 
disease and transplantation rejection is evolving, and this strategy is also used to 
enhance anti-tumor immunity by promoting long-lived memory cells ex vivo [118]. 
Whether this can be used in vaccination strategies remains to be examined. Although 
most studies have focused on the critical role of glycolysis in promoting effector T cell 
generation and function, it has become clear that mitochondrial-directed metabolism 
also plays an important role. Memory T cells rely for their energy upon OXPHOS and FAO. 
Because these metabolic pathways are dependent on mitochondria, the abundance 
and the organization of the mitochondria are instrumental for development of 
fit memory cells [119]. Alterations in the mitochondrial biogenesis can influence 
the differentiation of T cells, thereby providing opportunity to augment T-cell mediated 
immunity [120,121]. The transcription factor PGC1α promotes mitochondrial 
biogenesis and function [122]. Hence, pharmacologically or genetically enhancing 
PGC1α represents a potential strategy for improving vaccine-induced T cell responses. 
In ex vivo systems, it has already been shown that enforced overexpression of 
PGC1α, leads to improved metabolic fitness and effector cytokine function of CD8+ T 
cells [123]. Again, whether in vivo targeting is possible remains to be examined, 
and in this respect a major challenge may be the specificity of metabolic inhibitors/
enhancers as they may affect all cells of the body. However, inhibitors of glycolysis may 
preferentially affect effector T cells given their enhanced glycolytic need. The future 
will tell if indeed metabolic targeting is possible to enhance vaccines. Nevertheless, 
the metabolic profiles of (vaccine-induced) T cells are surely of interest and correlate to 
vaccine-mediated immunity [124].
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COSTIMULATION EMPOWERS T CELL ELICITING VACCINES 
Costimulatory signals transduced via the CD28 family members CD28 and ICOS, and via 
the tumor necrosis factor receptor (TNFR) family members CD27, 4-1BB, and OX40 play 
dominant roles in orchestrating the required signal 2 [125]. While CD28 and CD27 are 
constitutively expressed on naïve T cells ICOS, 4-1BB and OX40 are upregulated upon 
T cell activation [125,126]. The ligands for these costimulatory receptors are highly 
expressed on APCs upon activation, yet expression is also found on T cells, suggesting 
that these molecules may also mediate communication between T cells [127,128]. 
Synergy between these costimulatory molecules is expected [125,129], and is confirmed 
in experimental models [130]. 
There is extensive literature addressing the influence of the TNF/TNFR family 
interactions during a virus specific immune response. For instance, CD28 signals 
are required for sufficient T cell priming during the primary phase of an infection 
[131,132,133,134,135], while OX40 and 4-1BB gain importance during the late effector 
and memory stage of antigen-specific T cells either by providing pro-survival signals or 
by enhancing the quality of the memory T cells [136,137,138,139,140]. Thus, although 
an optimal immune response is the result of many receptor-ligand interactions, 
costimulatory signals dominate differentially during the diverse phases of the immune 
response (e.g. early versus late) to ensure optimal expansion and contraction of primary 
CD8+ T cells and the generation of memory CD8+ T cells. 
Agonistic Abs against costimulatory receptors have shown efficacy in various 
preventive and therapeutic preclinical vaccination settings. Enforced engagement of 
costimulatory molecules results in improved T cell activation, expansion, survival and 
establishment of long-term memory [139,141,142,143,144,145,146], and has thus 
the potential to serve as effective immunomodulatory components of prophylactic 
vaccines against chronic viruses [143,147,148]. Indeed, this has already been observed 
for DNA and adenovirus based vector vaccines in which enforced expression of 
4-1BBL, OX40L and CD70 leads to increased T cell expansion, enhanced CTL activity 
and antibody response [149,150]. Strikingly, agonistic antibodies to OX40 combined 
with synthetic peptide vaccines prompt robust effector and memory CD4+ and CD8+ 
antiviral T cell responses, improve T cell cytokine polyfunctionality and prophylactic 
vaccine efficacy against lytic MCMV infection [145]. Chronic viral infections are 
characterized by accumulation of functionally impaired antigen-specific CD8+ T cells. 
Studies have shown that activation via 4-1BBL alone or in combination with CD80 can 
enhance the generation of primary CD8+ T cell responses and induce expansion of 
the antigen-specific CD8+ T cells from this pool of impaired T cells [136,151]. Similarly, 
4-1BB stimulation has been shown to enhance the generation of primary CD8+ T cell 
responses [139,152,153] and synergizes with attenuated vaccinia virus (VACV) vectors 
to augment CD8+ T cell responses [139] .
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Targeting of inhibitory molecules on T cells such as PD-1 and CTLA-4 have been 
shown to restore the effector function of activated T cells in settings of chronic viral 
infections and cancer [154,155,156,157]. Inhibitor blockade synergizes in combination 
with therapeutic vaccines [158]. Targeting of inhibitory pathways during primary 
immunization with prophylactic vaccines may advance  the vaccine efficacy as well 
[159,160], but whether this results in significant improved vaccine efficacy remains to 
be established. 
Although the use of antibodies targeting costimulatory/inhibitory molecules 
as immunostimulatory modalities in vaccines can facilitate antigen-specific T cell 
responses, the use of such Abs, however, is associated with toxicity as demonstrated 
in selected settings in rodents and in clinical settings [157,161,162,163]. Nevertheless, 
given the potential benefit to significantly increase the effectiveness of vaccines, both 
the efficacy and safety of targeting costimulation is currently extensively examined in 
various immunotherapeutic approaches against persistent viral infections. Examining 
the timing and/or the dosing is in this respect an important aspect to not only prevent 
unwanted side-effects but this may also lead to improved effectiveness. In addition, 
CD28 costimulation modulates T cell metabolism via activation of PI3K pathways, and 
this is essential to control effector cytokine production [112,164]. TNFR family members 
are also able to metabolically program T cells [165,166]. Collectively, targeting of T 
cell costimulation can impact the important quantitative (magnitude, breadth) and 
qualitative (cytokine polyfunctionality, metabolic fitness) determinants of vaccine-
induced T cells, and provides thus major opportunities for further exploration in future 
vaccine designs. 
CONCLUSIONS AND PERSPECTIVES FOR VACCINE DESIGN 
The design of vaccines that imprint T cells with the ability to boost host defense against 
persistent viral pathogens has gained remarkable progress. An understanding of 
the appropriate initial programming signals is a key step, as is how the route of priming 
or boosting influences the development of effective memory T cells. A combination 
of several metrics such as the type of the vaccine elicited T cell response, breadth, 
polyfunctional quality and metabolic characteristics demonstrate a valid toolbox to 
define when a T-cell mediated response is protective. Unanswered questions about 
the anatomy, activation and differentiation of memory T cells in lymphoid compared to 
non-lymphoid organs need to be addressed. Costimulatory signaling pathways mediate 
basically all of the important T cell memory properties, and may serve as interesting 
targets for vaccine improvement. Experimental and clinical insight into their complex 
synergistic or antagonistic processes may identify requisite pathways and potentially 
other targets for immunotherapy. Identification of the best correlations of immunity 
with protection for persistent viral pathogens will enable the development of effective 
vaccination regimes.
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GENERAL DISCUSSION 
T cells are essential components of naturally acquired protective immune responses in 
many diseases. Although various ways of inducing potent T cell response by vaccination 
have been assessed, the majority result in low level, non-protective immune responses. 
Vaccine development has broadened and currently vaccine platforms range from 
replication-deficient (attenuated) or killed micro-organisms to viral vectored vaccines 
and more recently to protein subunit vaccines. Many highly effective vaccines designed 
to induce protective CD4+ and/or CD8+ T cells against chronic infections and cancer 
have been developed. Although their precise mechanisms of protection depend on 
the complexity and type of antigen, the quality of the vaccine-induced T cell response 
is gaining increasing attention. 
In this doctoral thesis, the SLP T cell-based vaccination strategy alone or in 
combination with agonistic antibodies triggering the costimulatory TNFR superfamily 
member OX40 were tested for their capacity to induce potent CD4+ and CD8+ T cell 
responses and to confer protection against lytic MCMV infection. Vaccination with 
MHC class I- and II-restricted MCMV epitope containing SLPs successfully eliminated 
virus spread in naïve mice but failed to boost host’s antiviral immune responses and 
treat established MCMV infection. Direct correlates of protection were thoroughly 
investigated. Another vaccination model tested was the MCMV-based vector vaccine 
against virus-induced cancer (HPV). Injection of the MCMV vectored vaccine expressing 
an immunodominant MHC class-I restricted HPV E7 epitope led to long term protection 
against tumor outgrowth in naïve hosts but exhibited limited efficacy in hosts with 
a strong pre-existing immunity to MCMV. To optimise both vaccination strategies, we 
explored essential components required to shape protective immune responses and 
ways to subvert existing immune responses and improve immune recognition.
COMBINATION IMMUNOTHERAPY AGAINST MCMV
Several approaches can be used to improve immunity to MCMV-associated disease. 
Concomitant stimulation of CD8+ and CD4+ T cell responses via MHC class I and II 
epitope-containing SLPs, respectively, and augmentation of costimulatory signals 
mediated by the TNFR family member OX40 are very promising tools, which will be 
extensively discussed below.
Maximum virus control through activation of CD4+ and CD8+ T cells
The last decades, numerous immunotherapeutic platforms mainly focused at 
the induction of neutralizing antibodies have been tested against CMV. The majority 
of these vaccines exhibited low or short-term efficacy [1]. Whether sterile immunity 
against CMV is an achievable goal remains questionable mainly due to the numerous 
immune evasion mechanisms exploited by the virus. T cell-based vaccines designed to 
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induce CD4+ or/and CD8+ T cell responses is a rapidly growing field. Many studies have 
demonstrated the importance of T cell immunity against CMV. There is solid evidence 
that CD4+ T cells are crucial for controlling CMV replication during the acute phase of 
the infection while CD8+ T cells play an essential role during latency and virus reactivation 
[2-4]. SLP T cell based immunotherapy is a safe and well-explored vaccination platform, 
which results in the activation of CD4+ and CD8+ T cells and has shown remarkable 
potency to treat HPV associated disease in both preclinical and clinical studies [5,6]. 
In chapter 2, MHC class I epitope containing SLPs along with TLR9 agonists were 
tested in a prime-boost vaccination setting in various mouse strains for their ability to 
contain high load systemic MCMV infection. Vaccination led to the induction of vigorous 
and poly-functional (IFN-γ+/ TNF+/ IL-2+) cytotoxic CD8+ T cell subsets mediating potent 
and long-term protective immunity against MCMV infection. Vaccine-induced CD8+ T 
cells slowly converted to a unique memory T cell subject sharing features from both 
effector and central memory T cells while their functionality was significantly improved 
throughout time. Notably, the size of each distinct SLP vaccine-induced CD8+ T cell 
response was found unrelated to the functional avidity and proportional to the naïve T 
cell precursor frequency. This finding suggests that T cell precursor frequencies may be 
considered as a powerful model to predict the subsequent size of the T cell response 
induced upon peptide vaccination. In shared antigen or neo-antigen cancer vaccine 
trials in vitro stimulation with the targeted antigen is used to provide insight into 
the patient’s immune system ability to respond to potential vaccination [7,8]. However, 
determination of the targeted antigen/peptide precursor frequency will possibly ease 
classic in vitro antigen selection processes and may form an important parameter to be 
considered in immunotherapeutic strategies that their efficacy is based on the selection 
of antigens.
Despite the importance of CD4+ T cells in the immune system, the role of CMV-specific 
CD4+ T cell responses in CMV infection has not been completely understood. CD4+ T 
cell ‘’help’’ is likely to be crucial for increasing the effectiveness of candidate vaccines 
for CMV. Therefore, in chapter 3 the efficacy of MCMV-specific CD4+ T cells to control 
MCMV was studied using a vaccine that comprises MHC class II epitopes. In addition, 
the capacity of the CD4+ T cell responses to enhance the efficacy of a MCMV-specific 
CD8+ T cell response was studied by simultaneous injection of MHC class I and II epitope 
SLPs. CD4+ T cells induced after vaccination with various MHC class II SLPs and OX40 
ligation elicited broad antiviral Th1 cytokine responses and showed direct antiviral 
function against MCMV infection. Interestingly, vaccine induced CD4+ T cell responses 
conferred moderate protection against lytic MCMV infection in both lymphoid and 
non-lymphoid organ tissues. These findings advance the findings of other reports 
showing direct antiviral effector function of CMV specific CD4+ T cells in both mice and 
human [2,9-12]. 
Moreover, inclusion of CD4+ T cell ‘’help’’ during vaccination with a combination of 
MHC class I SLP vaccines significantly enhanced CD8+ T cell expansion and remarkably 
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improved the overall prophylactic vaccine efficacy. Notably, CD4+ T cell signals increased 
priming of vaccine-evoked CD8+ T cells suggesting a direct synergy between these 
T cell subsets. The concept that CD4+ T cell ‘’help’’ to license DC for proper CD8+ CTL 
priming must be antigen specific has long been concluded [13-16]. Thus, MHC class 
II epitopes are likely to add value if included in the design of epitope-based vaccines 
against CMV. Consequently, in chapter 5 a plethora of highly immunogenic IE2 MHC 
class II restricted T cell epitopes where identified following traditional in silico screening 
methods. Whereas the T cell response to the IE1 HCMV protein is dominated by MHC 
class I T cell responses, limited CD8+ T cell reactivity was measured against the IE2 
protein. Since T cell responses to IE antigens predominate the lytic phase of the CMV 
infection, a vaccine formulation that will comprise IE1-specific MHC class I epitopes and 
IE2-specific MHC class II epitopes targeting immune dominant CD8+ and CD4+ T cell viral 
regions respectively is possible to act synergistically and inhibit the establishment of 
CMV latency. 
The need for enforced OX40 co-stimulation 
Therapeutic targeting of immune check point inhibitors (PD-1/ PD-L1 and CTLA-4) or 
costimulatory receptors (41BB/ 41BBL and OX40/ OX40L) has been beneficial against 
many chronic viral infections and cancer [17-24]. Costimulatory molecules provide 
critical interactions for inducing and maintaining adaptive immune response against 
CMV. Antibodies can specifically bind to costimulatory receptors and boost or inhibit 
an immune response. 
In chapter 3 agonistic OX40 antibodies in combination with various MHC class I 
and MHC class II epitope containing SLPs of MCMV-encoded antigens were tested 
in a prime-boost vaccination schedule. OX40 ligation synergized with the SLP-based 
vaccines and empowered overall vaccine efficacy but did not exhibit any therapeutic 
or prophylactic reaction when provided as monotherapy. Enforced OX40 activation 
strongly increased the number of-vaccine-induced CD4+ T cell and CD8+ T cell responses, 
especially when provided during booster vaccination. The effect of OX40 triggering was 
more pronounced on CD4+ T cells presumably due to the higher expression of the OX40 
molecule on this T cell subset [25,26]. OX40 mediated signals were not short lived or 
limited on effector T cells but influenced also memory T cell formation. Specifically, 
memory vaccine-derived CD8+ T cells treated with OX40 agonists during booster SLP 
vaccination exhibited improved functionality, survival and secondary clonal expansion 
compared to the untreated subjects. 
Interestingly, the timing and the number of doses OX40 agonistic antibody was 
administered regulated both the size and the quality of the subsequent vaccine-
mediated T cell response. Specially, when agonistic OX40 antibody was provided 
during both prime and booster SLP vaccination all the positive effects of the OX40 
triggering on T cell induction were diminished or utterly lost. A possible explanation 
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for this outcome is that short time intervals between the two vaccinations did not 
allow adequate memory T cell development and upon secondary OX40 stimulation 
apoptotic cell death events were dramatically accelerated. T cell susceptibility to 
activation-induced cell death (AICD) can occur in a cell-autonomous manner and is 
regulated by previous T cell activation history and the stage of the T cell maturity [27]. 
Repeated TCR activation and co-stimulation may promote the Fas/CD95 pro-apoptotic 
pathway whereas correct timing of co-stimulation can promote the Bcl-2 anti-apoptotic 
pathway [28]. Consistent with this, upregulation of the Bcl-2 molecule, known as 
a target of OX40, was measured when agonistic anti-OX40 antibody was provided only 
during booster vaccination and correlated with prolong T cell survival. In contrast, 
repeated enforced OX40 stimulation during both prime and booster SLP vaccination 
downregulated Ki67 and Bcl-2 expression leading to decreased T cell proliferation 
and survival. Additionally, it has been previously reported that Bcl-2 upregulation 
accompanied with increased expression of IL-2 inhibits AICD of previously activated 
T cells [28,29]. OX40 stimulation during booster SLP activation dramatically escalated 
autocrine IL-2 cytokine production levels and AICD events were delayed. Whether further 
treatment with IL-2 at the time of stimulation with OX40 agonists could overcome T cell 
susceptibility to AICD remains to be explored.
Another interesting observation was that IL-2 secretion was tightly regulated by 
OX40 costimulatory signals. Enforced OX40 stimulation mainly during booster SLP 
vaccination promoted ‘’Th1’’ cytokine production by both CD4+ and CD8+ vaccine-
specific T cell subsets. Strikingly, IL-2+ CD4+ and/or CD8+ cytokine T cell responses were 
significantly bolstered during the effector phase of the vaccine response by OX40 
stimulation and maintained at high levels throughout time. As a future development, 
it would be particularly intriguing to test whether IL-2 induction, currently provided in 
many combination immunotherapeutic settings through laborious adoptive transfers 
or high toxicity direct infusions could be complemented or even replaced by providing 
OX40 co-stimulation using agonistic antibodies.
Due to its capacity to regulate both CD4+ and CD8+ T cells, OX40 is considered 
a promising candidate in immunotherapy of persistent viral infections and cancer. 
However, there is preclinical evidence that anti-OX40 antibodies could induce off-
target toxicity causing deleterious immunosuppressive side effects by promoting 
the accumulation of MDSCs and the production of Th2 cytokines leading to 
autoimmunity or inflammatory diseases [30-32]. In chapter 3, NK cell augmentation and 
Th2 cytokine activity associated with pro-inflammatory and autoimmune conditions 
were not triggered by OX40 stimulation. Presumably, combination immunotherapy 
with peptide-vaccines and low dose schedules of OX40 stimulation did not allow 
development of off target toxicity events. Moreover, agonistic OX40 antibody 
treatment has exhibited mild toxicity and no expansion of Tregs, when applied as 
monotherapy for the treatment of  solid tumours [24], compared to the FDA approved 
CTLA-4 (ipilimumab) or PD-1/ PD-L1 mAb blockade therapies [33,34].
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Despite all the positive effects of OX40 agonists it is unlikely that anti-OX40 
as single agent will be sufficient to cure patients with different tumour types or 
viral infections. However, there is great promise that combination immunotherapy 
incorporating OX40 stimulation and vaccination may be able to increase efficacy. 
Finally, it would be particularly informative to investigate whether enforced OX40 
triggering could complement the therapeutic activity of other costimulatory antibody 
(anti-4-1BB), checkpoint inhibitor (PD-1/ PD-L1/ CDLA-4) and conventional treatments 
(i.e. radiotherapy, chemotherapy, cytokine infusions). Encouraging results come from 
recent studies where anti-OX40 antibody treatment uniquely synergized with PD1-
blockade to promote tumour regression in experimental models [34,35].
DIVERSITY IN SPECIFICITY
A valuable observation in chapter 2 was that the prophylactic efficacy of the distinct 
MHC class I MCMV epitope containing SLP vaccines was remarkably potentiated when all 
individual SLPs were combined and administered as a mixture. The efficacy of the MHC 
class I SLP vaccines to protect against lytic MCMV infection was primarily driven by 
the breadth of the CD8+ T cell responses rather than the magnitude of the response to 
all individual SLPs. Although the magnitude of the individual antigen-specific CD8+ T 
cell responses was significantly reduced when provided within a mixture and the overall 
T cell response size was approximately similar to individual SLP vaccines, the ability to 
contain virus spread was drastically enhanced. 
An interesting observation of the present work was the superior capacity of the M38 
and m139 MCMV MHC class I epitope containing SLPs to reduce viral titers upon lytic 
MCMV challenge. M38 and m139 antigens elicit strong inflationary CD8+ T cell responses 
during MCMV infection and presumably play an important role in regulating virus 
replication and persistence [36,37].  Conceivably, induction of strong CD8+ T cell vaccine 
responses to the M38 and m139 viral antigens in combination with high expression of 
these antigens on MCMV-infected cells may explain the advanced efficacy of the M38 
and m139 specific SLP vaccines in controlling virus spread.
Associations of potent T cell responses with increased breadth leading to decreased 
viremia or complete viral eradication has been observed in other chronic viral 
infections [38-41]. A possible explanation for this finding is that development of a robust 
cytotoxic T cell response with a diverse repertoire of specificities, targeting viral antigens 
which are expressed at different stages in the viral life cycle increases the likelihood of 
immune recognition of viral infected cells and the probability of virus dissemination 
control. Especially, there is evidence that potential encounter of viral infected cells with 
vaccine-induced T cells of different specificities boost cytokine-mediated direct cell 
killing and promote CTL cooperation events [42]. 
Although the exact mechanisms through which immune T cell repertoire diversity 
influences anti-viral immunity are not yet defined, it is important to consider induction 
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of a T cell response with increased breadth when designing prophylactic T cell-based 
vaccines against MCMV infection. Based on the results obtained from the chapter 2 
the breadth of the vaccine response may be an important goal in vaccine formulations 
and a determinant of vaccine efficacy.
SHAKING DOWN THE RIGID WALLS OF PRE-EXISTING IMMUNITY 
In many infection models, immunological memory to a viral vector is considered 
a hindrance for subsequent induction of cell-mediated and humoral immune responses. 
Various components of the immune system, including neutralizing antibodies, vector-
specific T cells and type I IFN-activated NK cells contribute to seriously compromised 
immune responses against the delivered heterologous antigen [43]. Additionally, 
pre-existing immunity to a viral vector impacts viral vector’s expression level, virus 
trafficking and alters homing patterns of vaccine induced T cells. Similarly, pre-existing 
immunity may modulate the magnitude, breadth and immune system’s antibody and 
T cell response to the inserted antigen [44]. CMV-based vectors are endowed with 
the capacity to stimulate robust CTL and humoral immune responses and have shown 
unprecedented efficacy against persistent viral infections and cancer [45-47]. Due to 
the high prevalence rate of CMV in the population, pre-existing immune responses 
in the host may exist. However, compared to other viruses and traditional viral vector 
systems (i.e. adenoviruses, lentiviruses), CMV has the ability to re-infect or even 
superinfect the same host and initiate a second cycle of immune responses. 
Thus, in chapter 5, the capacity of MCMV-based vector vaccines to induce antitumor 
responses against HPV-induced cancer was explored. Whether the presence of pre-
existing immune responses to MCMV is detrimental or can augment response to 
the vectored antigen was also investigated. MCMV vectors encoded a dominant MHC 
class I HPV16 E7 epitope in either inflationary of non-inflationary MCMV epitope regions 
were tested for both prophylactic and therapeutic efficacy against HPV+ tumors in mice. 
Notably, systemic or subcutaneous MCMV-vectored vaccine administration stimulated 
vigorous HPV-specific T cell responses recapitulating MCMV response pattern and 
provided complete and long term protection against tumor challenge in naïve mice. 
The therapeutic testing of the MCMV vector vaccine prolonged survival of challenged 
mice but exhibited moderate immunogenicity when compared to mice with no 
immunological memory to the vector, eventually leading to minor therapeutic effect. 
Interestingly, the efficacy of the vaccine was associated with the level of pre-existing 
humoral immunity to MCMV. Specifically, the initial viral infection dose determined 
the magnitude of the subsequent antibody and T cell vaccine- specific response. Mice 
initially infected through the systemic or subcutaneous routes developed strong anti-
viral immunity, which severely diminished viral vector’s impeding vaccine efficacy. In 
addition, there is supporting evidence that the therapeutic efficacy of the CMV vectors 
expressing tumour or viral antigens is significantly attenuated when the host harbours 
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latent CMV [47]. We and others have previously reported that the initial viral inoculum 
dose impacts virus immune response [48,49]. Hence, we tested whether different 
levels of pre-existing immunity to MCMV can influence the subsequent MCMV-vector 
vaccine efficacy. Strikingly, when initial infection administered orally, weak T cell and 
antibody responses were elicited, which were significantly boosted following systemic 
or subcutaneous MCMV- vector vaccine administration. Consistently, the vaccine 
efficacy was escalated leading to almost complete eradication of tumor-bearing 
mice. In contrast, strong pre-existing immunity to MCMV was not surpassed by any of 
the conventional vaccine injection routes tested. 
It is not surprising that MCMV – when applied as a vaccine vector containing tumor 
antigens – is not capable to overcome its own immunogenicity. Even therapeutic 
targeting of persistent MCMV infection using the strong SLP T cell-based vaccine 
concept in appendix of chapter 3 was not capable to boost the considerable high 
levels of pre-existing virus-specific T cells present 8 weeks after viral infection. Whether 
the efficacy of the peptide vaccines in therapeutic settings would have been improved 
in case of low dose pre-exposure to the virus remains to be tested.
Our results suggest that T cell-based vaccine vectors must be designed to generate 
sufficient quantities of antigen and induce broad cytotoxic CD4+ and CD8+ T cell 
responses. Key outstanding research challenges in the use of CMV vectors are dealing 
with the diversity in the level of pre-existing immunity of pre-exposed individuals 
and in discovering ways to minimize this response to ensure that all CMV vectored 
vaccines will reach the threshold levels of protective immunity needed for efficacy. 
Several strategies, such as augmentation of viral vector dose, immunization route and 
timing are important factors to circumvent pre-existing immunity to CMV and need to 
be considered. Moreover, strategies to lower pre-existing immunity through dynamic 
targeting of critical genes/proteins for virus replication and latency are likely to be 
particularly informative. Importantly, deletion of virally encoded inhibitors of MHC 
class I antigen presentation may be essential for blocking establishment of persistent 
secondary infection or superinfection in CMV rhesus macaques [50]. Finally, the design of 
distinct CMV serotypes to overcome immunological memory might be a feasible future 
direction. Analysis of the components involved at the regulation of pre-existing MCMV 
immunity will help further improve the development of therapeutic CMV vaccines and 
vector delivery systems for animal and human use. [51] 
CONCLUDING REMARKS
T cell mediated protection is multifaceted and driven by several factors. Despite 
differences among viral infectious diseases, common determinants of the vaccine 
efficacy is the magnitude, breadth, availability of co-stimulation, tissue location and 
functionality of CD8+ T cells (chapter 2, 3, 4 and 6). The role of CD4+ T cell ‘’help’’ in 
providing direct effector function and regulating the magnitude of the CD8+ T cell 
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response is crucial (chapter 3). Therapeutic interventions with MCMV vectors appear to 
be promising for chronic viral infections (chapter 5). A fundamental research question 
which the findings of this thesis put forward is whether other factors such as innate 
immunity and B cells are required for sufficient vaccine function and how these factors 
can be co-manipulated to optimize vaccination. 
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ENGLISH SUMMARY
The development of novel vaccine strategies for CMV is major research priority. 
Vaccines based on SLPs may form an efficient vaccination strategy against CMV 
infection. However, a detailed and systematic examination of the potentially promising 
prospects of SLP vaccines is lacking. This PhD thesis presents a series of experimental 
studies undertaking elaborate evaluations of the efficacy of SLP vaccines against MCMV 
infection. SLP vaccines alone or in combination with immunomodulatory agents of 
the TNFR superfamily were investigated for prophylactic and therapeutic efficacy 
in various mouse models of CMV infection. The pivotal knowledge obtained from 
the MCMV studies led to the investigation of highly immunogenic IE2 HCMV antigenic 
targets and formed the basis for the design of a HCMV vaccine in this doctoral thesis.
The first experimental study (chapter 2) tested the preventive efficacy of SLP vaccines 
comprising immunodominant MHC class I MCMV restricted epitopes that exclusively 
elicit cytotoxic MHC class I T cell responses against lytic MCMV infection in C57BL/6 and 
BALB/c mouse strains. Prime-booster vaccination induced strong and polyfunctional 
CD8+ T cell responses. Interestingly, the degree of the CD8+ T cell response was 
determined by the naive CD8+ T cell precursor frequency of each epitope rather than 
the T cell functional avidity. Vaccination with a combination of SLPs produced the best 
reduction in viral titers, suggesting that the breadth of the vaccine-induced CD8+ T cell 
response is critical for preventive vaccine strategies against MCMV.
The second study (chapter 3) examined whether the efficacy of the MHC class 
I SLP based vaccine is boosted with CD4+ T cell ‘’help’’ and/or OX40 co-stimulation. 
The prophylactic effects of SLPs containing MHC class II epitopes from 5 immunodominant 
MCMV antigens were examined alone or in combination with the MHC class I SLPs 
in C57BL/6 mice. Enforced OX40 signalling during booster SLP vaccination improved 
vaccine-specific CD4+ T cell and CD8+ T cell reactivity. The combined vaccination of SLPs 
containing various MHC class I and II SLPs plus OX40 agonistic antibodies produced 
the best protection and virus dissemination effects. Drawing on these promising 
findings, the therapeutic efficacy of the combinatorial MHC class I and II SLP vaccines 
was also tested in the C57BL/6 mouse strain (appendix section of chapter 3). The strong 
T cell response to MCMV was not boosted following SLP vaccination and no therapeutic 
effect was observed. These results do not support the therapeutic prospects of 
the combinatorial MHC class I and II SLP vaccines against MCMV infection. 
Chapter 4 presents an endeavour to translate this research in humans. A study to 
discover novel HCMV T cell epitopes, which would enlarge the choice of antigens for 
potential HCMV T cell- based SLP vaccines, was undertaken. IE2 HCMV T cell responses 
were tested in the peripheral blood of 15 HCMV- seropositive and 6 HCMV- seronegative 
healthy donors using IE2 SLP pools and cytokine flow cytometry. Whereas the IE1 protein 
is frequently recognized by CD8+ T cells, a limited number of HLA-class I restricted IE2 
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T cell epitopes were found. Several new HLA class II-restricted IE2 T cell epitopes were 
detected in addition to previously detected epitopes. Five highly immunogenic IE2 SLPs 
recognized by polyfunctional Th1 cytokine (IFN-γ+/ TNF+/ IL-2+) producing cells were 
identified during the functional characterization of the IE2-specific T cell responses. 
Testing of these 5 highly immunogenic IE2 SLPs as a potential T cell based vaccine for 
CMV is highlighted as a fruitful future research direction. 
Since CMV has a unique ability to re-infect the same host and initiate a second 
cycle of immune responses, a study (chapter 5) was performed in which the protective 
and therapeutic efficacy of MCMV-based viral vector vaccines against HPV+ tumours 
were evaluated in mice with and without pre-existing immunity. MCMV-based vaccine 
vectors expressing an immunodominant MHC class I-restricted HPV E7 epitope in either 
inflationary or non-inflationary T cell epitope regions were generated. The diversity of 
the inflationary versus non-inflationary HPV specific T cell responses was thoroughly 
examined over time and the vaccine effectiveness was compared. All MCMV vector-
based vaccines exhibited long term prophylactic vaccine efficacy. Interestingly, 
therapeutic evaluation of the MCMV vectored vaccines showed that the level of pre-
existing immunity determines the efficacy of MCMV-based vaccine vectors.  
The empirical findings presented in the previous 4 chapters are complemented by 
a narrative review of the literature in chapter 6, which critically evaluates the research 
evidence on the potency of prophylactic T cell eliciting vaccines for chronic viral 
infections. It outlines the main factors which determine the quality of the CD4+ and 
CD8+ T cell responses. In parallel, the complexities in understanding the mechanisms 
underpinning potent T cell responses are discussed as T cell mediated protection is 
driven by several factors. 
The final chapter 7 provides an insightful discussion of the key knowledge gaps 
filled in this thesis, the core strengths and limitations of the utilised methodologies 
and findings, and the most fruitful research ideas to be prioritised by future studies in 
this area. Importantly also, a balanced debate is presented about the likely direct and 
indirect clinical implications of this thesis in the design of efficacious prophylactic T cell 
based vaccines. 
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NEDERLANDSE SAMENVATTING
De ontwikkeling van nieuwe vaccinatiestrategieën tegen humaan cytomegalovirus (CMV) 
is een belangrijke onderzoeksprioriteit. Een mogelijke efficiënte vaccinatiestrategie 
tegen CMV infectie vormen vaccins gebaseerd op synthetische lange peptiden 
(SLP). Echter, tot op heden ontbreekt een gedetailleerd en systematisch onderzoek 
naar het gebruik van SLP vaccins als potentieel veelbelovend therapie tegen CMV. 
In dit proefschrift worden een reeks experimentele studies beschreven waarin 
de werkzaamheid van SLP vaccins tegen muizen CMV (MCMV)-infecties zijn 
geëvalueerd. SLP vaccins, alleen of in combinatie met stimulatie van het TNFR 
superfamilielid OX40, werden getest op profylactische en therapeutische 
werkzaamheid in diverse muismodellen van MCMV infectie. De door de MCMV studies 
verkregen kennis leidde tot een studie om immunogene aminozuur sequenties 
binnen het CMV IE2 eiwit te identificeren als eerste opstap naar een mogelijk SLP 
 vaccin voor CMV.
In het eerste onderzoek (hoofdstuk 2) werd de preventieve werkzaamheid van SLP 
vaccins, bestaande uit een aantal MHC klasse I-bindende MCMV peptiden, tegen een 
lytische MCMV infectie getest. Hieruit bleek dat vaccinatie met een combinatie van SLP’s 
de sterkste werking had. Dit suggereert dat de breedte van de vaccin geïnduceerde 
CD8+ T-cel reactie belangrijk is voor preventieve vaccinatie tegen MCMV. Daarnaast 
bleek dat de sterkte van de vaccin-geïnduceerde T-cel reactie afhankelijk was van het 
aantal circulerende naïeve CD8+ voorloper T-cellen.
In het tweede onderzoek (hoofdstuk 3) werd getracht de werkzaamheid van 
het eerder genoemde SLP-vaccin te verhogen door het vaccin uit te breiden met 
SLP’s, bestaande uit MHC klasse II-bindende MCMV peptiden, waardoor ook CD4+ 
T-helpercellen worden geactiveerd. Daarnaast werd er ook een antistof tegen OX40 
geïnjecteerd waardoor de T-cellen extra gestimuleerd werden. Uit deze studie kwam 
naar voren dat OX40 stimulatie tijdens booster SLP vaccinatie de vaccin-specifieke CD4+ 
T-cel en CD8+ T-cel reactiviteit sterk verbeterd. Tevens bleek dat de beste bescherming 
tegen MCMV infectie werd verkregen wanneer de muizen werden gevaccineerd met 
een combinatie van MHC klasse I en MHC klasse II-bindende SLP’s en OX40 stimulatie 
tijdens de booster vaccinatie. 
Op basis van deze veelbelovende bevindingen werd ook de therapeutische 
werkzaamheid van deze vaccinatiestrategie getest (bijlage hoofdstuk 3). De al aanwezige 
T-cel response tegen MCMV werd niet verbeterd door het vaccin en er werd ook geen 
therapeutisch effect waargenomen. Dus een eventuele therapeutische toepassing van 
dit vaccin bij een CMV infectie wordt niet door de resultaten ondersteund. 
In hoofdstuk 4 werd een eerste stap gedaan om dit onderzoek te vertalen naar 
de mens door binnen het IE2 eiwit van humaan CMV te zoeken naar aminozuur 
sequenties die door de T-cellen van verschillende CMV-geïnfecteerde personen herkend 
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werden. Het IE2 eiwit werd vooral door CD4+ T-helper cellen herkend en in mindere 
mate door CD8+ T-cellen. Uiteindelijk werden er vijf immunogene SLP’s geïdentificeerd 
die herkend werden door zogenoemde polyfunctionele type 1 T-helpercellen. Deze 
SLP’s zouden de basis kunnen vormen voor een potentieel vaccin tegen CMV.
Aangezien CMV een uniek vermogen heeft om dezelfde gastheer opnieuw te 
infecteren en een tweede cyclus van afweerreacties te initiëren, werd een studie 
uitgevoerd waarin de beschermende en therapeutische werkzaamheid van MCMV-
gebaseerde virale vector vaccins tegen humaan papillomavirus (HPV) veroorzaakte 
tumoren werd geëvalueerd (hoofdstuk 5). Alle MCMV-vector gebaseerde vaccins 
vertoonden langdurige profylactische werkzaamheid. De therapeutische werkzaamheid 
van een MCMV-gebaseerd virale vector vaccin was afhankelijk van het niveau van de al 
bestaande immuniteit tegen MCMV. Naarmate de bestaande immuniteit sterker was 
nam de therapeutische werking af. 
In hoofdstuk 6 worden de empirische bevindingen uit de voorgaande 4 hoofdstukken 
aangevuld met een uitgebreide bespreking van de literatuur op het gebied van 
profylactische T-cel activerende vaccins. Het schetst de belangrijkste factoren die van 
invloed zijn op de kwaliteit van de CD4+ en CD8+ T-cel reacties. Tegelijkertijd wordt 
de complexiteit van de verschillende mechanismen die een rol spelen bij het ontstaan 
van krachtige T-cel reacties besproken. 
Hoofdstuk 7 geeft een inzicht in hoe de studies in dit proefschrift bijdraagt 
aan de huidige kennis binnen dit onderzoeksgebied en beschrijft de sterktes en 
zwaktes van de gebruikte methodes en bevindingen. Tevens wordt er een evenwichtige 
beschouwing gegeven over de mogelijke directe en indirecte klinische implicaties bij 
het ontwerpen van effectieve profylactische T-cel gebaseerde vaccins en prioriteert het 
ideeën voor toekomstige studies. 




AICD  Activation-Induced Cell Death  
APCs  Antigen Presenting Cells
CTL  Cytotoxic T lymphocyte
CCMV  Chimpanzee CMV
CMV  Cytomegalovirus
DC  Dendritic Cell
GPCMV  Guinea Pig CMV  
HCMV  Human CMV
HIV  Human Immunodeficiency Virus
HLA  Human Leukocyte Antigen
HPV  Human Papilloma Virus
IE1  Immediate Early 1 protein 
IE2  Immediate-Early 2 protein




MCMV  Mouse CMV
MHC  Major Histocompatibility Complex
MVA  Modified Vaccinia Ankara
NK cells  Natural killer cells
PAMPs  Pathogen-Associated Molecular Patterns
PBMCs  Peripheral Blood Mononuclear Cells
PCD  Programmed Cell Death
PFU  Plaque-Forming Units
pp65  protein 65
PRRs  Pattern Recognition Receptors
RCMV  Rat CMV
RhCMV  Rhesus CMV
SIV  Simian Immunodeficiency Virus
SLP  Synthetic Long Peptide
TCM  Central Memory
TEM  Effector Memory
TRM  Tissue-Resident Memory
TNF  Tumor Necrosis Factor
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